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Abstract 
 
The FK506-binding protein 51 (FKBP51) plays an important role in steroid hormone receptors 
(SHRs) regulation and is related to many pathologic states and diseases such as stress-related 
disorder, cancer, metabolic syndrome, and chronic pain. FKBP51 acts on several cellular 
pathways likely through protein-protein interactions via its multifunctional domains. However, 
the functional basis of FKBP51 in signalling remains obscure due to the poor characterization 
of its biochemical properties. Importantly, the current FKBP51 inhibitors are not able to 
inactivate FKBP51 completely based on the occupancy-driven pharmacology.  
 
In this thesis, I synthesized a series of small molecules which aim to degrade FK506 binding 
proteins (FKBPs) via the recently developed proteolysis targeting chimera (PROTAC) strategy. 
A PROTAC is a heterobifunctional molecule consisting of a ligand for the target protein and a 
ligand for an E3 ligase, which induces the proteasomal degradation of the target protein. Unlike 
classical small molecule drugs, PROTACs intend to eliminate the aberrantly functioning protein 
rather than to inhibit it. By utilizing a selective FKBP51 ligand and non-selective FKBPs ligands 
developed by our group, two series of PROTACs were designed and synthesized. All of the 
selective SAFit-PROTACs showed affinities in the nanomolar range for FKBP51, while retaining 
high selectivity over the close homologue FKBP52. The degradation of cellular FKBP51 was 
observed upon treatment with the PROTAC MTQ202. In turn, I explored rigidified linkers based 
on MTQ202 to afford more potent PROTACs. The bicyclic ligand-based PROTACs exhibited 
outstanding affinities for all of the tested FKBPs in the low nanomolar range to subnanomolar 
range. The most potent compound, MTQ509, showed the highest binding affinity for FKBP51 
so far reported (Ki = 0.92 nM). 
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Zusammenfassung 
 
Das FK506-bindende Protein 51 (FKBP51) spielt eine wichtige Rolle bei der Regulation von 
Steroidhormonrezeptoren (SHRs) und wird mit  einer Vielzahl von Krankheiten assoziiert wie 
zum Beispiel stressbedingten Störungen, Krebs, metabolischem Syndrom und chronischem 
Schmerz. FKBP51 ist in verschiedenen zellulären Signalwegen involviert, wobei die 
multifunktionalen Domänen vermutlich die Signaltransduktion durch Protein-Protein-
Interaktionen vermitteln.  Bis heute ist die zelluläre Funktion von FKBP51 aufgrund der 
fehlenden biochemischen Charakterisierung unklar.  Die bisher entwickelten FKBP51-
Inhibitoren blockieren die Bindungstasche und können FKBP51 nicht vollständig inaktivieren.  
Im Rahmen meiner Doktorarbeit habe ich chemische Substanzen synthetisiert, die darauf 
abzielen, FK506-bindende Proteine (FKBPs) über die kürzlich entwickelte Proteolyse-Targeting-
Chimären-Strategie (PROTAC) abzubauen. Ein PROTAC ist ein heterobifunktionelles Molekül, 
das aus einem Liganden für das Zielprotein und einem Liganden, der an eine E3-Ligase bindet, 
besteht und den proteasomalen Abbau des Zielproteins induziert. Im Gegensatz zu klassischen 
Wirkstoffen zielen PROTACs eher darauf ab, das Zielprotein zu eliminieren, anstatt es zu 
inhibieren. Unter Verwendung eines selektiven FKBP51-Liganden und nicht-selektiver FKBP-
Liganden, die von unserer Gruppe entwickelt wurden, wurden zwei Serien von PROTACs 
entworfen und synthetisiert. Alle selektiven SAFit-PROTACs zeigten Affinitäten im 
nanomolaren Bereich für FKBP51 und Selektivität gegenüber dem homologen Protein FKBP52. 
Bei der zellulären Anwendung  des PROTAC s MTQ202 wurde der  Abbau von endogenem 
FKBP51 beobachtet. Zur Erhöhung der Wirksamkeit habe ich ausgehend von MTQ202 
verschiedene Linker untersucht. Die auf bicyclischen Liganden basierenden PROTACs zeigten 
Affinitäten für alle getesteten FKBPs im niedrigen nanomolaren bis subnanomolaren Bereich. 
Die potenteste Verbindung, MTQ509, zeigte die bisher höchste Bindungsaffinität für FKBP51 
(Ki = 0,92 nM). 
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1. Introduction 
 
1.1 The biology of FKBP51 
  
  
Figure 1. The structure of FK506 and the structure of FKBP12-FK506 complex (PDB ID: 
1FKJ) 
 
FK506 binding proteins (FKBPs) are a ubiquitous family of immunophilins that are present in 
all eukaryotes1, 2. This class of proteins features a peptidyl-prolyl cis/trans isomerase (PPIase) 
domain, to which immunosuppressants like FK506 and rapamycin bind3, 4. The PPIase domain 
also has the ability to catalyze the cis-trans isomerization of Xaa-Pro bonds, regulating folding, 
activation and degradation of many proteins5. Upon binding to immunosuppressive ligands, the 
PPIase enzymatic activity is abolished. 
Except for the canonical members FKBP12 and FKBP12.6, all other FKBPs contain additional 
functional domains besides the PPIase domain, which are often involved in protein-protein 
interactions. 
 
1.2 Structure of FKBP51 
The FK506 binding protein 51 (FKBP51), a 51 kDa member of the FKBP family, is encoded by 
the fkbp5 gene and was first identified as a co-chaperone of the heat shock protein 90 (HSP90) 
in a complex with steroid hormone receptors (SHRs)6, 7. FKBP51 is well known for its ability to 
modulate the activities of steroid hormone receptors, including glucocorticoid receptor (GR) 
and androgen receptor (AR), which leads to further gene expressions and protein level 
regulations. 
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Figure 2. X-ray crystallographic structures of FKBP51 (PDB ID: 1KT0) and FKBP52 (PDB 
ID: 1Q1C and 1P5Q). 
 
FKBP51 is composed of two FKBP-like domains (FK1 domain and FK2 domain) and a 
tetratricopeptide repeat domain (TPR domain)8, 9. The N-terminal FK1 domain possesses a 
PPIase catalytic pocket that displays PPIase activity and binds to the immunosuppressant drugs 
such as FK506 and rapamycin8, 10. Besides its catalytic function, some studies of the prototypic 
homologue FKBP12 show that the PPIase active site is involved in some protein-protein 
interactions, which implies that FKBP51 may adopt a similar mechanism for the regulation of 
steroid hormone receptors8, 11. The FK2 domain, following the FK1 domain, is structurally 
similar to FK1 domain but exhibits neither binding ability of immunosuppressant nor catalytic 
function due to a lack of key residues12. The C-terminal TPR domain is the binding site for 
HSP90 and often participates in mediating protein-protein interactions13, 14. 
FKBP52, the most similar homologue to FKBP51, shares 60% identity and 75% similarity in 
amino acid sequences with FKBP51, as well as a similar structural architecture, PPIase catalytic 
activity, FK506-binding ability and Hsp90 binding ability11, 15. However, FKBP52 shows 
antagonistic effect to FKBP51 in modulating SHRs activity16. 
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1.3 The function of FKBP51 
 
Figure 3. Model for the mechanism of action of FKBP51 and 52 on steroid hormone 
complex, ligand binding and nuclear translocation. 
 
FKBP51 has been observed to interact with many steroid hormone receptors (SHRs), such as 
the glucocorticoid receptor (GR), the estrogen receptor (ER), the androgen receptor (AR) and 
the mineralocorticoid receptor (MR)17-20. In most cases, FKBP51 is a negative modulator of 
SHRs except for AR21, 22. Meanwhile, FKBP52 is a positive regulator of SHRs23-25. FKBP51 and 
FKBP52 regulate SHR activity through interaction with the abundant molecular chaperone, 90 
kDa heat shock protein (Hsp90), which is involved in numerous protein-protein interactions 
that modulate important signaling pathways.  
According to a proposed mechanism, either FKBP51 or 52 bind to Hsp90 and form a 
heterocomplex with the co-chaperone p23 and SHR in the cytosol23, 26. Upon the steroid binding, 
FKBP51 and FKBP52 are exchangeable in the heterocomplex due to a ligand-induced 
conformational change of the receptor13, 19. Next, FKBP52 interacts with the dynein-dynactin 
motor complex by its PPIase pocket, whereas FKBP51 is not able to recruit dynein23, 27-29. As a 
result, the dynein-dynactin motor facilitates SHR translocation from the cytosol into the 
nucleus, followed by interaction between SHR and response elements leading to enhanced or 
reduced expression of various genes30. Inversely, high cytoplasmic levels of FKBP51 decrease
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dynein-dependent SHR nuclear translocation, leading to SHR resistance. This indicates that the 
expression ratio of FKBP51/FKBP52 is a regulatory factor for steroid receptor regulations19, 23, 
31. 
 
1.4 Risk for diseases 
1.4.1 Stress related disorders  
 
Figure 4. The Hypothalamic–Pituitary–Cortisol System 
 
The hypothalamic–pituitary–adrenal (HPA) axis is one of our main neuroendocrine pathways 
that regulates stress responses32, 33. Upon stress stimulation, neurons in the paraventricular 
nucleus of the hypothalamus release corticotrophin-releasing hormone (CRH) into the blood 
vessels connected to the pituitary gland, where adrenocorticotropic hormone (ACTH) is 
secreted by the stimulus of CRH34. In turn, the ACTH is released into the peripheral circulation, 
stimulating the synthesis and production of glucocorticoid by the adrenal glands. The resulting 
cortisol, the main glucocorticoid hormone in humans, is secreted into blood and diffuses into 
the cytoplasm of target cells, where it binds to hormone receptors, such as the mineralocorticoid 
receptor (MR) and GR.  
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To prevent a prolonged stress response, the HPA axis is regulated by negative-feedback loops 
mediated by cortisol to maintain hormone levels35, 36. In a stressful situation, the increased 
cortisol levels in blood and tissues saturate its high affinity receptors MRs, leading to the binding 
of excess cortisol to its low affinity receptors GRs. The resulting GR activation inhibits the 
secretion of ACTH/CRH and restores cortisol to basal levels, thus terminating the stress 
responses37. 
The GR sensitivity is regulated by FKBP51 via an ultra-short negative feedback loop38. Enhanced 
expression of FKBP5, the gene encoding FKBP51, by GR activation reduces the affinity of GR 
for cortisol and decreases the translocation of GR from the cytosol into the nucleus. The 
resulting GR resistance diminishes HPA negative feedback, leading to a prolonged stress 
response after stressor exposure32, 39. 
A well-functioning HPA axis is fundamental to trigger fight-or-flight response and survival. 
Thus, abnormal changes in FKBP51 levels due to genetic, hormonal or environmental factors 
can lead to the dysfunction of the Hsp90-FKBP51 complex, which in turn impairs the balance 
between activation and negative feedback of HPA stress response, and finally can contribute to 
various psychiatric disorders, such as major depression, post-traumatic stress disorder (PTSD) 
and anxiety31, 40-44. 
 
1.4.2 Reproductive Development and Success 
The studies of FKBP52 knockout mouse lines showed that FKBP52 plays important roles in the 
mammalian reproductive system. Male FKBP52 knockout (52KO) mice are still viable but 
exhibit phenotypes consistent with partial androgen insensitivity syndrome. Although their 
primary sex organs seem normal, the secondary sex organs are affected, such as smaller prostate 
glands and seminal vesicles, lower sperm motility and hypospadias45, 46. Females are 
morphologically normal but infertile. This can be attributed to failures in decidualization and 
embryonic implantation caused by progesterone insensitivity, indicating that FKBP52 plays a 
crucial role in the female reproduction system47. Compare to FKBP52 knockout mice, FKBP51 
knockout mice show no obvious morphological and reproductive abnormality. 
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1.5 Druggability of FKBP51 
1.5.1 Non-selective FKBP51 ligands 
 
Figure 5. The structures of FK506 and FKBP51/52 ligand SLF 
 
The first synthetic ligand which showed affinity in the micromolar range to FKBP51 and FKBP52 
was SLF, an analogue of FK506, which was originally developed as an FKBP12 ligand9, 48, 49. 
Compared to FK506 and rapamycin, SLF has no effector domain, which is responsible for the 
immunosuppressive activity, but it retains the pipecolic motif derived from the diketoamide 
pipecolinic core in FK506. Based on the co-crystal structure of SLF and FKBP51, Gopalakrishnan 
et al. investigated the first structure-activity relationship (SAR) study of SLF derivatives as 
FKBP51 and FKBP52 ligands50. This study revealed that the pipecolate core is essential for the 
binding affinity. Besides, replacing the carboxylic acid group on the top group with morpholine 
gives a 15 to 20-fold more potent for FKBP51/52 ligand compare to SLF. 
 
1.5.2 Selective FKBP51 ligands 
 
Figure 6. The structures of selective ligands SAFit1 and SAFit2 
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In 2015, Gaali et al. developed the first selective ligand for FKBP5151.  In order to distinguish 
between FKBP51 and FKBP52 pharmacologically, Gaali et al. adopted a chemical genetics 
approach, which originated from a study to develop artificial selectivity for FKBP12-fusion 
protein52. Based on this method, they expanded the FK506-binding pocket by generating 
FKBP51F67V and FKBP52F67V mutants. During the development of the complementary ligand 
for these mutants, they noticed that two of the analogues, iFit1 and iFit2, showed weak affinity 
to WT FKBP51 but did not bind to WT FKBP52. The FKBP51-iFit1 co-crystal structure revealed 
that a conformational change compare to the apo form or the FKBP51-FK506 complex was 
stabilized by iFit1. Upon the influence of the Cα allyl group on iFit1, the Phe67 side chain moves 
towards Lys58 and Lys60, which is subsequently stabilized by Phe129. Conversely, the side 
chain of Phe67 in FKBP52 adopted a different conformation because the corresponding 
residues, Thr58, Trp60 and Val129, are too bulky to undergo similar side chain rearrangements. 
Intrigued by this finding, a series of Cα-modified derivatives with bulky substituents was 
synthesized to improve the affinity and selectivity for FKBP51. Eventually, SAFit1 and SAfit2, 
the two most potent ligands, were developed, which have high affinity (Ki = 4 nM and 6 nM, 
respectively) and superb specificity (>10,000-fold selectivity for FKBP51 over FKBP52). The 
SAFit analogues provide a powerful tool for investigations of FKBP51, which is critical for 
understanding its biological functions. 
 
1.5.3 Bicyclic ligands 
 
Figure 7. The structure of [4.3.1] bicyclic ligand 
 
Based on the co-crystal structure of FKBP-FK506 and computational design, Babine et al. 
reported a series of FKBP12 ligands with the rigid bicyclic structure53, leading to the emergence 
of FKBP ligands with bridged bicyclic scaffolds. Inspired by these studies, our group developed 
a series of [4.3.1] bicyclic ligands which mimic the binding conformation of FK506 with the 
rigidified scaffold instead of the pipecolyl-monocyclic scaffold54, 55. The potent bicyclic ligands 
showed low micromolar to nanomolar affinities to many human FKBPs, including FKBP12, 
FKBP12.6, FKBP51 and FKBP52. 
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1.6 Chemical knockdown of protein by small molecule PROTACS 
1.6.1 The ubiquitin proteasome system 
 
 
Figure 8. Protein degradation mediated by ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) plays a crucial role in balancing the intracellular 
protein levels by degrading proteins. The UPS is a multistep procedure involving ubiquitin, a 9-
kDa protein highly conserved from yeast to humans, three kinds of enzyme and the 26S 
proteasome56, 57.  
Ubiquitination of target proteins is carried out via an enzymatic cascade conducted by the 
ubiquitin activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). 
At the beginning, ubiquitin is attached to E1 via a thioester bond formed by an ATP-dependent 
reaction. Then the activated ubiquitin is transferred to E2 with the formation of a new high-
energy thioester bond. Finally, E3 ubiquitin ligase binds to both ubiquitin-E2 complex and 
substrate, bringing them in close proximity to catalyze the conjugation of the ubiquitin and the 
substrate. This ubiquitination process occurs repeatedly in a cyclic manner, resulting in the 
formation of a polyubiquitinated adduct, which can be recognized and degraded by the 26S 
proteasome58, 59.  
Currently, there is only one major E1 enzyme, around 50 E2 enzymes and over 600 E3 ligases 
encoded in the human genome. Unsurprisingly, the variety of E3 ligases confers substrate 
specificity during ubiquitination and degradation processes. 
 
 11 
 
1.6.2 Proteolysis targeting chimera (PROTAC) 
 
 
 
Figure 9. Degradation induced by PROTACs  
 
In the recent decade, proteolysis-targeting chimeras (PROTACs) have emerged as a useful 
chemical knockdown strategy and have a promising application prospect in clinical therapies 
for diseases60-62. PROTACs are a new class of heterobifunctional molecules consisting of a 
recognition motif for binding the protein of interest (POI), a recognition motif for recruiting an 
E3 ligase and a linker to tether the first two together. By binding to the substrate and the E3 
ligase complex simultaneously, PROTACs are able to bring them into proximity to induce 
polyubiquitination of the substrate, leading to the recognition by the 26S proteasome and the 
proteasomal degradation63-65. 
 
1.6.3 Recruiting E3 ligases  
1.6.3.1 Recruiting E3 ligases MDM2 
 
Figure 10. SARM-nutlin PROTAC 
 
 
MDM2 is an E3 ligase, which has been found to be overexpressed in many tumors, inducing 
proteasomal degradation of the tumor suppressor protein p53 and thus drives tumor 
formation66. The first all-small molecule PROTAC P1 was reported in 2008 by Schneekloth et 
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al., which recruits MDM2 as the E3 ligase via its potent antagonist nutlin 3 attached to the AR 
ligand SARM to induce the degradation of ARs67, 68. This SARM-nutlin conjugate bound AR with 
Ki of 4 nM and caused its degradation it in HeLa cells at 10 μM. This cell permeable PROTAC 
validated the proof-of-concept of small molecule PROTACs. 
 
Figure 11. JQ1- idasanutlin PROTAC A1874 
 
 
Recently, Crews et al. developed a nutlin-based PROTAC A1874 which degraded the 
oncoprotein bromodomain-containing protein 4 (BRD4) at nanomolar concentration69. A1874 
has been shown to not only be able to induce the degradation of target protein, but also 
stabilized p53 by the idasanutlin motif, conferring a MDM2-recruiting PROTAC the ability to 
eliminate the oncogene and activate the tumor suppressor simultaneously. This indicates the 
potential of nutlin-based PROTACs against certain cancers in anticancer therapie due to its 
bifunctional mechanism. 
 
1.6.3.2 Recruiting E3 ligases clAP1 
 
Figure 12. ATRA-MeBS PROTAC  
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In 2010, Itoh et al. reported PROTACs that linked all-trans retinoic acid (ATRA), an endogenous 
ligand of CRABP1 and CRABP2, to methyl bestatin (MeBS) by PEG linkers of different lengths70. 
CRABP1 and -2 have been related to Alzheimer’s disease and some cancers. The MeBS binds to 
the BIR3 domain of the E3 ligase Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and thus 
facilitates ubiquitination and degradation. The MeBS-based PROTACs were confirmed to induce 
down-regulation of CRABPs with low micromolar to submicromolar potency in vitro. However, 
it also led the undesired self-degradation of cIAP1, resulting in the unsustainable down-
regulation of the target protein. In later work, this unwanted self-degradation was overcome by 
a replacement of the ester bond with an amide bond in the linker to afford the PROTAC, which 
specifically degrade CRABP271.  
 
1.6.3.3 Recruiting E3 ligases CRBN 
 
Figure 13. JQ1- pomalidomide PROTAC  
 
Although the small-molecule PROTACs based on MDM2 and cIAP1 E3 ligases are capable of 
inducing the proteasomal degradation of numerous proteins, these PROTACs were found to be 
active only in the double-digit-micromolar range. Thus, in terms of potency and target 
selectivity, recruitment of a novel E3 ligase that causes stronger degradation is needed.  
In the past decade, some studies found that thalidomide and its derivatives lenalidomide and 
pomalidomide are able to bind E3 ubiquitin ligase cereblon (CRBN), a component of a cullin–
RING ubiquitin ligase (CRL) complex72, 73. Based on these findings, a new PROTACs series 
coupling the ligand of the oncoprotein BRD4 with pomalidomide to hijack E3 ligase cereblon 
was developed74.  The PROTAC ARV-825, which consists of the BRD4-targeting drug OTX015 
coupled to pomalidomide via a short alkyl linker, caused almost complete BRD4 protein 
degradation at 10 nM within 6 h. 
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1.6.3.4 Recruiting E3 ligases von Hippel–Lindau Protein (VHL) 
Von Hippel-Lindau (VHL) is a tumor suppressor protein that binds Cullin RING E3 ubiquitin 
ligase and subsequently polyubiquitinates hypoxia inducible factor-1α (HIF-1α)75.  Recruiting 
E3 ligase Von Hippel-Lindau (VHL) by its peptidic ligands derived from HIF-1α has been known 
for decades76. To address the adverse pharmaceutical properties of the peptide derivatives, the 
first small molecule ligand for VHL with moderate affinity as well as improved permeability was 
developed by Buckley et al. in 201277. The hydroxyproline derivative was rationally designed 
and can bind VHL with IC50 value of 4.1 μM. 
 
Figure 14. PROTAC_ ERRα 
 
Based on this scaffold, the potent VHL ligand VH032 with nanomolar binding affinity was 
developed by the structure-guided optimization78. Later, VH032 was incorporated into 
PROTACs targeting estrogen-related receptor alpha (ERRα) and receptor-interacting 
serine/threonine-protein kinase 2 (RIPK2)79. The PROTAC_ERRα reduced the expression of 
ERRα with a 100nM DC50 value and a maximum level of degradation of 86% in MCF-7 cells. 
The PROTAC_RIPK2 induced a potent degradation of RIPK2 with a 1.4 nM DC50 value and a 
Dmax of 95% at concentration of 10 nM or higher. The proteasomal degradation was verified by 
the pretreatment of epoxomicin, leading to inhibited protein knockdown. 
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Figure 15. BRD4 targeting PROTAC MZ1 
 
In 2015, Zengerle et al. reported the BRD4 targeting PROTAC MZ1, which tethered the VHL 
recruiting motif VH032 to JQ1, an inhibitor of bromodomain and extra-terminal (BET) 
protein80. In HeLa cells, MZ1 was able to degrade more than 90% of BET family proteins, 
including BRD2, BRD3 and BRD4, at 1 μM concentration. Surprisingly, while JQ1 lacks 
selectivity within the BET protein family, MZ1 showed selectivity for BRD4 over BRD2 and 
BRD3 in the PROTAC induced degradation at low concentrations. Given the fact that no 
preferential binding to the bromodomains of BRD4 with MZ1 was observed, they speculated 
the selective depletion was caused by the preference for polyubiquitination of BRD4 compared 
to its homologous BRD2/3. This difference could either arise from the steric constraints or the 
protein-protein interactions between VHL and BRD proteins.  Two years later, Gadd et al. solved 
the co-crystal structure of BRD4 bromodomain-MZ1-VHL ternary complex to elucidate the 
functional basis of the selective degradation81. This research revealed the PROTAC MZ1 folds 
onto itself and in turn induced extensive protein-protein and protein-ligand interactions within 
the complex, promoting the cooperative ternary complex formation driven by the surface 
complementarity between VHL and the BRD4 bromodomain. The development of MZ1 and its 
analogues provided the proof-of-concept for converting non-selective ligands into selective 
degraders, which is highly desired for the drug discovery. 
 
1.7 Advantages of degradation by PROTACs over inhibition via small molecules 
Although many pharmaceuticals applied so far are small molecules which possess high cell 
membrane permeability and thereby can target intracellular proteins, some inherent 
shortcomings of small molecule drugs due to the inhibitory mechanism limited their application 
and development. The occupancy-based inhibitors act on the target protein by blocking the 
active binding site to deactivate its functions and thus interfere with the downstream regulation 
pathways. However, many proteins are difficult to block with cell permeable small molecules 
via protein-protein interactions, leading to undruggability of over 85% of human proteins based 
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on inhibitory mechanisms. Besides, reduced bioavailability and adverse side effects caused by 
off-target effect, drug resistance due to protein mutation and incomplete inhibition remain 
unresolved issues in drug development. 
 
 
Figure 16. Overview of the shortcomings of small molecule drugs 
 
Compare to the classic small molecular drugs, PROTACs catalyze the intercellular intracellular 
protein degradation driven by UPS, which may require a lower drug concentration in vivo. 
Mechanically, PROTACs eliminate the aberrantly functioning protein rather than to inhibit its 
active site, preventing the remaining subdomains exert their functions via protein-protein 
interactions.  
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2 Aim of the Project 
 
FKBP51 has emerged as a promising new therapeutic target for psychiatric disorders and several 
other diseases82. Although many efforts have been made to enhance the potency, small-
molecule inhibitors of FKBP51 remain limited in scope with respect to their use. This is due to 
the occupancy-driven pharmacology.  
In this research, we envisioned to develop a new class of small-molecule degraders based on 
the emerging PROTAC strategy. In order to obtain potent PROTAC molecules, combinations of 
different target protein ligands, E3 ligase ligands and linkers had to be explored. Therefore, two 
series of PROTACs which employed our FKBPs ligands with high affinities were designed.  
First of all, efficient synthetic procedures for the precursors of ligands and linkers had to be 
established respectively. Second, the protein binding motifs and the linker had to be assembled 
to form bifunctional PROTAC molecules while keeping their binding affinities. Third, the 
abilities to degrade the target protein of the synthesized PROTACs should be well characterized 
by western blotting. This project aimed to develop promising small-molecule degraders for 
further optimization of PROTAC-drugs and investigations of FKBPs. 
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3  Results and Discussion 
3.1 The synthesis of the FKBP51 ligand SAFit2  
 
Figure 17. The structure of SAFit2 and its key intermediate 1. 
 
The selective FKBP51 antagonists SAFit1 and SAFit2 developed by our group provided the first 
pharmacological useful tool to investigate the functions of FKBP5151. Compare to SAFit1, SAFit2 
has a better application in pharmacological studies in vivo due to the increased brain 
permeability, while keeping the high affinity and selectivity for FKBP51. However, in 
comparison to the high request for SAFit2 by our cooperators, the producibility was limited due 
to the availability of key intermediate 1. To fulfill the demand for SAFit2, a new synthesis 
procedure for 1 should be established. 
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3.1.1 Retrosynthetic analysis and strategy of SAFit2 
 
Scheme 1. Retrosynthesis of SAFit2 
 
The retrosynthesis of the SAFit2 is outlined in Scheme 1.   
Our synthetic strategy towards SAFit2 was derived from our previous work51, 83. The SAFit2 
molecule can be divided into two parts: the morpholine "top group" 1 and the corresponding 
trimethoxyphenyl "bottom group" 6. It was clear that the target molecule SAFit2 could be 
accessible from coupling pipecolate between top group 1 and bottom group 6. The top group 1 
was envisioned to be derived from 3 through sequential O-alkylation of 2-morpholinoethyl 
halide and asymmetric reduction of carbonyl. Compound 3 was expected to be obtained by a 
Claisen-Schmidt condensation between aldehyde 4 and ketone 5 followed by a selective double 
bond reduction84. The bottom group 6 was expected to be carried out by the asymmetric 
alkylation of 8 with Evans auxiliary to obtain the desired configuration85. 
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3.1.2 Synthesis of the top group 
 
Scheme 2: Synthesis of the SAFit top group 1 and the precursor 2. (a) KOH, H2O/EtOH, 0°C 
 RT, overnight. (b) H2, Lindlar catalyst, 35 bar, MeOH, 7d, 63% for two steps. (c) 2-
Morpholinoethyl chloride hydrochloride, K2CO3, acetonitrile, RT, overnight, 96% (d) H2, 
RuCl2[(S)-xylbinap][(S)-daipen], isopropanol, 35-40 bar, RT, 3d, 86%, ee ≥ 99%. (e) (S)-N-
Fmoc-piperidine-2-carboxylic acid, EDC, DMAP, DCM, overnight, RT, 97% (f) 4-
Methylpiperidine, DCM, RT, overnight, 73% 
 
The precursor 2 was prepared via a six-step synthetic route as presented in Scheme 2. 
The synthesis commenced with the Claisen-Schmidt condensation of commercially available 
veratraldehyde (3,4-dimethoxybenzaldehyde) and 3-hydroxyacetophenone in presence of 
potassium hydroxide. The reaction yielded the crude product 9 on large scale (~150 g) which 
could be used in the next step without further purification. 
The chemoselective reduction of the C=C double bond of α, β-unsaturated ketone 9 was carried 
out in a high pressure autoclave catalyzed by Lindlar catalyst in MeOH. The product could be 
purified in large scale by recrystallization from MeOH affording 3 in up to 63% yield. The free 
aromatic alcohol of 3 was subsequently alkylated with 2-morpholinoethyl chloride 
hydrochloride, a very cheap and commercially available chemical, under mild condition with 
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potassium carbonate in acetonitrile at room temperature to afford 10 with high yield of 96% 
by recrystallization. The chiral alcohol 1 was obtained by the asymmetric hydrogenation using 
RuCl2[(S)-xylbinap][(S)-daipen] at 35-40 bar hydrogen86. Compared to the catalyst previously 
used in our group, the Si-face selective asymmetric reduction yielded the top group 1 with a 
higher ee value of >99%. Esterification of the chiral alcohol 1 with commercially available N-
Fmoc-L-pipecolinic acid followed by deprotection gave the desired precursor 2 smoothly. 
 
3.1.3 Synthesis of the bottom group 
 
Scheme 3: Synthesis of the SAFit bottom group 6. (a) Pivaloyl chloride, DIPEA, DCM, 0°C  
RT, 2h. (b) (S)-(+)-4-Phenyl-2-oxazolidinone, n-BuLi, THF, -78°C  RT, overnight, 64% for 
two steps. (c) Bromocyclohexene, NaHMDS, THF, -78°C  4°C, overnight, 36%.  (d) H2, Pd/C, 
MeOH, RT, overnight, 99%. (e) LiOH, H2O2, THF/H2O, 0°C  RT, overnight, 80%. 
 
The bottom group 6 was prepared via a five-step synthetic route as presented in Scheme 3. To 
introduce the cyclohexyl group at Cα with the desired configuration, Evan's chiral auxiliary was 
reacted with the activated trimethoxyphenyl acetic acid 12 to form the imide 7. The Cα carbon 
of 7 was then deprotonated by NaHMDS and subsequently alkylated by bromocyclohexene to 
give 13 as a mixture of four diastereomers. 
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Scheme 4: The separation of diastereomers. 
 
Fortunately, the mixed fraction of the (S)-cyclohexenyl products 13a and 13b could be 
separated completely from the mixture with a moderate yield of 36%. The mixture of the two 
diastereomers 13a/13b was inconsequential due to the disappearance of the chiral center at 
Cβ in the following double bond reduction. The hydrogenation of cyclohexenyl group in H2 with 
Pd/C gave 14 with a diastereomeric excess of >99%. Finally, the oxazolidinone chiral auxiliary 
was cleaved by H2O2 under basic condition to regenerate the carboxylic group. 
 
 
Scheme 5: The cleavage of oxazolidinone chiral auxiliary. 
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3.1.4 Synthesis of SAFit2 
 
Scheme 6: Synthesis of SAFit2 (a) HATU, DIPEA, DCM/DMF = 2/1, RT, 16h, 80%. 
 
Eventually, the coupling between 2 and bottom group 6 with HATU gave the desired SAFit2 in 
80% yield. By our procedure we established for the synthesis of key intermediate 1, a larger 
scale of SAFit2 can be obtained rapidly and economically, which enabled pharmacological 
studies of FKBP5187, 88. With the SAFit2 we synthesized, the research carried out by Balsevich 
et al. has shown that chronic treatment with SAFit2 has the same effects of FKBP51 deletion, 
including weight regulation and glucose tolerance. In a shorter term of treatment, glucose 
tolerance was remarkably improved. In this research, a substrate of AKT2 which mediates 
glucose uptake was identified mechanistically as a new association between FKBP51 and AS160.  
Balsevich et al. proposed that FKBP51 is involved in the mediation between stress and T2D 
(type 2 diabetes), indicating a potential target for therapeutic approaches. 
 
3.2 Design of SAFit based PROTACs 
In order to degrade FKBP51 specifically, we use the SAFit motif as the protein of interest (POI) 
ligand of our PROTACs. Based on the co-crystal structure of the FKBP51-FK1 domain complexed 
with the SAFit analogue iFit4 (PDB ID: 4TW751), the methoxy groups and the morpholyl group 
on the aromatic rings of the top group are solvent exposed and are not involved in direct 
interactions with the binding pocket, making them suitable sites for tethering to E3 ubiquitin 
without impairing affinity to FKBP51. Replacement of alkyl groups with a propargyl group 
allows an easy conjugation of SAFit ligand with a polyethylene glycol (PEG) linker via click 
reaction. 
 
 24 
 
 
Figure 18. Exemplary co-crystal structure to guide the linker attachment for PROTACs. The exit 
vectors for linking are indicated by the arrows. (PDB ID: 4TW7) 
 
Among numerous E3 ligases, VHL and CRBN are the two most popular E3 ligases being utilized 
by present PROTACs to mediate ubiquitination and subsequent protein degradation via the 
proteasome89, 90. As a result, various potent ligands of VHL and CRBN have been studied and 
developed78, 91 92, 93. VH032, a potent and specific VHL ligand, and pomalidomide, a 
commercially available thalidomide analogue, which can recruit CRBN, where chosen to be 
conjugated to our SAFit motif via a linker respectively. 
 
Figure 19. Structures of SAFit-based PROTACs. 
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The linker of PROTACs connects the E3 ligase recognition motif and the small molecule ligand 
for the target protein. The length and configuration of the linker can impact the efficiency of a 
PROTAC to degrade a target protein94. An appropriate linker is usually crucial for inducing an 
optimal protein-protein interaction between a protein of interest and an E3-E2-ubiquitin 
complex to promote ubiquitination of target protein resulting in efficient proteasomal 
degradation. 
 
Figure 20. The proposed influence of a PROTAC linker in protein-protein interaction (PDB ID: 
4TW7, 4W9H). 
 
So far, due to the difficulty to predict the optimal length of the linker of a PROTAC, most of 
current PROTACs were developed by selecting linker with lengths from 12 to over 20 carbon 
randomly77, 95-97. Thus, to explore the influence of the distance between protein ligand and E3 
recruiting motif, we chose polyethylene glycol (PEG) containing different numbers of repeat 
units to tether the other two moieties. 
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3.2.1 Synthesis of SAFit based PROTACs 
 
Scheme 7: Disconnection of SAFit-based PROTAC structure (only the VHL analogue is shown). 
 
The SAFit-based PROTAC could be deconstructed to three parts: SAFit analogue (FKBP ligand), 
azido acid (PEG linker) and VH032 or pomalidomide (E3 ligase ligand).  
 
3.2.2 FKBP ligand 
3.2.2.1 Retrosynthetic analysis and strategy 
 
Scheme 8: Retrosynthesis of the SAFit analogue 16. 
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The retrosynthesis of the SAFit analogue 16 is outlined in Scheme 8.   
Our synthetic strategy towards the SAFit analogue 16 was derived from our previous work51. It 
was clear that the target molecule 16 could be accessible from coupling the top group 19 and 
bottom group 6. The synthesis of 6 was reported by our group. Compound 19 could be obtained 
by esterification of 20 with protected L-pipecolic acid. The unsaturated chiral alcohol 20 was 
envisioned to be derived from 3 through sequential asymmetric reduction of carbonyl and O-
alkylation of phenolic hydroxyl group.  
 
3.2.2.2 Synthesis of the SAFit analogue 16 
The free aromatic alcohol of 3 was subsequently alkylated with propargyl bromide under mild 
condition with potassium carbonate in acetone at room temperature to afford 21.  
Due to the poor selectivity of carbonyl group and alkynyl group in catalytic hydrogenation, 21 
was then subjected to (R)-stereoselective Corey-Bakshi-Shibata reduction of the carbonyl group 
with borane at -40°C98, 99. 20 was obtained with enantiomeric excess of 94%. Higher reaction 
temperature (-15°C) decrease the ee% of product, while no conversion was observed at a lower 
temperature (-78°C). 
Esterification of the chiral alcohol with commercially available N-Fmoc-L-pipecolinic acid 
followed by deprotection gave the desired O-propargyl top group 19. The desired product could 
be obtained by coupling 19 and bottom group 6 with HATU. 
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Scheme 9: Synthesis of the SAFit analogue 16. (a) Propargyl bromide, K2CO3, acetone, RT, 
overnight, 90%; (b) (S)-(−)-2-Methyl-CBS-oxazaborolidine, BH3-THF, THF, -40°C, 5h, quant., 
ee = 94%; (c) (S)-N-Fmoc-piperidine-2-carboxylic acid, EDC, DMAP, DCM, overnight, RT, 86%; 
(d) 4-Methylpiperidine, DCM, RT, overnight, 73%; (e) 6, HATU, DIPEA, DCM/DMF, RT, 
overnight, 67%. 
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3.2.2.3 Synthesis of the SAFit analogues 31a and 31b. 
 
Scheme 10: Synthesis of the SAFit analogues 31a and 31b. (a)KOH, H2O/EtOH, 10°C  50°C, 
overnight, 39-63%; (b) Zn, NH4OAc, H2O/EtOH, RT, 64%; (c) H2, RuCl2[(S)-dm-
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segphos®][(S)-daipen],  K2CO3, i-PrOH, 10 bar, RT, 3d, 94-99%; (d) propargyl bromide, 
K2CO3, acetone, RT, overnight, 89-93%; (e) (S)-N-Fmoc-piperidine-2-carboxylic acid, EDC, 
DMAP, DCM, overnight, RT, 95-96%; (f) 4-methylpiperidine, DCM,  RT, overnight, 89-96%; (g) 
6, HATU, DIPEA, DCM/DMF, RT, overnight, 65-67%. 
 
The students Christian Walz and Michael Walz contributed to these experiments.  
Similar to the synthesis described above, the first step was the coupling of commercially 
available vanillin 23a/isovanillin 23b and 3-methoxyacetophenone via Claisen-Schmidt 
condensation in KOH/EtOH. 
However, due to the deprotonation of vanillin in alkaline condition, the reaction rate decreased 
and could not be completed. The mesomeric effect increases the electron density of the carbon 
of the aldehyde, which makes the nucleophilic attack of 23 more difficult. Therefore, a higher 
temperature (50°C) and increased KOH concentration were applied to complete the reaction.  
Instead of high pressure hydrogenation, the selective reduction of the conjugated double bond 
was carried out in a Zn/NH4OAc system to give 26, which was then subjected to asymmetric 
hydrogenation catalyzed by the low-cost catalyst RuCl2[(S)-dm-segphos®][(S)-daipen] under 
a relatively low pressure (10 bar)100.  
Similar to the procedure as described above, the phenolic hydroxyl group was alkylated with 
propargyl bromide followed by esterification and deprotection to afford the key intermediate 
30. Coupling reaction between 30 and bottom group with HATU gave the desired product 31. 
 
 
3.2.3 E3 ligase ligand  
3.2.3.1 Retrosynthetic analysis and strategy 
The retrosynthesis of the VH032 is outlined in Scheme 11.   
The synthesis of the dipeptide-based VHL ligand 18 was carried out by peptide synthesis with 
Boc-protected L-hydroxyproline and L-tert-leucine starting from 34. 34 was obtained by Heck 
cross-coupling between 35 and 36 follow by nitrile reduction. Under most conditions, 
palladium-catalyzed cross-coupling of thiazoles with aryl halides results in alkylation at the C2-
position of the thiazole. The regioselective cross coupling in the presence of KOAc was 
anticipated to provide the C5-arylated thiazole product101. 
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Scheme 11: Retrosynthesis of the VH032 precursor 1878. 
 
 
 
Scheme 12: Synthesis of the VH032 precursor 38. (a) Pd(OAc)2, KOAc, dimethylacetamide, 
120°C, 19h, 82%; (b) Boc2O, CoCl2, NaBH4, MeOH, 0°C  RT, 58%; (c) TFA/DCM = 1/1; then 
Boc-Hyp-OH, EDC, HOBt, DIPEA, DMF, 0°C  RT, 68%; (d) TFA/DCM = 1/1; then Boc-Tle-
OH, EDC, HOBt, DIPEA, DMF, 0°C  RT, 70%. 
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3.2.3.2 Synthesis 
The first step was a Heck reaction of commercially available 4-methylthiazole and 4-
bromobenzonitrile in the presence of palladium acetate affording 34 in 81% yield. 
 
 
Attempts to reduce the nitrile with NaBH4 in the presence of CoCl2 at 0°C gave amine 33a, 
albeit in a low yield (less than 30%) of due to the difficult separation of the product caused by 
the free primary amine group.  In order to improve the yield and stability of the reduction 
product, in situ N-Boc protection was applied to give 33102. 
After in situ deprotection, 33 was further coupled successively with N-protected L-
hydroxyproline and N-protected L-tert-leucine to give the desired VHL ligand 38 protected with 
Boc. 
 
3.2.4 Linker 
3.2.4.1 Retrosynthetic analysis and strategy 
 
Scheme 13: Retrosynthesis of the linkers103. 
The retrosynthesis of the azido acids is outlined in Scheme 13.  Compound 17 could be carried 
out from 40 via substitution with tert-butyl bromoacetate followed by deprotection. 40 could 
be obtained by monotosylation of diol followed by substitution of tosyl by sodium azide. 
 
3.2.4.2 Synthesis 
The azido acids were prepared by a 4-step synthetic route as shown in Scheme 14. The synthesis 
of compound 41 was carried out by mono tosylation of commercially available diols mediated 
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by silver(I) oxide104. The azido group was simply introduced by nucleophilic substitution with 
sodium azide in DMF at room temperature. 40 was alkylated with tert-butyl bromoacetate and 
further deprotected to give azido acids 17 in different lengths. The low yield of the deprotection 
indicated that a lower reaction temperature is required.  
 
 
Scheme 14: Synthesis of the linkers 17. (a) 1 eq. TsCl, Ag2O, KI, DCM, 0°C, 30min, 70-78%; 
(b) NaN3, DMF, RT, overnight, 86-95%; (c) tert-butyl bromoacetate, tert-BuOK, tert-BuOH, RT, 
overnight, 63-90%; (d) TFA/DCM, RT, 30min, 20-51%. 
 
3.2.5 Assembly of PROTAC molecules 
Considering the variety of the FKBP51 ligands sought to be tested as PROTACs, the azido acid 
and E3 ligase ligand should be assembled first. The Boc group was removed via in situ 
deprotection by TFA to afford VH032, which was then coupled to azido acid 17 with HATU. 
The resulting azido-PEG-VH032 43 was conjugated with the SAFit analogues 16 or 31a/b by a 
copper-catalyzed click reaction105 to give the SAFit-based PROTACs MTQ199-203. 
Compare to the aliphatic amine group of VH032, the aromatic amine group of pomalidomide 
exhibits lower reactivity in acylation reactions. Therefore, for the CRBN-based PROTACs, the 
azido-PEG-acid was first activated by oxalyl chloride to form an acid chloride. After activation, 
substoichiometric amount of pomalidomide was added to afford the desired azido-PEG-
pomalidomide 44, which in turn was conjugated to the SAFit analogues. The resultant CRBN-
based PROTACs MTQ204-208 were obtained with good yield.  
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Scheme 15: Synthesis of the VHL-based PROTACs. (a) TFA/DCM = 1/1, RT, 30min; then 17, 
HATU, DIPEA, DCM, RT, overnight, 68-91%; (b) 16 or 31a/b, CuSO4, (+)-Sodium L-ascorbate, 
t-BuOH/H2O/DMSO, RT, overnight,74-89%. (Only shown for 16) 
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Scheme 16: Synthesis of the CRBN-based PROTACs. (a) (COCl)2, DMF, DCM, 0°C to RT, 3h; 
then pomalidomide, DMF, 0°C to RT, overnight, 34-99%; (b) 16 or 31a/b, CuSO4, (+)-Sodium 
L-ascorbate, t-BuOH/H2O/DMSO, RT, overnight, 68-78%. (Only shown for 16) 
 
 
3.2.6 Biochemical characterization 
3.2.6.1 Synthesis of the fluorescent tracer 
 
Scheme 17: Synthesis of the fluorescent tracer MTQ238. (a) TBTA, CuSO4, (+)-Sodium L-
ascorbate, t-BuOH/H2O = 43:1, 37°C, 6h, 23%. 
 
The fluorescent tracer MTQ238 was obtained via the click reaction of bicyclic ligand SP-16f 
and 5-TAMRA fluorophore55.   
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3.2.6.2 Evaluation of binding affinity 
 
  
Nr. 
SAFit 
Attachment 
point 
  
E3-ligase 
Ligand 
 PEG 
linker 
length 
Ki (nM) 
FKBP51FK1 FKBP52FK1 FKBP12 
SAFit151 1 / / 4 ± 0.3 >50000 90 ± 11  
SAFit251 1 / / 6 ± 2 >50000 87 ± 6 
16 1 / (propargyl) 32 ± 7 >3200 563 ± 220 
31a 2 / (propargyl) 70 ± 18 >3200 1867 ± 362  
31b 3 / (propargyl) 149 ± 39 >3200 1701 ± 256 
MTQ199 1 VHL 1 25 ± 6 >3200 408 ± 168 
MTQ200 1 VHL 2 24 ± 7 >3200 677 ± 87 
MTQ201 1 VHL 3 23 ± 7 >3200 436 ± 131 
MTQ202 1 VHL 4 24 ± 8 >3200 532 ± 164 
MTQ203 1 VHL 5 12 ± 3 >3200 814 ± 313 
MTQ204 1 CRBN 1 19 ± 5 >3200 306 ± 161 
MTQ205 1 CRBN 2 16 ± 5 >3200 256 ± 24 
MTQ206 1 CRBN 3 22 ± 6 >3200 206 ± 45 
MTQ207 1 CRBN 4 18 ± 4 >3200 256 ± 66 
MTQ208 1 CRBN 5 5 ± 1 >3200 226 ± 65 
MTQ229 1 VHL 0 36 ± 9 >3200 610 ± 181 
MTQ235 1 CRBN 0 32 ± 12 >3200 563 ± 220 
MTQ328 2 VHL 1 47 ± 19 >3200 409 ± 69 
MTQ329 2 VHL 2 60 ± 16 >3200 584 ± 79 
MTQ330 2 VHL 3 86 ± 26 >3200 410 ± 79 
MTQ331 2 VHL 4 59 ± 22 >3200 368 ± 110 
MTQ332 2 VHL 5 34 ± 10 >3200 455 ± 126 
MTQ333 2 CRBN 1 22 ± 6 >3200 111 ± 48 
MTQ334 2 CRBN 2 21 ± 10 >3200 177 ± 26 
Table 1. Binding affinities of SAFit-based PROTACs for FKBP51, FKBP52 and FKBP12.  The 
FP-assays were performed by Stephanie Merz. 
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Nr. 
SAFit 
Attachment 
point 
  
E3-ligase 
Ligand 
 PEG 
linker 
length 
Ki (nM) 
FKBP51FK1 FKBP52FK1 FKBP12 
MTQ335 2 CRBN 3 18 ± 4 >3200 111 ± 12 
MTQ336 2 CRBN 4 24 ± 6 >3200 81 ± 21 
MTQ337 2 CRBN 5 25 ± 6 >3200 162 ± 47 
MTQ338 3 VHL 1 100 ± 29 >3200 1345 ± 220 
MTQ339 3 VHL 2 59 ± 20 >3200 640 ± 319 
MTQ340 3 VHL 3 54 ± 12 >3200 601 ± 61 
MTQ341 3 VHL 4 50 ± 11 >3200 642 ± 287 
MTQ342 3 VHL 5 36 ± 9 >3200 506 ± 203 
MTQ343 3 CRBN 1 26 ± 9 >3200 1535 ± 382 
MTQ344 3 CRBN 2 26 ± 8 >3200 542 ± 113 
MTQ345 3 CRBN 3 34 ± 12 >3200 430 ± 107 
MTQ346 3 CRBN 4 40 ± 11 >3200 287 ± 49 
MTQ347 3 CRBN 5 30 ± 7 >3200 368 ± 57 
Table 1. (continued) 
 
The binding affinity of synthesized PROTACs including their precursors are assessed by a 
competitive binding fluorescence polarization assay (FP assay)9. A bicyclic FKBP ligand linked 
to a 5-TAMRA fluorophore was used as the tracer MTQ238. The binding affinity was measured 
by the competition ability of ligand with the tracer for FKBPs9, 55.  
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Figure 21: Biochemical characterization of MTQ202. 
 
As shown in table 1, most of the SAFit analogues and their corresponding PROTACs derivatives 
retained the binding ability but partially lose their affinity for both FKBP51 and FKBP12 
compare to the prototype compounds SAFit1 and SAFit2. All of them maintain the high 
selectivity for FKBP51 over FKBP52. The three propargyl SAFit analogues, 16, 31a and 31b, 
exhibited 3 to 13-fold decrease in binding affinity compared to SAFit2 (Ki = 11 nM in the same 
assay). Interestingly, after coupling to the linker and E3 ligase motif, the resulting triazole 
product shows a higher affinity for FKBP51 and FKBP12 compare to its precursor. Conjugation 
on the attachment point 1 gives better affinity than the other two attachment points. Compared 
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to VHL-based PROTACs, CRBN-based PROTACs exhibit higher affinity for both FKBP51 and 
FKBP12. Generally, a longer linker leads to a better binding affinity, indicating a modest steric 
hindrance around the attachment point. 
Among all of the PROTACs, MTQ208 shows the most potent binding affinity with Ki value of 5 
nM which is comparable to SAFit1. 
 
3.3 Bicyclic ligand based PROTACs 
3.3.1 Design of bicyclic ligand-based PROTACs 
Knocking down FKBP51 or FKBP52 by chemical approach specifically remains a topic of interest 
for therapeutic concerns. So far, SAFits are the only known potent inhibitors for FKBP51 with 
high selectivity. Unfortunately, the specific inhibition of FKBP52 by a classic small molecule 
ligand is currently impossible due to lack of a selective ligand for FKBP52 over FKBP51. As 
described before, additional selectivity is achievable by the cooperative interactions within 
target protein-PROTAC-E3 ligase ternary complex. Thus, integrating a non-selective FKBPs 
ligand into a PROTAC may induce the selectivity for a certain FKBP. Therefore, we designed a 
series of PROTACs with [4.3.1] bicyclic FKBPs ligand as the POI recognition motif, expecting to 
turn a non-selective ligand to a selective protein degrader for FKBP51 or FKBP52. 
 
Figure 22: The [4.3.1] bicyclic ligands and the co-crystal structure of SP-16h in complex with 
FKBP51 (PDB ID: 5OBK) 
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The [4.3.1] bicyclic 3,5-dichlorophenylsulfonamides have shown high potency in the 
nanomolar to subnanomolar concentration range against 11 different human and microbial 
FKBPs, including FKBP12,  FKBP12.6, FKBP51 and FKBP5255. Upon analyzing the binding mode 
of bicyclic ligand SP-16h with FKBP51, we found the pyridine substituent on N3 formed a key 
hydrogen bond with Try113, indicating the Cα of the substituent is an ideal attachment point 
for the conjugating to PROTAC molecule due to the similarity between the pyridine group and 
the triazole group obtained via click reaction. To tether the bicyclic scaffold to an E3 ligase 
ligand, a propargyl group is introduced as the substituent on N3 to conjugate to the linker via 
click reaction. As shown in Figure 23, the triazole derivative SP-11v, a bicyclic ligand with high 
similarity to our products resulted from a click reaction and showed moderate to high affinities 
for several FKBPs (Ki FKBP12 = 5 nM, Ki FKBP12.6 = 36 nM, Ki FKBP51 = 1.1 μM, Ki FKBP52 = 0.5 μM). 
In addition, the replacement of the hydrogen at Cα with a (S)- or (R)-methyl group can sterically 
restrict the free rotation of the substituent, leading to a favorable binding conformation of the 
ligand in the active site.  
 
 
 
Figure 23: The PROTACs based on the bicyclic ligands. The similar ligand SP-11v showed high 
affinities for FKBP12/12.6 and moderate affinities for FKBP51/52. 
  
 40 
 
3.3.2 Synthesis of bicyclic compounds 
3.3.2.1 Retrosynthetic analysis and strategy 
 
Scheme 18: Retrosynthesis of the bicyclic ligand precursor 45. 
 
The retrosynthesis of the derivatives 45 is outlined in Scheme 18.  The target molecule 45 could 
be synthesized by N-sulfonylation of 46 with 3,5-dichlorobenzenesulfonyl chloride. The 
formation of the bicyclic moiety of compound 46 was expected to be accessible from hydroxyl 
carbamate 47 and that the ring-closing reaction to be achieved throught the N-acyliminium 
cyclization reported by our group54.  Amide bond formation between 50 and commercially 
available (S)-6-oxo-2-piperidinecarboxylic acid followed by Boc protection of the amide would 
generate 48, which could undergo a selective reduction to give 47. Compound 51 could be 
obtained by metathesis of allyl-TMS with protected allylamine. 
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3.3.2.2 Synthesis 
 
Scheme 19: Synthesis of the key intermediate 45a-c. (a) K2CO3, allyl bromide, DMF, RT, 3 h, 
99%; (b) allyl-TMS, Grubbs I, DCM, 60 °C, 4 h, 66%; (c) NH2NH2, MeOH, 70 °C, 24 h; (d) 
Titanium(IV) isopropoxide, EtOH, -78°C, 5h; then NaBH4, -78°C  RT, 1h, 64-68%; (e) (S)-6-
Oxopiperidine-2-carboxylic acid, HATU, DIPEA, RT, DMF, 2 h; (f) Boc2O, DIPEA, DMAP, DCM, 
RT, overnight, 60% for two steps; (g) DIBAL, THF, −78 °C, 15 min; (h) HF-pyridine, DCM, −78 
°C, 1 h, 50-64% for two steps; (i) 3,5-Dichlorobenzenesulfonyl chloride, DIPEA, MeCN, RT, 
overnight; (j) K2CO3, MeOH, 1.5h, 50-58% for two steps.  
 
On the basis of our previous research work, we developed the synthesis for N-propargyl bicyclic 
compounds54, 55. The synthesis commenced with allylation of phtalimide. The resulting allyl-
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phtalimide, 55, was transformed by metathesis with allylTMS and Grubbs first-generation 
catalyst and subsequently deprotected to afford the amine 57. 
 
 
Scheme 20: Undesired 1,4-Michael addition product. 
 
 
Scheme 21: Synthesis of 59 via promoted reductive amination  
 
Unfortunately, exposure of amine 57 to acetylenic ketone under room temperature resulted in 
rapid formation of the 1,4-Michael addition product 50b.  
Thus, we use titanium(IV) isopropoxide and TMS-protected alkynyl ketone or aldehyde to 
promote the reductive amination of ketone to avoid the undesirable byproduct106. 
The resulting building block 59 was reacted with commercially available (S)-6-oxo-2-
piperidinecarboxylic acid and subsequently Boc-protected to furnish 61, the precursor for the 
key chemoselective reduction and asymmetric N-acyliminium cyclization. The S/R methyl 
diastereomers could be separated by chromatography after Boc protection. The chemoselective 
reduction of 61 gave instable intermediate hydroxyl carbamate 62, which was immediately 
subjected to cyclization by the treatment with hydrofluoric acid in pyridine resulted in bicyclic 
building block 63. Surprisingly, the trimethylsilylacetylenic group survived the HF- pyridine 
treatment. Reaction of 63 with dichlorphenyl sulfonyl chloride followed by deprotection 
furnished the desired N-propargyl bicyclic compound 45.  
Like for the synthesis of SAFit-based PROTACs, the bicyclic PROTACs were obtained by the Cu-
catalyzed click reaction between the propargyl FKBPs ligand and the azido-PEG-E3 ligase 
ligand.  
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Scheme 22: Synthesis of the bicyclic PROTACs. (a) CuSO4, (+)-Sodium L-ascorbate,  
t-BuOH/H2O/DMSO, RT, overnight, 47-97%.  
 
3.3.3 Biochemical characterization 
3.3.3.1 Evaluation of binding affinity 
 
 
 
  
Nr. 
  
R 
  
E3-
ligase 
  
linker  
length 
Ki (nM) 
FKBP51FK1 FKBP52FK1 FKBP12 FKBP12.6 
SP-16h55 / / / 57 ± 5 48 ± 3 1.8 ±0.1 1.9 ± 0.3 
45a H / / 544 ± 95 383 ± 83 36 ± 5 467 ± 41 
45b (S)-Me / / 2157 ± 738 1364 ± 422 150 ± 34 904 ± 73 
45c (R)-Me / / 3312 ± 1436 2923 ± 826 217 ± 31 1657 ± 115 
MTQ498 H VHL 1 80 ± 16 115 ± 29 4.7 ± 0.4 67 ± 5 
MTQ499 H VHL 2 8.8 ± 2.5 11 ± 3 0.1 ± 0.03 0.75 ± 0.2 
MTQ500 H VHL 3 20 ± 5 26 ± 7 0.6 ± 0.1 10 ± 0.8 
MTQ501 H VHL 4 31 ± 5 55 ± 11 1.4 ± 0.2 19 ± 1 
Table 2. Binding affinities of bicyclic PROTACs for FKBP51, FKBP52 and FKBP12.  The FP-
assays were performed by Stephanie Merz and Christian Meyners. 
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Nr. 
  
R 
  
E3-
ligase 
  
linker  
length 
Ki (nM) 
FKBP51FK1 FKBP52FK1 FKBP12 FKBP12.6 
MTQ502 H VHL 5 18 ± 3 29 ± 8 1.6 ± 0.3 16 ± 1 
MTQ503 H CRBN 1 8 ± 1 1.9 ± 0.5 0.2 ± 0.03 0.46 ± 0.1 
MTQ504 H CRBN 2 25 ± 6 43 ± 11 2.1 ± 0.2 17 ± 1.3 
MTQ505 H CRBN 3 17 ± 4 16 ± 5 2.4 ± 0.2 21 ± 2 
MTQ506 H CRBN 4 28 ± 5 30 ± 8 1.5 ± 0.2 19 ± 2 
MTQ507 H CRBN 5 12 ± 2 60 ± 12 0.7 ± 0.1 10 ± 1.2 
MTQ508 (S)-Me VHL 1 5.3 ± 1.5 6.3 ± 2 0.6 ± 0.1 2.5 ± 0.6 
MTQ509 (S)-Me VHL 2 0.9 ± 0.2 0.23 ± 0.5 0.01 ± 0.005 0.05 ± 0 
MTQ510 (S)-Me VHL 3 1.2 ± 0.3 2.9 ± 1.2 0.2 ± 0.02 1.9 ± 0.3 
MTQ511 (S)-Me VHL 4 1.1 ± 0.4 2.2 ± 0.9 0.1 ± 0.03 1.5 ± 0.3 
MTQ512 (S)-Me VHL 5 1.9 ± 0.5 1.7 ± 0.6 0.2 ± 0.02 1.7 ± 0.3 
MTQ513 (S)-Me CRBN 1 2.3 ± 0.4 0.7 ± 0.3 0.2 ± 0.02 0.41 ± 0.2 
MTQ514 (S)-Me CRBN 2 4.4 ± 1.2 5.7 ± 1.7 0.4 ± 0.1 2.4 ± 0.4 
MTQ515 (S)-Me CRBN 3 3.2 ± 0.9 5.0 ± 1.2 0.5 ± 0.1 4.8 ± 0.5 
MTQ516 (S)-Me CRBN 4 4.2 ± 0.8 8.4 ± 2.3 0.5 ± 0.1 3.7 ± 0.5 
MTQ517 (S)-Me CRBN 5 2.1 ± 0.4 4.9 ± 1.1 0.4 ± 0.05 1.5 ± 0.3 
MTQ518 (R)-Me VHL 1 676 ± 275 1619 ± 639 95 ± 8 678 ± 75 
MTQ519 (R)-Me VHL 2 745 ± 108 1726 ± 274 131 ± 13 454 ± 39 
MTQ520 (R)-Me VHL 3 355 ± 58 1513 ± 314 95 ± 9 385 ± 34 
MTQ521 (R)-Me VHL 4 317 ± 34 772 ± 174 67 ± 10 279 ± 25 
MTQ522 (R)-Me VHL 5 357 ± 85 609 ± 133 54 ± 5 294 ± 29 
MTQ523 (R)-Me CRBN 1 506 ± 313 1333 ± 214 84 ± 9 533 ± 57 
MTQ524 (R)-Me CRBN 2 387 ± 74 539 ± 93 62 ± 5 515 ± 40 
MTQ525 (R)-Me CRBN 3 590 ± 387 1685 ± 284 108 ± 14 675 ± 76 
MTQ526 (R)-Me CRBN 4 357 ± 48 817 ± 307 91 ± 10 360 ± 31 
MTQ527 (R)-Me CRBN 5 537 ± 68 783 ± 240 158 ± 13 622 ± 51 
Table 2. (continued) 
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Figure 24: Biochemical characterization of MTQ509. 
 
Compared to its pyridine analogue SP-16h55 (Ki FKBP51 = 57 ± 5 nM, Ki FKBP52 = 48 ± 3 nM, Ki 
FKBP12 = 1.8 ± 0.1 nM), the N-propargyl bicyclic compounds 45a, 45b and 45c showed quite 
weak binding affinity in the low micromolar to high nanomolar range for FKBPs. Surprisingly, 
upon conjugating with azido analogues by click reaction, most of the resulting PROTACs resume 
the potent affinities for all of FKBPs tested, indicating a heterocycle is essential for high affinity 
binding. With the (S)-methyl group as R substituent, the PROTACs MTQ508-517 showed 
outstanding affinities for all of the tested FKBPs in the low nanomolar range to subnanomolar 
range. For the PROTAC series without methyl substituent, compounds MTQ498-507 displayed 
high binding affinities, which are comparable to the pyridine bicyclic analogue. Where R = (R)-
methyl group, the PROTACs MTQ518-527 showed submicromolar affinities for FKBP51/52 and 
moderate affinities for FKBP12, indicating an R-configuration substituent is unfavorable.  For 
the VHL-based PROTACs, the molecule with the shortest linker always shows the worst binding 
affinity compare to the other analogues. When the linker has two PEG units, the PROTAC 
exhibits the best affinity in the series. Then, with the extension of the linker length, the affinities 
are deceased gradually.  For the CRBN-based PROTACs, the shortest linker affords the most 
potent compound.  
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3.4 Evaluation of degradation of FKBP51 
 
Figure 25. Western blotting showed the degradation of FKBP51 by the treatment of 
MTQ202 in HEK293T cells.  
 
To profile the degradation activity of our PROTACs, the levels of FKBP51 in several cell lines 
were monitored by Western blot analysis using GAPDH as the control. Andreas Hähle, Yannick 
Kristiansen and Thomas Geiger contributed to these experiments.  
After 24h incubation time, degradation of FKBP51 in HEK293T cell line was observed with 
MTQ202, the VHL-based PROTAC with 4-PEG-linker and attachment point 1, in the 
concentration range of 63 to 2000 nM, while no obvious degradation of FKBP51 was observed 
with any other PROTACs tested.  
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Figure 26. Western blotting has not shown clear evidence of the degradation of FKBP51 
by the treatment of MTQ201 in HEK293T cells.  
 
 
 
Figure 27. Degradation of FKBP51 has not been observed by the treatment of other SAFit-
based PROTACs with various attachment positions and linker lengths in HEK293T cells.  
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Figure 28. MTQ202 was able to induce the degradation of FKBP51 in Hela cells.   
 
Degradation of FKBP51 with MTQ202 was also observed in Hela cells. As shown above, the 
level of FKBP51 starts to decrease with 125 nM MTQ202. The re-appearance of protein levels 
upon treatment of high concentrations of MTQ202 was likely due to the “hook effect", where 
the high concentration of the PROTAC consumes E3 ligase and POI to form PROTAC-E3 and 
PROTAC-POI binary complexes, thereby disrupting the desired E3-PROTAC-POI ternary 
complexes79.  
 
 
Figure 29. The "hook effect" of PROTACs. 
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Figure 30. No obvious degradation of FKBP52 was shown in western blotting by the 
treatment of MTQ202 in HEK293 cells.   
 
As expected, MTQ202 was not able to reduce the concentraction of FKBP52 due to the lack of 
affinity for FKBP52.  
Among all the PROTACs I synthesized, the degradation of FKBPs was only observed with the 
SAFit-based PROTAC MTQ202. Either one PEG unit shorter (MTQ201) or longer (MTQ203) 
in the PROTAC with same POI ligand and E3 ligase ligand did not show a slight effect on the 
degradation. This result indicated the impact of the linker length for the ability of a PROTAC. 
A linker, which is too short might lead to a preference of forming dimer complex (PROTAC-
protein or PROTAC-E3), which in turn prevents the formation of protein-PROTAC-E3 ligase 
ternary complex. Inversely, a longer which is too long would confer excess steric freedom, 
leading to the failure of stabilizing protein-protein interaction.  
 
  
Figure 31. Bicyclic-based PROTACs with high affinities for FKBP51 have not exhibited 
abilities to degrade FKBP51 in HEK293T cells.  
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Although parts of the bicyclic ligand-based PROTACs possess potent affinity for FKBPs, none of 
them showed activity to promote the protein degradation in western blotting so far, indicating 
binding affinity is not the only influence factor of PROTACs. 
 
 
Figure 32. FKBP52 was not degraded in HEK293 cells by the treatment of bicyclic-based 
PROTACs with affinities for FKBP52. 
 
 
3.5 Improvement of PROTACs by conformational restriction 
3.5.1 Design 
Among the PROTACs I made, SAFit-based PROTAC MTQ202 shows a moderate ability to induce 
degradation of our target protein FKBP51. Although it provides a proof of principle for a 
chemical knockout strategy, our PROTACs had to become more potent to provide an efficient 
tool for degrading FKBP51. 
In an effort to enhance the degrading capability of MTQ202, we designed a series of 
conformationally restricted linker by methylation. By the addition of a methyl group to a carbon 
on the linker of MTQ202, the conformations the linker can adopt will be restricted due to the 
rotational preferences. The resulting spatial constraints can induce a preferred conformation of 
protein-protein interaction between E3-E2-ubiquitin complex and FKBP51, leading to a more 
efficient degradation of the target protein107.  
 
3.5.2 Retrosynthetic analysis and strategy 
 
 
Figure 33. Potential positions for modification. 
 
As shown above, 9 carbon positions on the PEG chain of the MTQ202-linker are possible to be 
modified by a methyl group substituent, which can be allocated into two groups: the methyl 
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group locates on the odd number of carbon (X = 1, 3, 5, 7, 9) or the even number of carbon (X 
= 2, 4, 6, 8). For each position, two configurations ((S)- or (R)-) of methyl group are possible. 
 
 
Figure 34. Potential positions for methylation. 
 
 
3.5.2.1 Odd numbered methyl linker 
Scheme 23: Retrosynthesis of the odd-numbered methyl linkers 65.  
 
The retrosynthesis of the odd-numbered methyl linkers 65 is outlined in Scheme 23. The target 
azido acid 65 can be obtained by the oxidation of azido alcohol 66. According to our synthesis 
route of the linkers, the azido group can be introduced by the nucleophile substitution of a tosyl 
group, which can be obtained by the tosylation of a hydroxyl group. This indicates the key 
intermediate is a diol, which require regioselectivity in the reactions. To synthesize PEG linkers 
with methyl groups at different positions systematically, we considered to employ a solid phase 
synthetic approach to extend the linker from one end to the other by adding building blocks. 
Thus, the hydroxyl group of 66, which will be oxidized to carboxylic acid is inactivated by 
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attaching to the solid support. The extension of the linker chain can be achieved by repeated 
substitution reactions of an electrophile containing a protected terminal hydroxyl group, 
followed by deprotection to expose the new hydroxyl group at the growing end.  
 
3.5.2.2 Even numbered methyl linker 
 
 
 Scheme 24: retrosynthesis of the even-numbered methyl linker 77. 
 
Similar to the synthesis route above, the even-numbered methyl linker can be obtained by the 
solid-phase synthesis but starts at another end. The hydroxyl group which will be tosylated 
should be attached to the resin to allow the introduction of chiral methyl group and the 
carboxylic acid group.  
 
3.5.3 Optimization of synthesis conditions in liquid phase 
Although PEGs are a widely utilized polymer in drug development and nanotechnology due to 
its biocompatibility, an efficient PEG-chain elongation remains a challenge due to the low yield 
of the available ether synthesis methods.   
Regarding the difficulties of monitoring the reaction progress and overall yield, the synthesis 
route and conditions were firstly optimized in liquid phase. Diethylene glycol monoethyl ether 
(84), a 2-unit PEG chain with one end capped by ethyl, was employed as the substitute for the 
intermediate bound to resin.  
First, we investigated the feasibility of using the cyclic sulfate as the suitable building block to 
elongate the PEG chain. Cyclic sulfates have been widely utilized in the monofunctionalization 
of diols, where the sulfate group acts as both the leaving group during the nucleophilic reaction 
and the protection group of hydroxyl group after the ring-opening reaction. Furthermore, cyclic 
sulfates can be prepared conveniently by the cyclization of low-cost polyethylene glycol with 
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thionyl chloride in the presence of TEA and DMAP followed by the oxidation to corresponding 
sulfate108.  
 
 
Scheme 25: The ring-opening reaction of the cyclic sulfate 85 or 87 with diethylene glycol 
monoethyl ether 84. (a) SOCl2, DIPEA, DMAP, DCM, 0°C, 2h, 68%; (b) NaIO4, RuCl3, 
DCM/MeCN/H2O = 2/2/3, 0°C, 1h, 92%; (c) NaH, THF, 0°C, 6h; then 20% H2SO4/ dioxane = 
1/2, 60°C, overnight. 85% for 86, 92% for 88. 
 
Here, we employed the smallest and commercially available cyclic sulfates, 1,3,2-dioxathiolane 
2,2-dioxide 85, and the 14-membered cyclic sulfates 87 (with 4 PEG units) as the electrophiles 
to explore the utility. As shown above, after the substitution with diethylene glycol monoethyl 
ether 84 and the subsequent deprotection in acidic condition, the extended PEG chains were 
obtained with the yield of 85% and 92%, respectively. This shows the cyclic sulfate is an ideal 
building block to extend PEG chain into different lengths flexibly with high yield. 
In order to introduce the asymmetric methyl group into our linker, we prepared several 
protected alcohols with different leaving groups.  
 
 
 
Scheme 26: Side reactions of ether synthesis with TBDPS- or TBDMS-protected alcohols. 
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First, we tried to conjugate the diethylene glycol monoethyl ether with the TBDPS-protected 
alcohol 89 under the basic condition. Unfortunately, the undesired side product 91 was 
detected by LC-MS. A replacement of TBDPS group with TBDMS group did not prevent the side 
reaction.  
After replacing the silyl protecting groups with the 4-methoxybenzyl group, the undesired side 
product was no longer detected by LC-MS, indicating a benzyl derivative is more suitable in this 
substitution reaction.  To optimize the reaction condition, a series of 4-methoxybenzyl protected 
alcohols were synthesized and reacted with 84 at different conditions. 
 
  
 
Scheme 27: The synthesis of 4-methoxybenzyl protected alcohols 99-101. (a) NaH, Cl3CCN, 
Et2O 0°C   RT, 1.5h; (b) (-)-Ethyl L-lactate, D-(+)-10-camphorsulfonic acid, DCM, RT, 
overnight, 86% for 2 steps; (c) LiAlH4, EtO2, 0°C  RT, 87%; (d) I2, PPh3, imidazole, DCM, 
0°CRT, 1d, 73%; (e) CBr4, PPh3, DCM, 0°C  RT, 1d, 70%; (f) p-TsCl, TEA, DMAP, DCM, 0°C 
 RT, 1d, 71%. 
 
 
As shown below, the best result was obtained in the presence of t-BuOK while a tosyl group was 
employed as the leaving group.  
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Entry -X 
(3eq.) 
base 
(2eq.) 
% product 
(determined by LC, 
@220nm) 
1 I NaH 3 
2 I tBuOK 1 
3 I KOH 4 
4 I TEA no reaction 
5 I DIPEA no reaction 
6 I DBU no reaction 
7 Br NaH 7 
8 Br tBuOK 11 
9 Br KOH 12 
10 Br TEA no reaction 
11 Br DIPEA no reaction 
12 Br DBU no reaction 
13 OTs NaH 11 
14 OTs tBuOK 19 
15 OTs KOH 16 
16 OTs TEA no reaction 
17 OTs DIPEA no reaction 
18 OTs DBU no reaction 
Scheme 28: The screening of leaving groups and bases. General conditions: 1 eq. 2-(2-
ethoxyethoxy)ethanol + 3 eq. R-X + 2 eq. base, THF, 60°C, 16h.  
 
 
 
Using t-BuOK as the base, the reaction was performed in several different solvent systems. 
Among all of the solvents tested, dioxane gave the highest yield determined by LC. 
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Entry solvent % product 
(determined by LC, 
@220nm 
1 Dioxane 17 
2 DMF 14 
3 DMSO 13 
4 NMP 13 
5 Toluene 10 
Scheme 29: The screening of solvents. General conditions: 1 eq. 2-(2-ethoxyethoxy)ethanol + 
3 eq. R-OTs + 2 eq. tBuOK,  60°C, 16h 
 
 
 
In order to prevent the cleavage of the product from resin during the deprotection, we employed 
a DMTr group, which has less stability to acids, to protect the hydroxyl group in the nucleophile 
substitution. The reaction under the optimized condition gave the moderate yield (49%) of 
desired product. 
 
 
Scheme 30: The synthesis of DMTr protected alcohol 103. (a) Pyridine, RT, 16h, 95%; (b) 
LiAlH4, THF, 0°C  RT, 1.5h, 98%; (c) p-TsCl, TEA, DMAP, DCM, 0°C  RT, overnight, 67%. 
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3.5.4 Synthesis of the linkers by solid support 
 
 
Scheme 31: The synthesis of azido acid 114. (a) tBuOK, THF, 0°C-RT, overnight; then 
TsOH/H2O/Dioxane, 60°C, 4h, THF; (b) 103, tBuOK, dioxane, 60°C, 2 times; (c) 1% TFA in 
DCM, RT, 4 times; (d) 1,3,2-dioxathiolane 2,2-dioxide, t-BuOK, THF, 0°C  RT, overnight; then 
TsOH/H2O/Dioxane, 60°C, 4h; (e) TsCl, TEA, DMAP 0°C  RT; (f) NaN3, DMF, 60°C, 4h; (g) 
10% TFA in DCM, 5 times; (h) Jones reagent, acetone, 0°C, 4h. 7% for 9 steps. 
 
The Wang resin was chosen to be used in the solid support synthesis because it has moderate 
acid-tolerance and affords a free hydroxyl group after cleavage, which will be oxidized to the 
carboxyl group of our azido-acid linker.  
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Figure 35. Mass spectrometry data of the product cleaved from 107 with 50% TFA in DCM.  
 
 
The synthesis started with the nucleophilic ring-opening reactions of the macrocyclic sulfate 
106 with deprotonated Wang resin. After the hydrolysis, a PEG chain attached on solid support 
with 3 units was obtained. The verification of the reaction product was performed by mass 
spectrometry to check the presence of desired product. After removing solvent of reaction, a 
small part of the washed resin was taken to a vial with 1 ml 50% TFA solution in DCM. The vial 
was shaked for a few minutes to cleave the product from the resin. The measurement result of 
the concentrated supernatant by mass spectrometry showed that the nucleophilic reaction and 
the ring-opening reaction were successfully achieved. 
 
 
Figure 36. Mass spectrometry data of the product cleaved from 108 with 50% TFA in DCM.  
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Figure 37. Mass spectrometry data of the product cleaved from 109 with 50% TFA in DCM.  
 
The chiral methyl group was introduced by the nucleophilic substitution of 103 with the 
deprotonated 107.  Instead of the protected product 108-clv, the deprotected alcohol 109-clv 
was detected, while an intensive signal of dimethoxytrityl cation was shown. This indicated the 
instability of DMTr group under acidic condition.   
The deprotection of DMTr group of 100 was conducted in diluted acidic solution (1% TFA in 
DCM) which did not cause obvious cleavage of Wang resin. Dimethoxytrityl cation was absent 
if 108 was deprotected completely. 
 
 
Figure 38. Mass spectrometry data of the product cleaved from 110 with 50% TFA in DCM.  
 
To finish the extension of PEG chain, the resulting compound 109 reacted with a smaller cyclic 
sulfate followed by the deprotection, tosylation and substitution by sodium azide.  
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Figure 39. Mass spectrometry data of the product cleaved from 111 with 50% TFA in DCM.  
 
The cleavage of Wang resin was completed in 10% TFA in DCM to afford azido alcohol 113 
which was oxidized to give the desired methyl-linker 114.  
 
Figure 40. Mass spectrometry data of the product cleaved from 112 with 50% TFA in DCM.  
 
 
Figure 41. Mass spectrometry data of the oxidized product of 113.  
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Scheme 32: The conjugation of azido acid 114 with VH032. (a) HATU, DIPEA, DCM, RT, 
overnight, 41%. 
 
The conjugation reaction between 114 and VH032 gave the key intermediate 116, which will 
be coupled to SAFit analogue via click reaction in further studies to afford a new class of 
PROTACs. 
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4 Summary and Outlook 
 
In order to induce specific degradation of target protein, a new class of PROTACs was designed 
based on the selective FKBP51 ligands SAFit1 and SAFit2. The SAFit analogue was proposed to 
conjugate with two E3 ligase ligands, VH032 and pomalidomide, via PEG linkers at different 
attachment points respectively. By the synthetic route we established, a series of SAFit-based 
PROTACs molecules, MTQ199-208 and MTQ328-347, were obtained. Competition binding 
fluorescence polarization assays showed that all of the compounds retain high selectivity for 
FKBP51 over the close homologue FKBP52 while exhibiting nanomolar range affinities. Upon 
the treatment with the PROTAC MTQ202 on several cell lines, the degradation of FKBP51 was 
observed in western blot assays. The other synthesized PROTACs with different linkers, E3 
ligase ligands or attachment points showed no abilities to influence the level of FKBP51. We 
postulated the structure of a PROTAC molecular is crucial to induce the formation of protein-
PROTAC-E3 ligase ternary complex, which promote the degradation of target protein.  
Illuminated by PROTAC MZ1, a non-selective FKBPs ligand featured with [4.3.1] bicyclic 
structure was introduced into the PROTACs in order to induce a selective degradation of our 
target protein FKBP51. Base on the co-crystal structure of SP-16h in complex with FKBP51, a 
series of bicyclic ligand-based PROTACs was designed and synthesized. Although no evidence 
of protein knock-down was observed by western blot assays, some of these compounds 
exhibited outstanding affinities for all of the tested FKBPs in the low nanomolar range to 
subnanomolar range. Compared to a (R)-methyl group or a hydrogen, a (S)-methyl group on 
the Cα enhances the affinities of a ligand for FKBPs. The most potent compound, MTQ509, 
showed the highest binding affinity for FKBP51 so far reported (Ki = 0.92 nM). The binding 
mode of MTQ509 to FKBPs need to be clarified by further crystallography studies. 
Base on SAFit-like PROTACs, we postulated that a FKBP51-PROTAC-E3 ligase ternary complex 
can be induced by a linker with conformational restriction. In order to obtain potent PROTACs 
for FKBP51, we designed a series of methyl PEG linker and the synthetic route was confirmed. 
A library of new linkers will be established in further studies to investigate the impact of the 
structure of PROTACs aim to degrade FKBP51 specifically. 
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5 List of Abbreviations 
 
ACTH Adrenocorticotropic Hormone 
AR Androgen Receptor 
BET Bromodomain And Extra-Terminal 
BRD Bromodomain-Containing Protein 
CH Cyclohexane 
cIAP1 Cellular Inhibitor Of Apoptosis Protein 1 
CRBN Cereblon 
CRH Corticotrophin-Releasing Hormone 
DCM Dichlormethane 
DIPEA N,N-Diisopropylethylamine 
DMAP 4-(Dimethylamino)Pyridine 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide 
DMTr 4,4′-Dimethoxytrityl 
EA Ethyl Acetate 
EDC N-(3-Dimethylaminopropyl)-N′-Ethylcarbodiimide Hydrochloride 
ERRα Estrogen-Related Receptor Alpha 
FKBP FK506 Binding Protein 
FP assay Fluorescence Polarization assay 
GR Glucocorticoid Receptor  
HATU 1-[Bis(Dimethylamino)Methylene]-1H-1,2,3-Triazolo[4,5-
B]Pyridinium 3-Oxid Hexafluorophosphate 
HOBt 1-Hydroxybenzotriazol 
HPA Hypothalamic–Pituitary–Adrenal 
HR-MS High-Resolution Mass Spectrometry 
Hsp90 Heat Shock Protein 90 
iFit Induced Fit 
LC-MS Liquid Chromatography–Mass Spectrometry 
MeOH Methanol 
MR Mineralocorticoid Receptor 
NMR Nuclear Magnetic Resonance 
PDB Protein Data Bank 
PEG Polyethylene Glycol 
POI Protein Of Interest 
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PPIase Peptidyl-Prolyl Cis/Trans Isomerase 
PROTAC Proteolysis Targeting Chimera 
PTSD Post-Traumatic Stress Disorder 
SAFit Selective Antagonist Of FKBP51 By Induced Fit 
SAR Structure-Activity Relationship 
SHR Steroid Hormone Receptor 
TEA Triethylamine 
TFA Trifluoroacetic Acid 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
Ub Ubiquitin 
UPS Ubiquitin-Proteasome System 
VHL Von Hippel-Lindau 
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6 Experimental Section 
 
General Methods  
All of the reactions were performed in round bottom glass flasks under argon atmosphere 
(ALPHAGAZTM 1 Argon, 99.999 %) if no additional information was indicated. When water- 
or air sensitive reagents were used, the reaction was carried out with extra dry solvent in the 
reaction vessel which was heated with a heat gun, evacuated in vaccum, sealed with a silicone 
or rubber septum and filled with argon.  
 
NMR spectroscopy  
NMR spectroscopy were performed by the Department of Chemistry and Pharmacy of LMU or 
the NMR Department of TU Darmstadt. 1H, 13C, DEPT, 2D COSY, NOESY, HSQC, and HMBC 
NMR spectra were recorded either on a Brucker AC 300, a Bruker XL400, a Bruker Avance II 
300 MHz, a Bruker Avance III, a Bruker DRX 500 or a Bruker AMX 600 NMR spectrometer at 
room temperature. Chemical shifts are reported in ppm (δ) and residual protio solvent peaks 
were used as internal references (1H NMR: chloroform-d: δ = 7.26 ppm, DMSO-d6: 2.50 ppm; 
13C: chloroform-d: δ = 77 ppm, DMSO-d6: 39.52 ppm). Multiplicities are reported as singlet 
(s), doublet (d), triplet (t), quartet (q) or multiplet (m). Coupling constants (J) are reported 
in Hertz (Hz). 
 
LC-MS  
Liquid chromatography–mass spectrometry (LC-MS) was measured by the following 
instruments: 
Pump: Beckman Coulter System Gold 126 solvent module 
Autosampler: Beckman Coulter System Gold 508 autosampler  
Detector: Beckman Coulter System Gold 166 detector or System Gold Diode Array Detector 
Module 168; wavelength: 220 nm or 280 nm 
Column:  YMC-Pack Pro C8 3 μm 120Å, 100x4.6 mm from YMC.  
Eluents: Eluent A: 0.1 % formic acid in water; Eluent B: 0.1 % formic acid in acetonitrile  
Standard method: 0 % B to 100 % B in 19 min.  
MS: Thermo Finnigan LCQ Deca XP Plus, mode: Electrospray ionization (ESI). 
 
Analytic HPLC  
Pump: Beckman Coulter System Gold 126 solvent module or Dionex P580 pump 
Autosampler: Beckman Coulter System Gold 508 autosampler or Dionex ASI-100 automated 
sample injector 
Detector: Beckman Coulter System Gold Diode Array Detector Module 168 or Dionex UVD 
340U Photodiode Array Detector; wavelength: 220 nm, 280 nm 
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Column:  Phenomenex Kinetex 5 μm C18 100 Å, 250 x 4.6 mm or Phenomenex Jupiter 4μ 
Proteo 90Å, 250 x 4.6 mm  
Eluents: Eluent A: 0.1 % TFA in water; Eluent B: 0.1 % TFA in acetonitrile  
Method: Gradients are given in percentage B  
 
Chiral HPLC  
Pump: Beckman Coulter System Gold 126 solvent module  
Autosampler: Beckman Coulter System Gold 508 autosampler  
Detector: Beckman Coulter System Gold Diode Array Detector Module 168; wavelength: 220 
nm, 280 nm 
Column:  DAICEL Chiralcel OD-H 
Eluents: Eluent A: n-Hexane; Eluent B: i-Propanol  
 
Semi-Preparative HPLC  
Pump: Beckman Coulter System Gold Programmable Solvent Module 126 NMP 
Detector: Beckman Coulter Programmable Detector Module 166; wavelength: 254 nm 
Collector: Beckman Coulter SC 100 fraction collector 
Column:  Phenomenex Jupiter 10μ Proteo 90 Å, 250 x 21.2 mm 10 micron  
Eluents: Eluent A: 0.1 % TFA in water; Eluent B: 0.1 % TFA in acetonitrile  
Method: Gradients are given in percentage B  
 
HR-MS  
High resolution mass spectrometry (HR-MS) was performed by the Mass Spectrometry 
Department of TU Darmstadt. Mass spectra were recorded on a Bruker Daltonics Impact II, 
quadrupol-time-of-flight spectrometer.  
 
Flash chromatography  
Flash chromatography was performed either with an Interchim Puriflash 430 system or 
manually. The manual column chromatography was performed with silica gel 60 (Carl Roth, 
0.04-0.063 mm, 230-400 mesh). 
 
Thin layer chromatography  
Thin layer chromatography (TLC) was performed on aluminium sheets coated with silica gel 
(Merck Millipore, Silica gel 60 F254). UV-active compounds were detected by UV lamps (λ = 
254 nm or 365 nm). Non-UV-active compounds were detected by TLC staining solutions. 
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Reagents and solvents 
All of the reagents and solvents bought from commercial sources were used without further 
purification unless noted additionally.  
Solvent CAS-
number 
Grade Company 
Acetone 67-64-1 ROTISOLV® HPLC Carl Roth 
Acetonitril 75-05-8 ROTISOLV® HPLC Gradient Carl Roth 
Cyclohexane 110-82-7 ROTISOLV® HPLC or > 99,5 %, 
zur Synthese 
Carl Roth 
Dichloromethane 75-09-2 ROTISOLV > 99,9 % Carl Roth 
Diethylether 60-29-7 ROTIPURAN® ≥99,5 %, p.a. Carl Roth 
Dimethylformamid
e 
68-12-2 > 99,8 % zur Peptidsynthese Carl Roth 
Ethyl acetate 141-78-6 ROTISOLV® HPLC or Extra Pure, 
SLR 
Carl Roth or Fisher 
Scientific 
i-Propanol 67-63-0 ROTISOLV® HPLC Carl Roth 
Methanol 67-56-1 ROTISOLV® HPLC Carl Roth 
n-Hexane 110-54-3 ROTISOLV® HPLC Carl Roth 
Tetrahydrofuran 109-99-9 ROTIDRY® ≥99,9 % (≤50 ppm 
H2O) 
Carl Roth 
 
Fluorescence Polarization Assay 
The competition binding fluorescence polarization assay was performed as described9 by 
Stephanie Merz and Christian Meyners. 
 
Chemical Synthesis 
General method A for synthesis of monotosylate alcohol  
To a stirred solution of diol 15-17 (1 eq.) in DCM were added Ag2O (1.5 eq.), TsCl (1 eq.), 
and KI (0.2 eq.). The reaction mixture was stirred at 0°C for 30 min and then filtered through 
a small pad of silica gel and washed with EtOAc. Evaporation of the solvent, followed by 
column chromatography, gave the desired monotosylate product. 
 
General method B for synthesis of azido alcohol 
To a stirred solution of monotosylate alcohol 41 (1 eq.) in DMF sodium azide (2 eq.) was 
added. The mixture was stirred for 16 h at room temperature. Dichloromethane was added 
and the mixture was washed with brine. The organic phase was dried over magnesium 
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sulfate, filtered, and evaporated under reduced pressure. The crude was purified by flash 
chromatography to give a yellow oil. 
 
General Method C for synthesis of azides 
To a stirred solution of alcohol 40 (1 eq.) in tert-butanol, potassium tert-butoxide (1.5 eq.) 
was added. The mixture was stirred at 30°C for 15 min and tert-butyl bromoacetate (2 eq.) 
was added. The mixture was stirred at 30°C for 16 h, and then evaporated under reduced 
pressure. The crude was dissolved in dichloromethane and washed with brine. The organic 
phase was dried over magnesium sulfate, filtered, and evaporated under reduced pressure. 
The crude product was purified by flash chromatography. 
 
General Method D for synthesis of azido acids 
Azides 39 (1 eq.) was dissolved in dichloromethane/TFA (1/1, v/v) and the mixture was 
stirred at room temperature for 30 min. The mixture was evaporated under reduced pressure, 
and then the crude was dissolved in water. The pH was adjusted to 10 by addition of an 
aqueous sodium hydroxide solution (1 M). The solution was washed with ethyl acetate and 
the pH was adjusted to 2 by addition an aqueous hydrochloric acid solution (3 M). The 
aqueous layer was extracted with ethyl acetate. The combined extracts were dried over 
magnesium sulfate, filtered, and evaporated under reduced pressure. The crude product was 
purified by flash chromatography. 
General Method E 
37 (90 mg, 0.170 mmol, 1 eq.) was dissolved in a solution of TFA/DCM (v/v = 1:1, 3mL) and 
stirred at RT under Ar. Then the solvent was removed in reduced pressure and the given brown 
oil was added to a solution of azido acid (0.170 mmol, 1 eq.) in DCM (4 ml). HATU (97 mg, 
0.255 mmol, 1.5 eq.) was added and the pH adjusted to >9 by addition of DIPEA (0.148 ml, 
0.850 mmol, 5 eq.). After stirring overnight at RT the reaction mixture was extracted with water. 
The organic phase was dried over magnesium sulfate and evaporated to dryness. The crude 
product was purified by flash column chromatography. 
 
General Method F 
Oxalyl chloride (2M in DCM, 3.9 eq.) was added dropwise into a solution of azido acid (3 eq.) 
and DMF (1 drop) in DCM (2 ml) at 0°C. After stirring at 0°C  RT for 3h, the solvent and 
oxalyl chloride were removed under reduced pressure. The resulting product was dissolved in 
DMF (1 ml) and added into a solution of pomalidomide (1 eq.) in DMF at 0°C. The reactants 
were stirred at 0°C  RT for 5h. Then the mixture was diluted by DCM (100mL) and washed 
with brine (25 mL x 3). The organic phase was dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. Purification by flash column chromatography gave a light 
yellow solid. 
 
General Method G 
To a solution of 16/31a/31b/45 (1 eq.) and 43/44 (1 eq.) in t-BuOH-H2O (1:1,1 mL) at RT 
were added copper(II) sulfate pentahydrate (1M in H2O, 5.5 μl, 5.5 μmol) and (+)-Sodium L-
ascorbate (1M in H2O, 5.5 μl, 5.5 μmol). The reaction mixture was stirred at RT overnight. Then 
the mixture was diluted by DCM (50mL) and washed with brine (25 mL x 2). The organic phase 
was dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
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General Method H  
To a solution of carboxylic acid 6 (1 eq.) in DCM/DMF (2/1), HATU (1.1 eq.), DIPEA (3 eq.) 
and 19 (1 eq.) were added. After stirring for 16 h, the mixture was poured into brine and 
extracted 3 times with Et2O. The combined organic layer was washed 3 times with brine, 
dried over magnesium sulfate, filtered and condensed. The crude product was purified by 
flash chromatography. 
 
2-(3,4,5-Trimethoxyphenyl)acetic pivalic anhydride (12) 
 
DIPEA (0.425 ml, 2.43 mmol, 1.1 eq.) and pivaloyl chloride (0.3 ml, 2.43 mmol, 1.1 eq.) were 
added to a solution of 2-(3,4,5-trimethoxyphenyl)acetic acid (0.5 g, 2.21 mmol, 1 eq.) in DCM 
(4 mL) at 0°C. The solution was stirred at 0°C for 30 min and RT for 1h. Then it was quenched 
by the addition of saturated NH4Cl solution and the product was extracted with DCM (50 ml). 
The combined organics were dried over magnesium sulfate, filtered and then the solvent was 
removed to obtain the pivalic acid mixed anhydride. 
 
(S)-4-Phenyl-3-(2-(3,4,5-trimethoxyphenyl)acetyl)oxazolidin-2-one (7) 
 
BuLi (2.5M in THF, 0.97 ml, 2.42 mmol, 1.1 eq.) was added into a solution of (S)-4-
phenyloxazolidin-2-one (0.36 g, 2.20 mmol, 1 eq.) in THF (8 mL) at -78°C and stirred at that 
temperature for 1h.  The solution of pivalic acid mixed anhydride in DCM (1 mL) was added 
and stirred for 16h at -78°C to RT. Then it was quenched by the addition of saturated NH4Cl 
solution and the product was extracted with EtOAc. The combined organics were dried over 
magnesium sulfate, filtered and the solvent was removed under reduced pressure. Purification 
by flash column chromatography (c-Hexane:EtOAc, gradient EtOAc 0 to 30%) gave a yellow oil 
(535mg, 1.43 mmol, 65%) 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.28. 
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HPLC [30-100% Solvent B, 20 min]: Rt = 12.92 min, purity (220 nm) = 98%. 
 
1H NMR: (400 MHz, Chloroform-d) = 7.32 (m, 3 H), 7.18 (m, 2 H), 6.45 (s, 2 H), 5.43 (dd, J 
= 4.0, 8.8 Hz, 1 H), 4.69 (t, J = 8.9 Hz, 1 H), 4.27 (d, J = 17.7 Hz, 1 H), 4.25 (dd, J = 4.0, 
8.8 Hz, 1 H), 4.15 (d, J = 14.7 Hz, 1 H), 3.82 (s, 3 H), 3.77 (s, 6 H). 
 
13C NMR: (101 MHz, Chloroform-d) = 170.58, 153.68, 153.25, 138.81, 137.23, 129.22, 128.86, 
128.84, 126.12, 106.76, 69.99, 60.95, 57.88, 56.15, 41.81. 
 
MS (ESI+): m/z: found 371.97 [M+H]+, calculated 372.14[C20H21NO6+H]+ 
 
 (S)-3-((S)-2-((R)-Cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)-4-
phenyloxazolidin-2-one (13) 
 
NaHMDS (1.0M in THF, 2.11 ml, 5.25 mmol, 1.5 eq.) was added dropwise to a solution of 7 
(0.52 g, 1.41 mmol, 1 eq.) in THF (20 mL) at -78°C. The mixture was stirred for 1 h, then 3-
bromocyclohex-1-ene (1.13 g, 7.04 mmol, 5 eq.) was added dropwise. The reaction mixture 
was stirred at -78°C for 1 h and then at 0°C for 16 h. Then it was quenched by the addition of 
saturated NH4Cl solution and the product was extracted with EtOAc. The combined organics 
were dried over magnesium sulfate, filtered and the solvent was removed. Purification by flash 
column chromatography (c-Hexane:EtOAc, gradient EtOAc 0 to 10%) gave a light yellow oil 
(191mg, 0.43 mmol, 31%) 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.31. 
 
HPLC [60-80% Solvent B, 20 min]: Rt = 14.15 min, purity (220 nm) = 98%. 
 
1H NMR: (800 MHz, Chloroform-d) = 7.41 (m, 2 H), 7.35 (m, 3 H), 6.67 (s, 2 H), 5.62 (d, 1 
H, J = 10.0 Hz), 5.39 (dd, J = 9.0, 3.8 Hz, 1 H), 5.05 (d, J = 10.0 Hz, 1 H), 4.84 (d, J = 11.3 
Hz, 1 H), 4.60 (t, J = 9.0 Hz, 1 H), 4.23 (dd, J = 9.0, 3.8 Hz, 1 H), 3.85 (s, 6 H), 3.83 (s, 3 H), 
2.80 (m, 1 H), 1.95 (m, 2 H), 1.66 (m, 1 H), 1.43 (m, 1 H), 1.33 (m, 1 H), 1.12 (m, 1 H). 
 
13C NMR: (201 MHz, Chloroform-d) = 173.63, 153.47, 153.22, 139.40, 137.37, 132.77, 129.50, 
129.31, 129.25, 128.92, 128.54, 126.19, 126.07, 106.16, 69.54, 60.97, 58.25, 56.30, 56.26, 
53.71, 39.67, 26.22, 25.41, 20.54. 
 
MS (ESI+): m/z: found 452.01 [M+H]+, calculated 452.21 [C26H29NO6+H]+ 
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(S)-3-((S)-2-Cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)-4-phenyloxazolidin-2-one 
(14) 
 
13 (0.19 g, 0.43 mmol, 1 eq.) was dissolved in MeOH (10 mL) and the solution was degassed 
with Ar.  
Then palladium on carbon (45 mg, 0.042 mmol, 0.1 eq.) was added. In the following step H2 
was bubbled through the reaction mixture for 5 min. The reaction was then stirred under H2 
atmosphere for 16 h. Then the dark suspension was filtered through celite and the solvent was 
removed under reduced pressure. Purification by flash column chromatography (c-
Hexane:EtOAc, gradient EtOAc 0 to 13%) gave a yellow oil (190mg, 0.42 mmol, 99%). 
 
TLC [cyclohexane/EtOAc 8/2]: Rf = 0.23. 
 
HPLC [65-80% Solvent B, 20 min]: Rt = 14.72 min, purity (220 nm) ≥ 99%. 
 
1H NMR: (800 MHz, DMSO-d6) δ 7.41 (t, J = 7.6 Hz, 2H), 7.35 – 7.32 (m, 3H), 6.59 (s, 2H), 
5.46 (dd, J = 8.7, 3.6 Hz, 1H), 4.77 (d, J = 10.6 Hz, 1H), 4.68 (t, J = 8.8 Hz, 1H), 4.15 (dd, 
J = 8.9, 3.6 Hz, 1H), 3.74 (s, 6H), 3.64 (s, 3H), 1.94 – 1.88 (m, 1H), 1.55 – 1.51 (m, 3H), 1.28 
– 1.25 (m, 1H), 1.19 – 1.15 (m, 1H), 1.11 – 1.02 (m, 3H), 0.94 – 0.89 (m, 1H), 0.81 – 0.75 (m, 
1H). 
 
13C NMR: (201 MHz, DMSO-d6) δ 173.30, 153.98, 153.09, 140.37, 137.16, 133.30, 129.19, 
128.63, 126.46, 106.57, 70.08, 60.41, 57.89, 56.28, 54.02, 41.82, 31.25, 30.26, 26.26, 25.65. 
 
MS (ESI+): m/z: found 454.03 [M+H]+, calculated 454.22 [C26H31NO6+H]+ 
 
 (S)-2-Cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetic acid (6) 
 
Lithium hydroxide (41.6 mg, 1.74 mmol) and hydrogen peroxide solution (30% w/w in water, 
199 μl, 1.93 mmol) were added to a solution of 14 in THF/H2O (10 mL, 8:5) at 0°C. After 
stirring for 16h, the reaction was quenched by the addition of saturated NaSO3 solution and 
extracted 3 times with DCM. The aqueous phase was acidified with conc. HCl to PH = 2 and 
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extracted with DCM. The combined organic layer was dried over magnesium sulfate, filtered 
and concentrated under reduced pressure to afford a white foam (95mg, 0.31 mmol, 80%). 
 
TLC [cyclohexane/EtOAc+1%AcOH 6/4]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.57 min, purity (220 nm) = 90%. 
 
1H NMR: (599 MHz, Chloroform-d) δ 6.54 (s, 2H), 3.84 (s, 6H), 3.82 (s, 3H), 3.13 (d, J = 10.7 
Hz, 1H), 1.96 – 1.87 (m, 2H), 1.77 – 1.73 (m, 1H), 1.67 – 1.61 (m, 2H), 1.39 – 1.29 (m, 2H), 
1.17 – 1.13 (m, 2H), 1.07 (ddd, J = 12.7, 3.8, 1.7 Hz, 1H), 0.75 (ddd, J = 23.9, 11.7, 3.2 Hz, 
1H). 
 
13C NMR: (151 MHz, Chloroform-d) δ 179.64, 153.28, 137.44, 132.97, 105.72, 60.98, 59.10, 
56.28, 41.03, 32.08, 30.42, 26.40, 26.07. 
 
MS (ESI+): m/z: found 309.00 [M+H]+, calculated 309.17 [C17H24O5+H]+ 
 
3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)propan-1-one (3) 
 
3,4-Dimethoxybenzaldehyde (100 g, 602 mmol, 1.0 eq.) and 1-(3-hydroxyphenyl)ethanone 
(82.0 g, 602 mmol, 1.0 eq.) were dissolved in EtOH (800 mL) and cooled to 3°C. A solution of 
KOH (135 g, 2.41 mol, 4.0 eq.) in cold H2O (640 mL) was added dropwise over 1 h to the 
reaction mixture, which was then stirred over night while warming to RT. Orange solids 
precipitated and the resulting suspension was poured onto ice (1.5 L). After acidification with 
conc. HCl to pH = 2, the precipitated clots were resuspended via sonification and pounding. 
Filtration of the resulting suspension yielded orange solids, which were dissolved in EtOAc 
and dried over MgSO4. After removal of the solvent in vacuo, (E)-3-(3,4-dimethoxyphenyl)-1-
(3-hydroxyphenyl)prop-2-en-1-one 8 (153 g) was obtained as crude product with slight 
impurities and used without further purification in the next reaction step. For the subsequent 
reduction reaction, an autoclave (Modell II, Roth) was flushed with argon and then charged 
with crude product 8 (25.6 g, 90 mmol, 1.0 eq.; pureness assumed), Lindlar catalyst (400 mg, 
3.76 mmol, 42 mol%) and MeOH (150 mL). The autoclave was again flushed with argon, 
then closed and filled with hydrogen gas (35 bar). After stirring for 7 d at RT, the reaction 
mixture was filtered through celite and the solvent was removed in vacuo. The obtained 
yellow solid was purified via recrystallization from MeOH (70 mL) yielding white solids, 
which were washed with cold MeOH (2×10 mL) and cold hexane (2×15 mL). 3 (16.3 g, 56.9 
mmol, 63%) was obtained as white powder.  
TLC [cyclohexane/EtOAc 2/1]: Rf = 0.20. 
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1H NMR (400 MHz, Chloroform-d) δ 7.55 – 7.46 (m, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.07 (dd, 
J = 8.1, 2.6 Hz, 1H), 6.82 – 6.72 (m, 3H), 6.24 (s, 1H), 3.85 (d, J = 2.4 Hz, 6H), 3.26 (t, J = 
7.6 Hz, 2H), 3.00 (t, J = 7.6 Hz, 2H).  
13C NMR (101 MHz, CDCl3) δ 200.10, 156.48, 149.00, 147.52, 138.37, 133.88, 130.04, 
120.70, 120.34, 114.70, 112.04, 111.56, 56.08, 55.98, 40.93, 29.98. 
 HPLC [0%–100% eluent B, 20 min]: Rt = 15.8 min, 92% purity 
 
3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propan-1-one (10) 
 
K2CO3 (31.1 g, 225 mmol, 4 eq.) was added to a suspension of 3 (16.1 g, 56.3 mmol, 1.0 eq.) 
in acetonitrile (280 mL) at RT. 2-Morpholinoethyl chloride hydrochloride (11.5 g, 61.9 mmol, 
1.1 eq.) was added to the reaction mixture. After stirring at RT overnight, the mixture was 
filtered and the filtrate was evaporated under reduced pressure. The residue was purified by 
recrystallization from i-propanol affording morpholine 10 (21.57 g, 21.6 mmol, 96%) as a 
white powder. 
 
TLC [EtOAc + 2% MeOH]: Rf = 0.30. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 9.9 min, ≥ 99% purity 
 
1H NMR (300 MHz, Chloroform-d) δ 7.56 – 7.46 (m, 2H), 7.35 (t, J = 7.9 Hz, 1H), 7.11 (dd, 
J = 8.1, 2.5 Hz, 1H), 6.78 (dd, J = 5.1, 2.0 Hz, 3H), 4.15 (t, J = 5.7 Hz, 2H), 3.86 (d, J = 
3.9 Hz, 6H), 3.76 – 3.69 (m, 4H), 3.26 (t, J = 7.6 Hz, 2H), 3.01 (t, J = 7.6 Hz, 2H), 2.81 (t, J 
= 5.7 Hz, 2H), 2.62 – 2.50 (m, 4H). 
13C NMR (75 MHz, Chloroform-d) δ 199.23, 159.14, 149.09, 147.59, 138.44, 134.02, 129.74, 
120.96, 120.33, 120.11, 113.30, 112.05, 111.55, 67.06, 66.16, 57.72, 56.10, 56.01, 54.24, 
40.94, 29.99. 
MS (ESI+): m/z: found 400.28 [M+H]+, calculated [C23H29NO5+H]+ 
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(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propan-1-ol (1) 
 
An autoclave (Modell II, Roth) was flushed with argon and then charged with 10 (2 g, 5 
mmol, 1.0 eq.), RuCl2[(S)-xylbinap][(S)-daipen] (61 mg, 0.05 mmol, 1 mol%), K2CO3 (692 
mg, 5 mmol, 1 eq.) and i-propanol (25 mL). The autoclave was again flushed with argon, then 
closed and filled with hydrogen gas (35-40 bar). After stirring for 3 d at RT, the reaction 
mixture was filtered through celite and the solvent was removed in vacuo. The obtained 
yellow solid was purified by chromatography (EtOAc + 2% MeOH + 1% TEA) yielding 1 (1.7 
g, 4.3 mmol, 86%) 
TLC [EtOAc + 2% MeOH + 0.1% TEA]: Rf = 0.14. 
HPLC [0%–100% eluent B, 20 min]: Rt = 9.1 min, ≥ 99% purity 
1H NMR (300 MHz, Chloroform-d) δ 7.25 (t, J = 8.2 Hz, 1H), 6.97 – 6.88 (m, 2H), 6.85 – 
6.77 (m, 2H), 6.76 – 6.69 (m, 2H), 4.65 (dd, J = 7.5, 5.5 Hz, 1H), 4.10 (t, J = 5.6 Hz, 2H), 
3.89 – 3.81 (m, 6H), 3.77 – 3.67 (m, 4H), 2.80 (t, J = 5.6 Hz, 2H), 2.75 – 2.53 (m, 6H), 2.18 
– 1.90 (m, 2H). 
13C NMR (75 MHz, Chloroform-d) δ 158.92, 148.93, 147.29, 146.68, 134.49, 129.57, 120.29, 
118.60, 113.63, 112.21, 111.93, 111.42, 73.70, 66.81, 65.66, 57.68, 56.02, 55.92, 54.08, 
40.74, 31.74. 
ee ≥ 99% 
 
 (S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl piperidine-2-
carboxylate (2) 
 
1 (519 mg, 1.3 mmol, 1.0 eq.) and (S)-N-Fmoc-piperidine-2-carboxylic acid (500 mg, 1.4 mmol, 
1.1 eq.) were dissolved in DCM (6.5 mL) followed by the addition of EDC (273 mg, 1.4 mmol, 
1.1 eq.) and DMAP (32 mg, 0.26 mmol, 0.2 eq.) at RT. After stirring for 16h, the mixture was 
concentrated under reduced pressure and purified by flash column chromatography 
(cyclohexane:EtOAc, gradient EtOAc 0 to 15%) to give 11 as a yellow oil (926 mg, 1.26 mmol, 
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97%).  
11 (880 mg, 1.2mmol, 1 eq.) was dissolved in 6 mL 4-methylpiperidine/DCM (v/v= 1:9). The 
solution was stirred at RT overnight. Then the solution was diluted with 30 ml DCM, and 
washed with saturated NH4Cl solution (20 mL x 3). The organic layer was dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (DCM  DCM + 5% MeOH) gave 2 (198 mg, 0.45 mmol, 73%) as a 
yellow oil. 
 
TLC [DCM + 5% MeOH]: Rf = 0.58. 
 
1H NMR (599 MHz, Chloroform-d) δ 7.25 – 7.22 (m, 1H), 6.92 – 6.90 (m, 1H), 6.88 – 6.86 
(m, 1H), 6.82 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 6.68 – 6.64 (m, 2H), 
5.75 (dd, J = 8.0, 5.6 Hz, 1H), 4.10 (t, J = 5.8 Hz, 2H), 3.85 (d, J = 4.7 Hz, 6H), 3.74 – 3.72 
(m, 4H), 3.40 (dd, J = 9.9, 3.3 Hz, 1H), 3.09 (dt, J = 12.1, 3.6 Hz, 1H), 2.80 (t, J = 5.7 Hz, 
2H), 2.69 – 2.59 (m, 2H), 2.59 – 2.56 (m, 4H), 2.55 – 2.50 (m, 1H), 2.26 – 2.21 (m, 1H), 
2.07 – 2.02 (m, 2H), 1.79 (dd, J = 9.0, 4.7 Hz, 1H), 1.67 – 1.56 (m, 2H), 1.52 – 1.43 (m, 
2H). 
13C NMR (151 MHz, Chloroform-d) δ 172.62, 158.95, 149.01, 147.47, 141.90, 133.71, 
129.72, 120.27, 119.18, 113.99, 113.23, 111.81, 111.42, 75.86, 67.04, 65.87, 58.71, 57.81, 
56.07, 56.01, 54.25, 45.65, 38.08, 31.52, 29.22, 25.69, 24.12. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (SAFit2) 
 
SAFit2 was synthesized from 2 (120 mg, 0. 23 mmol) according to the General Method H. 
Purification by flash column chromatography (cyclohexane  EtOAc + 2% MeOH + 0.1% TEA) 
gave a white solid (150 mg, 0.18 mmol, 80%). 
 
TLC [EtOAc + 2% MeOH + 1% TEA]: Rf=0.41. 
 
HPLC [30-100% Solvent B, 20 min]: Rt = 14.77 min, purity (220 nm) = 98%. 
 
1H NMR (800 MHz, Chloroform-d) (3:1 mixture of rotamers) δ 7.29 (t, J = 7.9 Hz, 0.25H), 
7.10 (t, J = 7.9 Hz, 0.75H), 6.96 (d, J = 7.7 Hz, 0.25H), 6.90 (s, 0.25H), 6.87 (dd, J = 8.1, 
2.1 Hz, 0.25H), 6.79 (d, J = 8.2 Hz, 0.25H), 6.77 – 6.74 (m, 1.5H), 6.70 – 6.67 (m, 1H), 6.66 
– 6.61 (m, 1.75H), 6.48 (s, 1.5H), 6.43 – 6.37 (m, 1.25H), 5.83 – 5.77 (m, 0.25H), 5.55 (dd, 
J = 8.1, 5.6 Hz, 0.75H), 5.48 – 5.44 (m, 0.75H), 4.72 (d, J = 5.3 Hz, 0.25H), 4.58 – 4.51 (m, 
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0.25H), 4.18 – 4.04 (m, 2H), 3.94 (d, J = 13.6 Hz, 0.75H), 3.87 – 3.81 (m, 9H), 3.77 (s, 6H), 
3.71 (s, 4H), 3.37 (d, J = 9.8 Hz, 0.75H), 2.98 (d, J = 9.7 Hz, 0.25H), 2.84 (s, 1.5H), 2.78 
(td, J = 13.4, 2.7 Hz, 1H), 2.75 – 2.51 (m, 4.5H),2.47 (ddd, J = 14.3, 9.4, 5.3 Hz, 1H), 2.41 
– 2.35 (m, 1H), 2.31 – 2.25 (m, 1H), 2.10 – 2.06 (m, 1H), 1.96 (dtd, J = 13.9, 8.8, 5.4 Hz, 
1H), 1.90 – 1.85 (m, 1H), 1.85 – 1.80 (m, 1H), 1.70 – 1.55 (m, 6H), 1.45 – 1.42 (m, 1H), 
1.35 – 1.23 (m, 3H), 1.18 – 1.11 (m, 2H), 1.02 – 0.86 (m, 1H), 0.79 – 0.54 (m, 1H). 
13C NMR (201 MHz, Chloroform-d) (major) δ 172.45, 170.67, 153.15, 148.94, 147.39, 
142.01, 136.90, 133.74, 133.56, 129.71, 120.37, 113.86, 113.11, 111.88, 111.37, 105.86, 
77.35, 75.74, 60.91, 57.70, 56.45, 56.17, 56.04, 55.96, 55.17, 54.10, 52.13, 43.74, 41.48, 
38.20, 32.94, 31.18, 30.78, 27.04, 26.91, 26.70, 26.35, 26.31, 25.67, 21.10. 
 
3-(3,4-Dimethoxyphenyl)-1-(3-(prop-2-yn-1-yloxy)phenyl)propan-1-one (21) 
 
To a solution of 3 (3 g, 10.48 mmol, 1 eq.) and K2CO3 (4.35 g, 20.96 mmol, 3 eq.) in acetone 
(50 mL) was added 3-bromoprop-1-yne (80% wt in toluene, 1.356 mL, 13.62 mmol, 1.3 eq.) 
and stirred at RT for 16h. Then the mixture was filtered and the precipitate was washed with 
DCM. The solvent was removed under reduced pressure and the crude product was 
recrystallized from methanol to obtain white crystal (3.07g, 9.4 mmol, 90%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.63. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.60 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 7.60 – 7.53 (m, 2H), 7.41 – 7.32 (m, 1H), 7.20 – 7.12 (m, 
1H), 6.81 – 6.73 (m, 3H), 4.72 (d, J = 2.3 Hz, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.26 (t, J = 7.4 
Hz, 2H), 3.00 (t, J = 7.6 Hz, 2H), 2.53 (t, J = 2.3 Hz, 1H). 
 
13C NMR (75 MHz, Chloroform-d) δ 198.91, 157.76, 148.94, 147.45, 138.31, 133.83, 129.68, 
121.45, 120.19, 120.16, 113.68, 111.90, 111.42, 78.09, 75.94, 55.95, 55.85, 40.76, 29.84. 
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(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(prop-2-yn-1-yloxy)phenyl)propan-1-ol (20) 
 
To a stirred solution of 21 (250 mg, 0.77 mmol, 1 eq.) and (S)-(−)-2-methyl-CBS-
oxazaborolidine solution (1M in toluene, 464 μl, 0.46 mmol, 0.6 eq.) in dry THF (15 mL) borane 
tetrahydrofuran complex solution (1M in THF, 1.16 mL, 1.16 mmol, 1.5 eq.) was added at  
-40°C and the mixture was stirred at the same temperature under Ar atmosphere for 5h. Then 
2 mL MeOH was added, and the mixture was warmed to room temperature. Saturated NH4Cl 
solution was added and the mixture was extracted with EtOAc. The crude product was 
concentrated and purified by flash column chromatography (cyclohexane  1% MeOH in DCM). 
20 was afforded as a colorless oil (253mg, 0.77 mmol, 100%).  
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.49. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.10 min, purity (220 nm) = 97%. 
 
1H NMR (400 MHz, Chloroform-d) δ 7.29 (t, J = 7.9 Hz, 1H), 7.01 – 6.96 (m, 2H), 6.90 (ddd, 
J = 8.2, 2.5, 0.9 Hz, 1H), 6.81 – 6.77 (m, 1H), 6.75 – 6.70 (m, 2H), 4.70 (d, J = 2.4 Hz, 2H), 
4.68 (dd, J = 7.8, 5.4 Hz, 1H), 3.86 (s, 3H), 3.86 (s, 3H), 2.75 – 2.57 (m, 2H), 2.51 (t, J = 2.4 
Hz, 1H), 2.15 – 1.96 (m, 2H). 
 
13C NMR (101 MHz, Chloroform-d) δ 157.90, 149.01, 147.37, 146.57, 134.46, 129.71, 120.34, 
119.28, 114.04, 112.72, 111.93, 111.43, 78.68, 75.68, 73.87, 56.08, 55.98, 55.95, 40.70, 31.74. 
 
 
(S)-1-((9H-Fluoren-9-yl)methyl) 2-((R)-3-(3,4-dimethoxyphenyl)-1-(3-(prop-2-yn-1-
yloxy)phenyl)propyl) piperidine-1,2-dicarboxylate (22) 
 
20 (240 mg, 0.735 mmol, 1.0 eq.) and (S)-N-Fmoc-piperidine-2-carboxylic acid (284 mg, 0.809 
mmol, 1.1 eq.) were dissolved in DCM (3.5 mL) followed by the addition of EDC (155 mg, 
0.809 mmol, 1.1 eq.) and DMAP (18 mg, 0.147 mmol, 0.2 eq.) at RT. After stirring for 16h, the 
mixture was concentrated under reduced pressure and purified by flash column 
chromatography (cyclohexane:EtOAc, gradient EtOAc 0 to 15%) to give a yellow oil (419mg, 
0.63 mmol, 86%) 
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TLC [cyclohexane/EtOAc 6/4]: Rf = 0.51. 
 
HPLC [50-100% Solvent B, 20 min]: Rt = 20.91 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.80 – 7.69 (m, 2H), 7.60 (t, J = 8.4 Hz, 1H), 7.51 – 7.17 
(m, 6H), 6.98 – 6.84 (m, 3H), 6.74 (d, J = 8.1 Hz, 1H), 6.67 – 6.57 (m, 2H), 5.82 – 5.76 (m, 
1H), 5.08 – 4.84 (m, 1H), 4.70 – 4.57 (m, 2H), 4.49 – 4.07 (m, 4H), 3.86 – 3.78 (m, 6H), 3.20 
– 2.95 (m, 1H), 2.62 – 2.42 (m, 3H), 2.37 – 2.29 (m, 1H), 2.26 – 2.15 (m, 1H), 2.08 – 2.04 (m, 
1H), 1.77 – 1.66 (m, 3H), 1.53 – 1.40 (m, 1H), 1.34 – 1.27 (m, 1H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.01, 157.82, 156.47, 156.03, 149.01, 147.46, 144.22, 
144.13, 143.98, 143.93, 141.85, 141.60, 141.39, 133.62, 133.50, 129.73, 127.76, 127.14, 
125.16, 125.03, 120.22, 120.04, 119.89, 119.77, 114.43, 113.59, 113.37, 111.88, 111.81, 
111.50, 78.57, 76.53, 76.26, 75.78, 75.71, 67.87, 60.45, 56.03, 55.92, 55.02, 54.65, 47.35, 
42.12, 42.00, 38.16, 31.23, 27.11, 26.92, 24.89, 24.66, 21.11, 20.91, 20.80, 14.30. 
 
MS (ESI+): m/z: found 682.09 [M+Na]+, calculated 682.28 [M+Na]+ 
 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(prop-2-yn-1-yloxy)phenyl)propyl piperidine-2-
carboxylate (19) 
 
22 was dissolved in 3mL 4-methylpiperidine/DCM (v/v= 1:9). The solution was stirred at RT 
overnight. 
Then the solution was diluted with 100 ml DCM, and washed with saturated NH4Cl solution. 
The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced 
pressure. Purification by flash column chromatography (cyclohexane  cyclohexane: EtOAc 
=2:8 + 1% TEA) gave a yellow oil (198mg, 0.45 mmol, 73%). 
 
TLC [EtOAc + 1% TEA]: Rf = 0.23. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.37 min, purity (220 nm) = 96%. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.19 (t, J = 8.0 Hz, 1H), 6.90 – 6.85 (m, 2H), 6.85 – 6.80 
(m, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.62 – 6.56 (m, 2H), 5.70 (dd, J = 7.8, 5.7 Hz, 1H), 4.61 
(d, J = 2.4 Hz, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.29 (dd, J = 9.9, 3.2 Hz, 1H), 2.99 (dt, J = 
11.0, 3.4 Hz, 1H), 2.61 – 2.45 (m, 3H), 2.44 (t, J = 2.4 Hz, 1H), 2.22 – 2.12 (m, 1H), 2.04 – 
1.93 (m, 2H), 1.77 – 1.69 (m, 1H), 1.58 – 1.46 (m, 2H), 1.45 – 1.32 (m, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ 172.92, 157.79, 149.04, 147.49, 142.06, 133.72, 129.67, 
120.27, 119.86, 114.19, 113.47, 111.86, 111.50, 78.60, 75.71, 75.51, 58.87, 56.04, 55.98, 
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55.95, 45.78, 38.05, 31.41, 29.39, 25.96, 24.26. 
 
MS (ESI+): m/z: found 438.02 [M+H]+, calculated 438.23 [M+H]+ 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(prop-2-yn-1-yloxy)phenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (16) 
 
16 was synthesized from 19 (180 mg, 0. 41 mmol) according to the General Method H. 
Purification by flash column chromatography (cyclohexane:EtOAc, gradient EtOAc 0 to 20%) 
gave a white solid (200mg, 0.275 mmol, 67%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.45. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 18.5 min, ≥ 99% purity 
 
1H NMR (500 MHz, DMSO-d6, 353K) δ 7.27 (m, 1H), 7.06 – 6.58 (m, 8H), 5.58 (dd, J = 7.9, 
5.6 Hz, 1H), 5.30 (dd, J = 6.0, 2.7 Hz, 1H), 4.84 – 4.72 (m, 2H), 4.16 (d, J = 13.8 Hz, 1H), 
3.84 – 3.59 (m, 16H), 3.46 – 3.35 (m, 1H), 2.89 – 2.75 (m, 1H), 2.62 (m, 1H), 2.50 – 2.33 
(m, 2H), 2.29 – 2.12 (m, 1H), 2.12 – 1.76 (m, 3H), 1.73 – 1.37 (m, 6H), 1.34 – 0.66 (m, 8H).  
13C NMR (126 MHz, DMSO-d6, 353K) δ 172.04, 170.21, 157.33, 152.67, 149.15, 147.54, 
141.90, 137.02, 133.63, 133.59, 129.30, 120.29, 118.87, 114.22, 113.19, 113.07, 112.98, 
106.84, 79.18, 77.71, 74.92, 59.85, 56.35-55.50, 52.97, 51.84, 42.99, 40.96, 37.32, 31.69, 
30.35, 29.82, 26.33-25.02, 20.43.  
HRMS: m/z: found 728.37910 [M+H]+, calculated 728.37931 [M+H]+ 
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 (E)-3-(4-hydroxy-3-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (25a) 
 
4-Hydroxy-3-methoxybenzaldehyde (vanillin) (22.8 g, 0.15 mmol, 1 eq.) was dissolved in 
ethanol (150 mL) and 1-(3-methoxyphenyl)ethan-1-one (22.5 g, 20.6 mL, 0.15 mmol, 1 eq.) 
was added. The mixture was cooled to 0 °C. Potassium hydroxide (33.7 g, 0.6 mmol, 4 eq.) 
was dissolved in water (100 mL) and the solution was cooled to ~10°C. The KOH solution 
was added slowly to the reaction mixture. To dissolve the formed precipitation, ethanol (260 
mL) was added. The solution was warmed to room temperature and stirred overnight. After 
25 h, potassium hydroxide (8.4 g, 0.15 mmol, 1 eq.) was added and the solution was heated 
to 40 °C. After 28.5 h potassium hydroxide (8.4 g, 0.15 mmol, 1 eq.) was added, the solution 
was heated to 50°C and stirred overnight. Most of the ethanol was removed under vacuum 
and the solution was stirred at 40°C for another day. Water was added to dissolve the 
precipitation and conc. HCl (~80 mL) was added to acidify (pH<2) the reaction mixture. The 
mixture was extracted three times with 250 mL DCM. The combined organic phases were 
washed with brine, dried over magnesium sulfate, filtered, and the solvent was removed 
under vacuum. The crude product was filtered through a silica gel pad with pure DCM, then 
with cyclohexane:EtOAc = 3/2. The combined product fractions were dissolved in NaOH (1 
M) and washed with DCM. The formed precipitation was filtered and washed with DCM. The 
precipitation was dissolved in water, acidified with conc. HCl and extracted with DCM. The 
combined organic phases were dried over magnesium sulfate, filtered, and the solvent was 
removed under vacuum to give 16.5 g (57.9 mmol, 39%) 25a as a brown-yellow oil which 
became solid after 2 days.  
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.41. 
 
HPLC [20-80% Solvent B, 20 min]: Rt = 13.66 min, purity (220 nm) = 99%. 
1H-NMR (300 MHz, Chloroform-d): δ = 7.75 (d, J = 15.6 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 
7.55 – 7.51 (m, 1H), 7.40 (m, 1H), 7.35 (d, J= 15.6 Hz, 1H), 7.19 (dd, J = 8.2, 1.9 Hz, 1H), 
7.14 – 7.08 (m, 2H), 6.95 (d, J = 8.2 Hz, 1H), 6.20 (s, 1H), 3.92 (s, 3H), 3.86 (s, 3H) ppm. 
13C-NMR (75 MHz, Chloroform-d): δ = 190.45, 159.92, 148.52, 146.98, 145.40, 139.96, 
129.58, 127.51, 123.53, 121.04, 119.81, 119.01, 115.03, 113.07, 110.18, 56.09, 55.55 ppm. 
Mass (ESI+): m/z: calculated 285.11 [C17H16O4+H]+, found 285.17 [M+H]+. 
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(E)-3-(3-hydroxy-4-methoxyphenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (25b) 
 
Isovanillin (22.8 g, 150 mmol) and 3′-Methoxyacetophenone (22.5 g, 150 mmol) were 
dissolved in 150 mL EtOH and cooled to 0°C in an ice bath. KOH (33.7 g, 600 mmol) was 
dissolved in 100 mL H2O and added to the aforementioned ketone/aldehyde solution. 
Another 200 mL EtOH were added.  The reaction mixture was allowed to warm to RT and 
stirred for 1 d. The solution was poured into ice and the solution was acidified with conc. HCl 
to pH < 2. The solution was extracted with ethyl acetate, dried over MgSO4, filtered and 
concentrated in vacuum to dryness. The resulting solid was dissolved in DCM and filtered by a 
silica gel pad. The resulting residue was recrystallized in methanol to afford 25b (26.6 g, 93.6 
mmol, 63%).  
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.41. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 13.6 min, 91% purity 
 
Mass: (ESI+), m/z: calculated 285.11 [C17H16O4 + H]+, found 285.18 [M + H]+    
 
1H-NMR (300 MHz, Chloroform-d): δ 7.74 (d, J = 15.6 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.53 
(s, 1H), 7.39 (dd, J = 15.8, 8.8 Hz, 2H), 7.28 (d, J = 2.1 Hz, 1H), 7.13 (t, J = 2.5 Hz, 2H), 
6.88 (d, J = 8.3 Hz, 1H), 5.68 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): δ 144.78, 129.51, 122.72, 120.97, 120.36, 119.18, 113.02, 
112.76, 110.58, 56.03, 55.48 ppm. 
 
3-(4-hydroxy-3-methoxyphenyl)-1-(3-methoxyphenyl)propan-1-one (26a) 
 
25a (2.3 g, 8.23 mmol, 1 eq.) was dissolved in ethanol (820 mL). Ammoniumacetate 
(NH4OAc) (31.7 g, 412 mmol, 50 eq.) was dissolved in water (66 mL) and was added to the 
reaction mixture. Zinc powder (1.6 g, 24.69 mmol, 3 eq.) was added in two portions within 2 
min. The mixture was stirred at room temperature for 12 – 15 min. After filtration, the solvent 
was removed under vacuum. The solution was diluted with water (40 mL) and was extracted 
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with DCM. The combined organic phases were dried over magnesium sulfate, filtered and the 
solvent was removed under vacuum. The crude product was purified by column 
chromatography (cyclohexane:EtOAc, gradient EtOAc 20 to 40%) to give 6.1 g (21.13 mmol, 
64%) 26a.  
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.58. 
 
HPLC [20-80% Solvent B, 20 min]: Rt = 12.54 min, purity (220 nm) = 99%. 
 
1H-NMR (300 MHz, Chloroform-d): δ = 7.53 (d, J = 7.7 Hz, 1H), 7.50 – 7.46 (m, 1H), 7.35 
(t, J = 7.9 Hz, 1H), 7.10 (dd, J = 8.5, 2.9 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 6.74 (d, J = 8.9 
Hz, 2H), 5.34 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.26 (t, J = 7.6 Hz, 2H), 3.00 (t, J = 7.6 Hz, 
2H) ppm. 
13C-NMR (75 MHz, Chloroform-d): δ = 199.41, 159.95, 146.57, 144.08, 138.40, 133.26, 
129.68, 120.98, 120.78, 119.61, 114.50, 112.46, 111.30, 55.99, 55.54, 41.01, 30.09 ppm. 
Mass (ESI+): m/z: calculated 287.13 [C17H18O4+H]+, found 286.96 [M+H]+. 
 
3-(3-hydroxy-4-methoxyphenyl)-1-(3-methoxyphenyl)propan-1-one (26b) 
 
A 0.05 M solution of ketone 25b (7.0 g, 24.61 mmol) in 95% ethanol was added to 55 mL water 
containing ammonium acetate (94.9 g, 1230.6 mmol) at room temperature. The solution was 
stirred vigorously while zinc powder (3.2 g, 73.85 mmol) was added in five equal portions at 
intervals of 15 min. Stirring was continued for further 15 min. The suspended material was 
removed by filtration and washed with ethanol and the filtrate was evaporated under reduced 
pressure nearly to dryness. The residue was poured into ice-cooled water and it was extracted 
with DCM (5 x 100 mL), dried over MgSO4, filtered and concentrated in vacuum to dryness. 
The crude product was purified by chromatography (cyclohexane:EtOAc, gradient EtOAc 10 to 
30%) to afford ketone 4 (4.5 g, 13.8 mmol, 64%). 
 
TLC [cyclohexane/EtOAc 8/2]: Rf = 0.23. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 13.4 min, 97% purity 
1H-NMR (300 MHz, Chloroform-d): δ 7.53 (d, J = 7.6 Hz, 1H), 7.49 (s, 1H), 7.35 (t, J = 7.9 
Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.83 (s, 1H), 6.75 (q, J = 8.2 Hz, 2H), 5.64 (s, 1H), 3.86 (s, 
3H), 3.85 (s, 3H), 3.25 (t, J = 7.7 Hz, 2H), 2.97 (t, J = 7.6 Hz, 2H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): δ 199.15, 159.84, 145.60, 144.99, 138.28, 134.56, 129.56, 
120.68, 119.77, 119.57, 114.59, 112.25, 110.78, 56.02, 55.43, 40.67, 29.62 ppm. 
 
Mass: (ESI+), m/z: calculated 287.13 [C17H18O4 + H]+, found 287.08 [M + H]+    
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(R)-4-(3-hydroxy-3-(3-methoxyphenyl)propyl)-2-methoxyphenol (27a) 
 
Ketone 26a (5.4 g, 18.9 mmol) was suspended in 90 mL isopropanol and the solution was 
degassed with argon in an autoclave. K2CO3 (2.6 g, 18.9 mmol) and the catalyst RuCl2[(S)-
(DM-SEGPHOS)][(S)-DAIPEN] (182 mg, 0.15 mmol) were added. The autoclave was closed 
and flushed with H2 for three times. A pressure of 10 bar H2 was applied and the mixture was 
stirred for 2 d. The solution was filtered and the filtrate was concentrated in vacuum. The crude 
product was purified by chromatography (cyclohexane:EtOAc, gradient EtOAc 10 to 40%) to 
give 5.1 g (17.7 mmol, 94%) alcohol 27a. 
 
TLC [cyclohexane/EtOAc 6/4]: Rf=0.42. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.20 – 7.15 (m, 1H), 6.86 – 6.81 (m, 2H), 6.76 – 6.71 (m, 
2H), 6.61 – 6.57 (m, 2H), 5.46 (s, 1H), 4.57 (dd, J = 7.8, 5.2 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 
3H), 2.65 – 2.44 (m, 2H), 2.06 – 1.82 (m, 3H). 
 
13C NMR (126 MHz, CDCl3) δ 159.90, 146.53, 146.47, 143.82, 133.78, 129.63, 121.07, 118.36, 
114.39, 113.14, 111.58, 111.17, 73.92, 55.99, 55.35, 40.78, 31.84. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 11.4 min, 95% purity 
 
(R)-5-(3-hydroxy-3-(3-methoxyphenyl)propyl)-2-methoxyphenol (27b) 
 
Ketone 26b (3.32 g, 11.62 mmol) was suspended in 100 mL isopropanol and the solution was 
degassed with argon in an autoclave. K2CO3 (1.61 g, 11.62 mmol) and the catalyst RuCl2[(S)-
(DM-SEGPHOS)][(S)-DAIPEN] (0.11 g, 0.09 mmol) were added. The autoclave was closed and 
flushed with H2 for three times. A pressure of 10 bar H2 was applied and the mixture was stirred 
for 2 d. The solution was filtered and the filtrate was concentrated in vacuum. The crude 
product was purified by chromatography (cyclohexane:EtOAc, gradient EtOAc 20 to 40%) to 
give 3.30 g (11.44 mmol, 98.8%) alcohol 27b. 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.43. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 10.8 min, 99% purity 
 
ee = 99% 
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HR-MS: (ESI+), m/z: calculated 311.13 [C17H20O4 + Na]+, found 311.13 [M + Na]+    
 
1H-NMR (300 MHz, Chloroform-d): 7.27 (t, J = 8.1 Hz, 1H), 6.93 (dd, J = 4.4, 1.8 Hz, 2H), 
6.83 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H), 6.80 – 6.75 (m, 2H), 6.68 (dd, J = 8.2, 2.0 Hz, 1H), 4.66 
(dd, J = 7.7, 5.4 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 2.63 (td, J = 9.0, 6.6 Hz, 2H), 2.16 – 1.95 
(m, 2H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): 159.77, 146.38, 145.51, 144.81, 135.11, 129.49, 119.73, 
118.26, 114.75, 113.08, 111.37, 110.73, 73.71, 56.02, 55.23, 40.48, 31.38 ppm. 
 
(R)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-methoxyphenyl)propan-1-ol (28a) 
 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.47. 
 
Mass (ESI+): m/z: calculated 309.15 [C20H22O4+H–H2O]+, found 309.17 [M+H–H2O]+. 
HPLC [0%–100% eluent B, 20 min]: Rt = 13.9 min, 98% purity 
ee = 93%. 
1H-NMR (300 MHz, Chloroform-d): δ = 7.56 (t, J = 8.1 Hz, 1H), 7.29 – 7.17 (m, 3H), 7.16 – 
7.08 (m, 1H), 7.06 – 7.00 (m, 2H), 5.02 (d, J = 2.4 Hz, 2H), 4.96 (dd, J = 7.7, 5.4 Hz, 1H), 
4.14 (s, 3H), 4.10 (s, 3H), 3.08 – 2.86 (m, 2H), 2.79 (t, J = 2.4 Hz, 1H), 2.47 – 2.20 (m, 2H) 
ppm. 
13C-NMR (75 MHz, Chloroform-d): δ = 159.90, 149.75, 146.44, 145.06, 136.15, 129.63, 
120.25, 118.33, 114.90, 113.12, 112.41, 111.57, 78.97, 75.68, 73.89, 57.08, 55.96, 55.33, 
40.58, 31.81 ppm. 
 
(R)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)-1-(3-methoxyphenyl)propan-1-ol (28b) 
 
To a solution of 27b (9.98 g, 34.6 mmol) and K2CO3 (47.84 g, 346.1 mmol) in 150 mL acetone, 
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3-Bromprop-1-yne (3.71 mL, 4.94 g, 41.5 mmol) was added and stirred at RT for 4 d. The 
solution was filtered and the filter cake wash washed with acetone. The combined solution was 
concentrated in vacuum and purified by chromatography (cyclohexane:EtOAc, gradient EtOAc 
30 to 40%) to give 10.5 g (32.0 mmol, 93%) alcohol 28b. 
 
TLC [cyclohexane/EtOAc 8/2]: Rf = 0.13. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 13.4 min, ≥ 99% purity 
 
Mass: (ESI+), m/z: calculated 309.15 [C20H22O4+H–H2O]+, found 309.13 [M + H – H2O]+    
 
1H-NMR (300 MHz, Chloroform-d): 7.25 (t, J = 8.1 Hz, 1H), 6.91 (dd, J = 4.6, 2.4 Hz, 2H), 
6.88 (s, 1H), 6.85 – 6.77 (m, 3H), 4.73 (d, J = 2.4 Hz, 2H), 4.64 (dd, J = 7.8, 5.3 Hz, 1H), 
3.84 (s, 3H), 3.80 (s, 3H), 2.66 (td, J = 8.8, 6.6 Hz, 2H), 2.50 (t, J = 2.4 Hz, 1H), 2.13 – 1.94 
(m, 3H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): 159.78, 147.95, 146.60, 146.41, 134.27, 129.50, 121.83, 
118.23, 115.13, 112.97, 111.92, 111.48, 78.79, 75.71, 73.61, 56.81, 55.98, 55.23, 40.47, 31.47 
ppm. 
 
(S)-1-((9H-fluoren-9-yl)methyl) 2-((R)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-
methoxyphenyl)propyl) piperidine-1,2-dicarboxylate (29a) 
 
EDC-HCl (1.20 g, 6.25 mmol), DMAP (0.18 g, 1.56 mmol) and (S)-N-Fmoc-piperidine-2-
carboxylic acid (1.83 g, 5.21 mmol) were dissolved in 52 mL DCM at 0°C. Alcohol 28a (1.70 g, 
5.21 mmol) was added and the mixture was stirred at 0°C for 15 min and at RT overnight. The 
solution was concentrated in vacuum and purified by chromatography (cyclohexane:EtOAc, 
gradient EtOAc 20 to 30%)  to afford ester 29a (3.3 g, 5.00 mmol, 96%) as a yellow oil. 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.67. 
 
1H NMR (rotamers represent) (500 MHz, Chloroform-d) δ 7.84 – 7.71 (m, 2H), 7.63 (t, J = 
7.3 Hz, 1H), 7.54 – 7.45 (m, 1H), 7.45 – 7.30 (m, 3H), 7.29 – 7.20 (m, 2H), 6.97 – 6.88 (m, 
3H), 6.87 – 6.79 (m, 1H), 6.71 – 6.59 (m, 2H), 5.87 – 5.74 (m, 1H), 5.11 – 4.87 (m, 1H), 
4.74 (d, J = 2.2 Hz, 2H), 4.54 – 4.10 (m, 4H), 3.85 – 3.71 (m, 6H), 3.22 – 2.95 (m, 1H), 2.66 
– 2.46 (m, 3H), 2.39 – 2.19 (m, 2H), 2.07 – 2.02 (m, 1H), 1.80 – 1.68 (m, 3H), 1.55 – 1.43 
(m, 1H), 1.30 – 1.27 (m, 1H). 
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13C NMR (126 MHz, CDCl3) (major) δ 171.05, 159.81, 156.48, 149.75, 145.17, 144.21, 
143.99, 141.73, 141.39, 135.28, 129.72, 127.77, 127.14, 125.16, 120.07, 118.81, 114.87, 
113.48, 112.39, 112.33, 78.92, 76.42, 75.69, 67.88, 57.04, 55.92, 55.30, 54.65, 47.34, 42.14, 
38.11, 31.34, 26.91, 24.90, 20.91. 
 
(S)-1-((9H-fluoren-9-yl)methyl) 2-((R)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)-1-(3-
methoxyphenyl)propyl) piperidine-1,2-dicarboxylate (29b) 
 
EDC-HCl (0.71 g, 3.68 mmol), DMAP (0.11 g, 0.92 mmol) and (S)-N-Fmoc-piperidine-2-
carboxylic acid (1.08 g, 3.06 mmol) were dissolved in 30 mL DCM at 0°C. Alcohol 28b (1.00 g, 
3.06 mmol) was added and the mixture was stirred at 0°C for 15 min and at RT overnight. The 
solution was concentrated in vacuum and purified by chromatography (cyclohexane:EtOAc, 
gradient EtOAc 0 to 20%)  to afford ester 29b (1.92 g, 2.91 mmol, 95%) as a yellow oil. 
 
TLC [cyclohexane/EtOAc 8/2]: Rf = 0.23. 
 
HPLC [50%–100% eluent B, 20 min]: Rt = 15.6 min, ≥ 99% purity 
 
Mass (ESI+), m/z: calculated 682.28 [C41H41NO7 + Na]+, found 682.29 [M+ Na]+    
 
1H-NMR (300 MHz, Chloroform-d): 7.75 (dd, J = 13.6, 7.5 Hz, 2H), 7.60 (t, J = 6.1 Hz, 1H), 
7.53 - 7.16 (m, 6H), 6.91 (d, J = 7.7 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.85 – 6.62 (m, 4H), 
5.76 (s, 1H), 5.08 – 4.85 (m, 1H), 4.73 – 4.67 (m, 2H), 4.51 – 4.04 (m, 4H), 3.83 (s, 3H), 3.75 
(d, J = 18.1 Hz, 3H), 3.08 (dt, J = 43.4, 12.5 Hz, 1H), 2.61 – 2.40 (m, 3H), 2.38 – 2.14 (m, 
2H), 2.05 (t, J = 7.1 Hz, 1H), 1.70 (dt, J = 9.7, 5.2 Hz, 3H), 1.55 – 1.15 (m, 6H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): 170.92, 159.71, 148.09, 146.64, 144.12, 143.91, 141.67, 
141.29, 133.40, 129.62, 127.66, 127.05, 125.08, 121.73, 119.95, 118.86, 118.71, 115.02, 
113.35, 112.41, 112.31, 111.93, 78.71, 75.73, 67.79, 56.81, 55.96, 55.20, 54.92, 54.55, 47.25, 
42.02, 41.92, 38.01, 31.00, 27.04, 26.93, 26.82, 24.82, 24.58, 20.82, 20.72 ppm. 
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(S)-(R)-3-(4-(ethynyloxy)-3-methoxyphenyl)-1-(3-methoxyphenyl)propyl piperidine-2-
carboxylate (30a) 
 
Ester 29a (3.25 g, 4.93 mmol) was dissolved in 25 mL 4-methylpiperidine/DCM (v/v=1:9) and 
the mixture was stirred at RT for 2 h. Then the solution was diluted with DCM, washed with 
sat. NH4Cl, dried over MgSO4 and concentrated in vacuum. The crude product was purified by 
chromatography (cyclohexane:EtOAc with 1% TEA, gradient EtOAc 0 to 80%) to afford 30a 
(2.09 g, 4.78 mmol, 96%). 
 
TLC [EtOAc + 1% TEA]: Rf = 0.28. 
 
1H NMR (300 MHz, Chloroform-d) δ 7.24 (t, J = 7.9 Hz, 1H), 6.96 – 6.87 (m, 2H), 6.87 – 6.77 
(m, 2H), 6.72 – 6.62 (m, 2H), 5.77 (dd, J = 7.9, 5.7 Hz, 1H), 4.71 (d, J = 2.4 Hz, 2H), 3.83 
(s, 3H), 3.78 (s, 3H), 3.36 (dd, J = 9.7, 3.2 Hz, 1H), 3.05 (dt, J = 11.8, 3.4 Hz, 1H), 2.71 – 
2.50 (m, 3H), 2.48 (t, J = 2.4 Hz, 1H), 2.32 – 2.17 (m, 1H), 2.12 – 2.02 (m, 2H), 1.85 – 1.71 
(m, 1H), 1.66 – 1.37 (m, 4H). 
 
13C NMR (75 MHz, CDCl3) δ 172.89, 159.73, 149.73, 145.15, 141.84, 135.32, 129.62, 120.12, 
118.85, 114.84, 113.24, 112.43, 112.25, 78.86, 75.67, 75.59, 58.79, 57.00, 55.93, 55.28, 
45.70, 37.92, 31.47, 29.34, 25.90, 24.20. 
 
 
 
(S)-(R)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)-1-(3-methoxyphenyl)propyl 
piperidine-2-carboxylate (30b) 
 
Ester 29b (1.82 g, 2.76 mmol) was dissolved in 13.5 mL 4-methylpiperidine/DCM (v/v=1:9) 
and the mixture was stirred at RT for 2 h. Then the solution was diluted with DCM, washed 
with sat. NH4Cl, dried over MgSO4 and concentrated in vacuum. The crude product was purified 
by chromatography (cyclohexane:EtOAc with 1% TEA, gradient EtOAc 40 to 60%) to afford 
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30b (1.07 g, 2.45 mmol, 89%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.13. 
 
HPLC [0%–100% eluent B, 20 min]: Rt = 12.0 min, 98% purity 
 
1H-NMR (300 MHz, Chloroform-d): 7.28 – 7.19 (m, 1H), 6.90 (d, J = 7.7 Hz, 1H), 6.87 – 6.78 
(m, 4H), 6.74 (dd, J = 8.2, 1.9 Hz, 1H), 5.75 (dd, J = 7.9, 5.7 Hz, 1H), 4.74 (d, J = 2.4 Hz, 
2H), 3.83 (s, 3H), 3.79 (s, 3H), 3.37 (dd, J = 9.7, 3.2 Hz, 1H), 3.06 (dt, J = 12.0, 3.4 Hz, 1H), 
2.69 – 2.53 (m, 3H), 2.51 (t, J = 2.4 Hz, 1H), 2.32 – 2.20 (m, 2H), 2.12 – 1.99 (m, 3H), 1.83 
– 1.75 (m, 1H), 1.63 – 1.40 (m, 4H) ppm. 
 
13C-NMR (75 MHz, Chloroform-d): 172.73, 159.68, 148.13, 146.66, 141.82, 133.51, 129.54, 
121.78, 118.79, 115.11, 113.16, 112.40, 111.95, 78.72, 75.76, 75.48, 58.68, 56.88, 55.97, 
55.23, 45.59, 37.86, 31.18, 29.21, 25.78, 24.10 ppm. 
 
(S)-(R)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-1-(3-methoxyphenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (31a) 
 
31a was synthesized from 30a (853 mg, 1.95 mmol) according to the General Method H. 
Purification by flash column chromatography (cyclohexane:EtOAc, gradient EtOAc 0 to 30%) 
gave a white solid (894 mg, 1.23 mmol, 63%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.45. 
 
HPLC [50-100% Solvent B, 20 min]: Rt = 14.26 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) (3:1 mixture of rotamers) δ 7.23 (t, J = 7.9 Hz, 0.25H), 
7.04 (t, J = 7.9 Hz, 0.75H), 6.91 – 6.76 (m, 2H), 6.70 – 6.62 (m, 1H), 6.59 – 6.54 (m, 2H), 
6.45 – 6.30 (m, 3H), 5.75 (t, J = 6.9 Hz, 0.25H), 5.51 (dd, J = 7.9, 5.8 Hz, 0.75H), 5.41 (d, J 
= 4.7 Hz, 0.75H), 4.67 – 4.63 (m, 2H), 4.49 (d, J = 13.5 Hz, 0.25H), 3.89 (d, J = 13.7 Hz, 
1H), 3.78 – 3.74 (m, 6H), 3.70 – 3.62 (m, 9H), 3.31 (d, J = 9.9 Hz, 0.75H), 2.90 (d, J = 9.6 
Hz, 0.25H), 2.71 (td, J = 13.3, 2.7 Hz, 1H), 2.54 – 2.30 (m, 3H), 2.22 (d, J = 14.0 Hz, 1H), 
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2.06 – 1.99 (m, 1H), 1.92 – 1.72 (m, 3H), 1.62 – 1.48 (m, 6H), 1.28 – 1.17 (m, 3H), 1.14 – 
0.89 (m, 3H), 0.86 – 0.45 (m, 2H). 
13C NMR (126 MHz, CDCl3) (major) δ 172.37, 170.65, 159.56, 153.18, 149.75, 145.14, 
141.82, 136.99, 135.27, 133.75, 129.62, 120.29, 118.52, 114.91, 113.18, 112.50, 112.44, 
105.87, 78.94, 75.78, 75.68, 60.85, 57.07, 56.15, 55.97, 55.26, 52.12, 43.77, 41.53, 38.05, 
32.90, 31.21, 30.77, 26.85, 26.71, 26.33, 26.29, 25.70, 21.09. 
HRMS: m/z: found 728.37926 [M+H]+, calculated 728.37931 [M+H]+ 
 
(S)-(R)-3-(4-methoxy-3-(prop-2-yn-1-yloxy)phenyl)-1-(3-methoxyphenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (31b) 
 
31b was synthesized from 30b (500 mg, 1.15 mmol) according to the General Method H. 
Purification by flash column chromatography (cyclohexane:EtOAc, gradient EtOAc 0 to 40%) 
gave a white solid (546 mg, 0.75 mmol, 65%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.60. 
 
HPLC [50%–100% eluent B, 20 min]: Rt = 12.4 min, 98% purity 
Mass (ESI+): m/z:  calculated 728.38 [C43H53NO9 + H]+, found 728.23 [M+ H]+ 
 
1H NMR (500 MHz, Chloroform-d) (3:1 mixture of rotamers) δ 7.29 (t, J = 7.9 Hz, 0.25H), 
7.10 (t, J = 7.9 Hz, 0.75H), 6.95 – 6.71 (m, 4H), 6.69 (dd, J = 8.2, 1.9 Hz, 0.75H), 6.63 – 
6.60 (m, 0.75H), 6.49 (s, 1.5H), 6.42 (d, J = 5.6 Hz, 1H), 5.83 – 5.76 (m, 0.25H), 5.55 (dd, J 
= 7.9, 5.9 Hz, 0.75H), 5.47 (d, J = 5.0 Hz, 0.75H), 4.74 – 4.72 (m, 2H), 4.70 (d, J = 2.3 Hz, 
0.25H), 4.55 (d, J = 13.7 Hz, 0.25H), 3.95 (d, J = 14.0 Hz, 0.75H), 3.86 – 3.77 (m, 7H), 
3.75 (d, J = 7.5 Hz, 4H), 3.71 (s, 4H), 3.37 (d, J = 9.9 Hz, 0.75H), 2.96 (d, J = 9.7 Hz, 
0.25H), 2.78 (td, J = 13.4, 2.7 Hz, 1H), 2.63 – 2.34 (m, 3H), 2.28 (d, J = 9.8 Hz, 1H), 2.13 – 
2.07 (m, 1H), 2.00 – 1.76 (m, 3H), 1.72 – 1.51 (m, 6H), 1.43 – 1.26 (m, 3H), 1.22 – 1.03 (m, 
3H), 1.00 – 0.64 (m, 2H). 
13C NMR (126 MHz, CDCl3) (major) δ 172.36, 170.60, 159.56, 153.16, 148.19, 146.74, 
141.88, 137.02, 133.72, 133.47, 129.58, 122.00, 118.51, 115.26, 113.13, 112.51, 112.04, 
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105.92, 78.87, 75.89, 75.68, 60.84, 56.95, 56.15, 56.08, 55.24, 55.10, 52.10, 43.75, 41.49, 
37.98, 32.89, 30.94, 30.77, 26.83, 26.70, 26.31, 26.27, 25.69, 21.07. 
HRMS: m/z: found 728.37899 [M+H]+, calculated 728.37931 [M+H]+ 
 
2-Azidoethanol (40a) 
 
2-Chloroethanol (4.16 mL, 62.10 mmol) was added to a solution of NaN3 (4.97 g, 76.38 
mmol) and NaOH (0.25 g, 6.21 mmol) in water (20 mL). The mixture was stirred at room 
temperature for 3 days, and sodium sulfate (5.8 g) was added. After 10 min, the mixture was 
extracted with DCM (3 x 70 mL). The combined extracts were dried in magnesium sulfate and 
concentrated. The residue was distilled to give light yellow oil (2.97g, 34.14 mmol, 55%) 
1H NMR (300 MHz, Chloroform-d) δ 3.73 (q, J = 5.4 Hz, 2H), 3.44 – 3.34 (m, 2H), 2.97 (t, J 
= 5.6 Hz, 1H). 
13C NMR (75 MHz, Chloroform-d) δ 61.34, 53.47. 
Tert-butyl 2-(2-azidoethoxy)acetate (39a) 
 
39a was synthesized from 40a (2.87 g, 32.96 mmol) according to the General Method C. 
Purification by flash column chromatography (0% to 6% EtOAc in cyclohexane) gave a light 
yellow oil (4.18 g, 20.76 mmol, 63%). 
TLC [CH:EA 8:2]: Rf = 0.47. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.70 – 3.65 (m, 2H), 3.65 – 3.60 (m, 14H), 3.58 – 3.53 
(m, 2H), 3.38 – 3.31 (m, 2H), 2.89 (s, 1H). 
 
13C NMR (75 MHz, Chloroform-d) δ 72.61, 70.70, 70.62, 70.57, 70.33, 70.03, 61.71, 50.70. 
 
 
2-(2-Azidoethoxy)acetic acid (17a) 
 
17a was synthesized from 39a (2 g, 9.94 mmol) according to the General Method D. 
Purification by flash column chromatography (cyclohexane to 2% MeOH in DCM) gave a light 
yellow oil (0.292 g, 1.99 mmol, 20%). 
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TLC [(DCM:MeOH 95:5) +1% HCOOH]: Rf = 0.58. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.14 (s, 1H), 4.19 (s, 2H), 3.79 – 3.68 (m, 2H), 3.49 – 
3.40 (m, 2H). 
 
13C NMR (75 MHz, Chloroform-d) δ 175.39, 70.48, 68.07, 50.75. 
 
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (41c) 
 
41c was synthesized from triethylene glycol (3 g, 20 mmol) according to the General Method 
A. Purification by flash column chromatography (0% to 100% EtOAc in cyclohexane) gave a 
light yellow oil (4.7 g, 15.60 mmol, 78%). 
 
TLC [CH:EA 2:8]: Rf = 0.32. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.16 
– 4.13 (m, 2H), 3.70 – 3.66 (m, 4H), 3.58 (s, 4H), 3.56 – 3.53 (m, 2H), 2.42 (s, 3H). 
 
13C NMR (126 MHz, Chloroform-d) δ 144.96, 133.05, 129.92, 128.02, 72.59, 70.83, 70.33, 
69.26, 68.76, 61.78, 21.69. 
 
2-(2-(2-Azidoethoxy)ethoxy)ethanol (40c) 
 
40c was synthesized from 41c (4.7 g, 15.44 mmol) according to the General Method B. 
Purification by flash column chromatography (0% to 80% EtOAc in cyclohexane) gave a light 
yellow oil (2.54 g, 14.51 mmol, 94%). 
 
TLC [CH:EA 2:8]: Rf = 0.29. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.75 – 3.69 (m, 2H), 3.69 – 3.64 (m, 6H), 3.62 – 3.57 (m, 
2H), 3.42 – 3.34 (m, 2H), 2.42 (s, 1H). 
 
13C NMR (75 MHz, Chloroform-d) δ 72.62, 70.77, 70.49, 70.14, 61.86, 50.77. 
 
Tert-butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetate (39c) 
 
39c was synthesized from 40c (1.40 g, 8 mmol) according to the General Method C. Purification 
by flash column chromatography (0% to 30% EtOAc in cyclohexane) gave a light yellow oil 
(2.10 g, 7.20 mmol, 90%). 
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TLC [CH:EA 6:4]: Rf = 0.54. 
 
1H NMR (500 MHz, Chloroform-d) δ 3.99 (s, 2H), 3.70 – 3.62 (m, 10H), 3.36 (t, J = 5.1 Hz, 
2H), 1.45 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 169.70, 81.56, 70.81, 70.75, 70.73, 70.09, 69.14, 50.78, 
28.18. 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)acetic acid (17c) 
 
17c was synthesized from 39c (2.06 g, 7.12 mmol) according to the General Method D. 
Purification by flash column chromatography (cyclohexane to 2% MeOH and 0.4% HCOOH in 
DCM) gave a light yellow oil (1.30 g, 2.85 mmol, 40%). 
 
TLC [(DCM:MeOH 95:5) +1% HCOOH]: Rf  = 0.33. 
 
1H NMR (300 MHz, Chloroform-d) δ 9.95 (s, 1H), 4.15 (s, 2H), 3.74 – 3.71 (m, 2H), 3.70 – 
3.62 (m, 8H), 3.39 – 3.33 (m, 2H). 
 
13C NMR (75 MHz, Chloroform-d) δ 173.85, 71.26, 70.68, 70.52, 70.44, 70.07, 68.54, 50.68. 
 
2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (41d) 
 
41d was synthesized from tetraethylene glycol (0.93 g, 4.8 mmol) according to the General 
Method A. Purification by flash column chromatography (0% to 100% EtOAc in cyclohexane) 
gave a light yellow oil (1.20 g, 3.46 mmol, 72%). 
 
TLC [CH:EA 2:8]: Rf  = 0.12. 
 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethanol (40d) 
 
40d was synthesized from 41d (1.00 g, 2.87 mmol) according to the General Method B. 
Purification by flash column chromatography (0% to 80% EtOAc in cyclohexane) gave a light 
yellow oil (0.65 g, 2.47 mmol, 86%). 
 
TLC [CH:EA 2:8]: Rf = 0.20. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.73 – 3.68 (m, 2H), 3.65 (s, 10H), 3.61 – 3.56 (m, 2H), 
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3.41 – 3.34 (m, 2H), 2.83 (s, 1H). 
 
13C NMR (75 MHz, CDCl3) δ 72.51, 70.64, 70.60, 70.52, 70.28, 69.97, 61.64, 50.64. 
 
Tert-butyl 14-azido-3,6,9,12-tetraoxatetradecan-1-oate (39d) 
 
39d was synthesized from 40d (1.40 g, 8 mmol) according to the General Method C. 
Purification by flash column chromatography (0% to 30% EtOAc in cyclohexane) gave a light 
yellow oil (0.79 g, 6.96 mmol, 87%). 
 
TLC [CH:EA 6:4]: Rf = 0.30. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.98 (s, 2H), 3.71 – 3.60 (m, 14H), 3.39 – 3.32 (m, 2H), 
1.44 (s, 9H). 
 
13C NMR (75 MHz, Chloroform-d) δ 169.71, 81.56, 70.79, 70.78, 70.75, 70.71, 70.68, 70.65, 
70.08, 69.11, 50.76, 28.17. 
 
14-Azido-3,6,9,12-tetraoxatetradecan-1-oic acid (17d) 
 
17d was synthesized from 39d (0.74   g, 2.22 mmol) according to the General Method D. 
Purification by flash column chromatography (cyclohexane to 2% MeOH and 0.4% HCOOH in 
DCM) gave a light yellow oil (0.31 g, 1.13 mmol, 51%). 
 
TLC [(DCM:MeOH 95:5) +1% HCOOH]: Rf = 0.60. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.85 (s, 1H), 4.13 (s, 2H), 3.74 – 3.60 (m, 14H), 3.39 – 
3.32 (m, 2H). 
 
13C NMR (75 MHz, Chloroform-d) δ 173.14, 71.22, 70.67, 70.62, 70.54, 70.46, 70.33, 69.99, 
68.69, 50.66. 
 
14-Hydroxy-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate (41e) 
 
41e was synthesized from pentaethylene glycol (1.50 g, 6.30 mmol) according to the General 
Method A. Purification by flash column chromatography (0% to 100% EtOAc in cyclohexane) 
gave a light yellow oil (1.74 g, 4.41 mmol, 70%). 
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TLC [EA]: Rf = 0.14. 
 
1H NMR (300 MHz, Chloroform-d) δ 7.72 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 4.13 
– 4.04 (m, 2H), 3.65 – 3.48 (m, 18H), 2.78 (s, 1H), 2.37 (s, 3H). 
 
13C NMR (75 MHz, Chloroform-d) δ 144.82, 133.04, 129.85, 127.97, 72.53, 70.73, 70.59, 70.54, 
70.51, 70.33, 69.30, 68.68, 61.70, 21.64. 
 
14-Azido-3,6,9,12-tetraoxatetradecan-1-ol (40e) 
 
40e was synthesized from 41e (1.61 g, 4.11 mmol) according to the General Method B. 
Purification by flash column chromatography (0% to 100% EtOAc in cyclohexane) gave a light 
yellow oil (1.02 g, 3.90 mmol, 95%). 
 
TLC [DCM:MeOH]: Rf = 0.53. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.70 – 3.65 (m, 2H), 3.65 – 3.60 (m, 14H), 3.58 – 3.53 
(m, 2H), 3.38 – 3.31 (m, 2H), 2.89 (s, 1H). 
 
13C NMR (75 MHz, CDCl3) δ 72.61, 70.70, 70.62, 70.57, 70.33, 70.03, 61.71, 50.70. 
 
Tert-butyl 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-oate (39e) 
 
39e was synthesized from 40e (0.974 g, 3.70 mmol) according to the General Method C. 
Purification by flash column chromatography (0% to 30% EtOAc in cyclohexane) gave a light 
yellow oil (1.15 g, 3.03 mmol, 82%). 
 
TLC [CH:EA 4:6]: Rf = 0.28. 
 
1H NMR (300 MHz, Chloroform-d) δ 3.98 (s, 2H), 3.71 – 3.57 (m, 18H), 3.40 – 3.30 (m, 2H), 
1.44 (s, 9H). 
 
13C NMR (75 MHz, Chloroform-d) δ 169.69, 81.54, 70.77, 70.75, 70.72, 70.65, 70.07, 69.10, 
50.75, 28.16. 
 
17-Azido-3,6,9,12,15-pentaoxaheptadecan-1-oic acid (17e) 
 
17e was synthesized from 39e (1.11   g, 2.91 mmol) according to the General Method D. 
Purification by flash column chromatography (cyclohexane to 2% MeOH and 0.4% HCOOH in 
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DCM) gave a light yellow oil (0.41 g, 1.28 mmol, 44%). 
 
TLC [(DCM:MeOH 95:5) +1% HCOOH]: Rf= 0.33. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.97 (s, 1H), 4.13 (s, 2H), 3.75 – 3.57 (m, 18H), 3.35 (t, 
J = 4.3 Hz, 2H). 
 
13C NMR (75 MHz, Chloroform-d) δ 172.81, 71.24, 70.70, 70.64, 70.61, 70.48, 70.39, 70.02, 
68.80, 50.70. 
 
4-(4-Methylthiazol-5-yl)benzonitrile (34) 
 
4-Bromobenzonitrile (2 g, 10.99 mmol, 1 eq.), 4-methylthiazole (1.09 g, 10.99 mmol, 1 eq.), 
potassium acetate (2.16 g, 21.98 mmol, 2 eq.), palladium (II) acetate (0.025 g, 0.110 mmol, 
0.01 eq.) were dissolved in dimethylacetamide (20 mL) and stirred under argon. The mixture 
was heated to 120°C and stirred for 19 hours, then diluted with 500 mL EtOAc, and washed 4 
times with 70 mL brine. The first wash was then back extracted with 100 mL EtOAc, and then 
washed 4 times with 20 mL brine. The combined organic layer was dried over magnesium 
sulfate, filtered and concentrated under vacuum. The crude product was concentrated and 
purified by column chromatography (cyclohexane:EtOAc, gradient EtOAc 0 to 40%). 34 was 
afforded as a yellow solid (1.8 g, 8.99 mmol, 82%). 
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.40 min, purity (220 nm) = 97%. 
 
1H NMR (599 MHz, Chloroform-d) δ 8.77 (s, 1H), 7.74 – 7.71 (m, 2H), 7.58 – 7.55 (m, 2H), 
2.57 (s, 3H). 
 
13C NMR (151 MHz, Chloroform-d) δ 151.71, 150.06, 136.91, 132.64, 130.29, 129.84, 118.57, 
111.69, 16.44.. 
 
MS (ESI+): 201.01 [M+H]+, calculated 201.05 [M+H]+ 
 
 
 
Tert-butyl 4-(4-methylthiazol-5-yl)benzylcarbamate (33) 
 
To a suspension of 34 (1.3 g, 6.49 mmol, 1 eq.), di-tert-butyl dicarbonate (4.25 g, 19.47 mmol, 
3 eq.) and cobalt(II) chloride (0.421 g, 3.25 mmol, 0.5 eq.) in methanol was added sodium 
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borohydride (1.228 g, 32.5 mmol, 5 eq.) over 30 min at 0°C. The reaction was allowed to 
proceed for 30 min at RT. The mixture was filtered through celite and the filter cake was washed 
with 50 mL EtOAc. The crude product was concentrated and purified by flash column 
chromatography (DCM  DCM+1% MeOH).  33 was afforded as a yellow solid (1.14 g, 3.74 
mmol, 58%).  
 
TLC [cyclohexane/EtOAc 6/4]: Rf = 0.49. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.55 min, purity (220 nm) = 96%. 
 
1H NMR (599 MHz, Chloroform-d) δ 8.69 (s, 1H), 7.41 – 7.38 (m, 2H), 7.34 (d, J = 8.1 Hz, 
2H), 4.99 (s, 1H), 4.35 (d, J = 5.2 Hz, 2H), 2.52 (s, 3H), 1.46 (s, 9H). 
 
13C NMR (151 MHz, Chloroform-d) δ 156.03, 150.42, 148.39, 139.12, 131.84, 130.89, 129.60, 
127.85, 79.77, 44.38, 28.53, 16.09. 
 
MS (ESI+): m/z: found 305.04 [M+H]+, calculated 305.13 [M+H]+ 
 
 
(2S,4R)-Tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-
1-carboxylate (37) 
 
 
A solution of TFA (15 ml) and DCM (15 mL) was degassed by Ar for 5 min. Then 33 (940 mg, 
3.09 mmol, 1 eq.) was added into the solution and stirred at RT for 60 min. Then the solvent 
was removed in reduced pressure to give the corresponding deprotected intermediate (TFA salt) 
without further purification.  
(2S,4R)-1-(Tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.929 g, 4.02 mmol, 
1.3 eq.), EDC (0.770 g, 4.02 mmol, 1.3 eq.) and HOBt (0.615 g, 4.02 mmol, 1.3 eq.) were 
dissolved in DMF (15 mL) and cooled to 0 °C. DIPEA (2,70 ml, 15.45 mmol, 5 eq.) was added, 
and the solution was stirred for 30 min. Then the deprotected intermediate (in 1 mL DMF) was 
added, and the solution was allowed to warm slowly to room temperature. After 20 hours the 
mixture was poured into 100 mL brine and extracted 4 times with EtOAc. The combined organic 
layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane to 5% MeOH/DCM) gave a light 
yellow form (880 mg, 2.11 mmol, 68%) 
 
TLC [DCM + 5% MeOH]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 12.48 min, purity (220 nm) >99%. 
 
1H NMR (300 MHz, DMSO-d6) δ 8.97 (s, 1H), 8.46 (q, J = 7.2, 6.7 Hz, 1H), 7.44 – 7.35 (m, 
4H), 5.00 (d, J = 3.5 Hz, 1H), 4.41 – 4.14 (m, 4H), 3.52 – 3.36 (m, 1H), 3.33 – 3.25 (m, 1H), 
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2.44 (s, 3H), 2.14 – 2.02 (m, 1H), 1.87 (ddd, J = 14.2, 7.8, 4.6 Hz, 1H), 1.41 (s, 3H), 1.26 (s, 
6H). 
 
13C NMR (75 MHz, DMSO-d6) δ 172.50, 172.24, 153.92, 153.52, 151.42, 147.76, 139.42, 
131.04, 129.93, 128.78, 128.67, 128.08, 127.42, 78.64, 78.46, 68.50, 67.81, 58.92, 55.01, 
54.74, 41.80, 41.52, 28.10, 27.87, 15.87, 15.83. 
 
MS (ESI+): m/z: found 417.96 [M+H]+, calculated 418.18 [M+H]+ 
 
 
Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (38) 
 
 
37 (650 mg, 1.56 mmol, 1 eq.) was dissolved in a solution of TFA/DCM (2 ml, 1:1) and stirred 
at RT under Ar overnight. Then the solvent was removed in reduced pressure to give the 
corresponding deprotected intermediate (TFA salt) without further purification. 
(S)-2-((Tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid (397 mg, 1.72 mmol, 1.1 eq.), 
EDC (329 mg, 1.72 mmol, 1.1 eq.) and HOBt (263 mg, 1.72 mmol, 1.1 eq.) were dissolved in 
DMF (1 mL) and cooled to 0 °C. DIPEA (1.36 ml, 7.8 mmol, 5 eq.) was added, and the solution 
was stirred for 15 min. Then the deprotected intermediate (in 0.5 mL DMF) was added, and 
the solution was allowed to warm slowly to room temperature. After 20 hours the mixture was 
poured into brine and extracted 4 times with EtOAc. The combined organic layer was dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. Purification by flash 
column chromatography (cyclohexane to 5% MeOH in DCM) gave a light yellow solid (580 mg, 
1.09 mmol, 70%) 
 
TLC [DCM + 5% MeOH]: Rf = 0.23. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.97 min, purity (220 nm) = 97%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.42 (s, 1H), 7.30 – 7.22 (m, 4H), 5.17 (d, J 
= 9.0 Hz, 1H), 4.66 (t, J = 7.8 Hz, 1H), 4.46 (dd, J = 15.1, 6.1 Hz, 2H), 4.24 (dd, J = 15.0, 
5.2 Hz, 1H), 4.12 (d, J = 9.3 Hz, 1H), 3.92 (d, J = 11.1 Hz, 1H), 3.64 (br, s, 1H), 3.55 (dd, J 
= 11.0, 3.2 Hz, 1H), 2.43 (s, 3H), 2.42 – 2.37 (m, 1H), 2.07 – 1.99 (m, 1H), 1.33 (s, 9H), 0.85 
(s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 172.39, 170.85, 156.25, 150.29, 148.41, 138.15, 131.61, 
130.86, 129.45, 128.01, 80.26, 70.05, 58.87, 58.54, 56.51, 43.19, 36.05, 35.09, 28.32, 26.31, 
15.99. 
 
MS (ESI+): m/z: found 531.02 [M+H]+, calculated 531.26 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-Azidoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-
(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (43a) 
 
43a was synthesized from 38 and 17a according to the General Method E. Purification by flash 
column chromatography (cyclohexane to 5% MeOH in DCM) gave a white foam (77 mg, 0.14 
mmol, 81%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 10.9 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.65 (s, 1H), 7.48 (t, J = 5.9 Hz, 1H), 7.35 – 7.29 (m, 
4H), 7.20 (d, J = 8.8 Hz, 1H), 4.69 (t, J = 7.9 Hz, 1H), 4.54 – 4.46 (m, 3H), 4.30 (dd, J = 
15.1, 5.4 Hz, 1H), 4.02 – 3.94 (m, 3H), 3.71 – 3.59 (m, 3H), 3.49 – 3.35 (m, 2H), 2.48 (s, 3H), 
2.44 – 2.40 (m, 1H), 2.12 – 2.03 (m, 1H), 0.95 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.18, 171.07, 169.69, 150.40, 148.50, 138.24, 131.71, 
130.93, 129.53, 128.10, 70.59, 70.33, 70.17, 58.81, 57.29, 56.84, 50.76, 43.25, 36.32, 35.28, 
26.44, 16.09. 
 
MS (ESI+): m/z: found 558.08 [M+H]+, calculated 558.25 [M+H]+ 
 
 
(2S,4R)-1-((S)-2-(2-(2-(2-Azidoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (43b) 
 
 
43b was synthesized from 38 and (2-(2-azidoethoxy)ethoxy)acetic acid according to the 
General Method E. Purification by flash column chromatography (cyclohexane to 5% MeOH in 
DCM) gave a light yellow foam (99 mg,  0.15 mmol, 91%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.32. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.0 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.36 (t, J = 5.9 Hz, 1H), 7.30 – 7.25 (m, 
4H), 7.20 (d, J = 8.6 Hz, 1H), 4.63 (t, J = 7.9 Hz, 1H), 4.48 – 4.42 (m, 3H), 4.27 (dd, J = 
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15.0, 5.4 Hz, 1H), 3.97 – 3.87 (m, 3H), 3.69 – 3.54 (m, 9H), 3.36 – 3.27 (m, 2H), 2.43 (s, 3H), 
2.42 – 2.37 (m, 1H), 2.08 – 2.00 (m, 1H), 0.89 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.20, 170.90, 170.33, 150.29, 148.43, 138.15, 131.60, 
130.88, 129.45, 128.05, 71.08, 70.36, 70.33, 70.10, 70.04, 58.65, 57.15, 56.67, 50.55, 43.18, 
36.11, 35.09, 26.37, 16.01. 
 
MS (ESI+): m/z: found 602.12 [M+H]+, calculated 602.28 [M+H]+ 
 
 
(2S,4R)-1-((S)-14-Azido-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecan-1-oyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (43c) 
 
 
43c was synthesized from 38 and 17c according to the General Method E. Purification by flash 
column chromatography (cyclohexane to 5% MeOH in DCM) gave a light yellow foam (85 mg, 
0.13 mmol, 77%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.18. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.0 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.39 (t, J = 5.9 Hz, 1H), 7.32 – 7.25 (m, 
4H), 7.23 (d, J = 8.5 Hz, 1H), 4.63 (t, J = 7.9 Hz, 1H), 4.50 – 4.39 (m, 3H), 4.27 (dd, J = 
15.1, 5.4 Hz, 1H), 3.98 – 3.88 (m, 3H), 3.63 – 3.52 (m, 11H), 3.33 – 3.24 (m, 2H), 2.43 (s, 
3H), 2.42 – 2.32 (m, 1H), 2.09 – 1.98 (m, 1H), 0.89 (s, 9H). 
 
13C NMR (75 MHz, Chloroform-d) δ 171.25, 171.05, 170.43, 150.39, 148.49, 138.27, 131.69, 
130.91, 129.52, 128.10, 71.22, 70.74, 70.55, 70.36, 70.13, 70.10, 58.76, 57.16, 56.77, 50.73, 
43.23, 36.26, 35.24, 26.46, 16.11. 
 
MS (ESI+): m/z: found 646.09 [M+H]+, calculated 646.30 [M+H]+ 
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(2S,4R)-1-((S)-17-Azido-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecan-1-oyl)-
4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (43d) 
 
 
43d was synthesized from 38 and 17d according to the General Method E. Purification by flash 
column chromatography (cyclohexane to 5% MeOH in DCM) gave a yellow oil (79 mg, 0.12 
mmol, 68%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.35. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.2 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.48 (t, J = 5.9 Hz, 1H), 7.36 – 7.31 (m, 
4H), 7.28 (d, J = 8.8 Hz, 1H), 4.70 (t, J = 7.8 Hz, 1H), 4.55 – 4.47 (m, 3H), 4.34 (dd, J = 
15.1, 5.5 Hz, 1H), 3.99 (t, J = 9.2 Hz, 3H), 3.68 – 3.61 (m, 15H), 3.38 – 3.34 (m, 2H), 2.50 (s, 
3H), 2.43 (ddd, J = 12.8, 7.7, 4.7 Hz, 1H), 2.14 – 2.06 (m, 1H), 0.96 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.33, 171.20, 170.49, 150.48, 148.58, 138.40, 131.80, 
131.00, 129.61, 128.19, 71.31, 70.81, 70.76, 70.74, 70.55, 70.48, 70.21, 70.17, 58.89, 57.25, 
56.88, 50.84, 43.32, 36.43, 35.39, 26.56, 16.20. 
 
MS (ESI+): m/z: found 690.25 [M+H]+, calculated 690.33 [M+H]+ 
 
 
(2S,4R)-1-((S)-20-Azido-2-(tert-butyl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosan-1-oyl)-4-
hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (43e) 
 
 
43e was synthesized from 38 and 17e according to the General Method E. Purification by flash 
column chromatography (cyclohexane to 5% MeOH in DCM) gave a yellow oil (93 mg, 0.13 
mmol, 74%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.28. 
 
 102 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.4 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.68 (s, 1H), 7.49 (t, J = 5.9 Hz, 1H), 7.38 – 7.28 (m, 
5H), 4.71 (t, J = 7.9 Hz, 1H), 4.56 – 4.48 (m, 3H), 4.35 (dd, J = 15.1, 5.4 Hz, 1H), 4.05 – 3.94 
(m, 3H), 3.72 – 3.57 (m, 21H), 3.37 (t, J = 5.1 Hz, 2H), 2.51 (s, 3H), 2.45 (ddd, J = 12.9, 7.9, 
4.7 Hz, 1H), 2.15 – 2.07 (m, 1H), 0.97 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.23, 171.09, 170.44, 150.37, 148.48, 138.30, 131.70, 
130.90, 129.52, 128.11, 71.22, 70.73, 70.69, 70.66, 70.64, 70.60, 70.47, 70.42, 70.12, 70.06, 
58.77, 57.15, 56.80, 50.75, 43.23, 36.29, 35.27, 26.47, 16.10. 
 
MS (ESI+): m/z: found 734.23 [M+H]+, calculated 734.35 [M+H]+ 
 
2-(2-Azidoethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide 
(44a) 
 
44a was synthesized from 17a (70 mg, 0.483 mmol) according to the General Method F. 
Purification by flash column chromatography (0% to 60% EtOAc in cyclohexane) gave a light 
yellow solid (57 mg, 0.14 mmol, 90%). 
 
TLC [CH:EA 4:6]: Rf = 0.37. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.1 min, purity (220 nm) = 97%. 
 
MS (ESI+): m/z: found 400.96 [M+H]+, calculated 401.12 [M+H]+ 
 
1H NMR (500 MHz, DMSO-d6) δ 11.15 (s, 1H), 10.36 (s, 1H), 8.73 (d, J = 8.5 Hz, 1H), 7.89 
(t, J = 7.9 Hz, 1H), 7.65 (d, J = 7.3 Hz, 1H), 5.18 (dd, J = 12.7, 5.4 Hz, 1H), 4.27 (s, 2H), 
3.83 (t, J = 4.7 Hz, 2H), 3.61 – 3.58 (m, 2H), 2.98 – 2.84 (m, 1H), 2.68 – 2.55 (m, 2H), 2.17 
– 2.05 (m, 1H). 
 
13C NMR (126 MHz, DMSO-d6) δ 172.73, 169.72, 168.98, 168.23, 166.68, 136.55, 135.92, 
131.32, 124.47, 118.42, 116.20, 70.00, 69.78, 49.95, 49.01, 30.94, 21.93. 
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2-(2-(2-Azidoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)acetamide (44b) 
 
44b was synthesized from (2-(2-Azidoethoxy)ethoxy)acetic acid (95 mg, 0.503 mmol) 
according to the General Method F. Purification by flash column chromatography (0% to 60% 
EtOAc in cyclohexane) gave a light yellow solid (25 mg,  0.056 mmol, 34%). 
 
TLC [CH:EA 4:6]: Rf = 0.28. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.4 min, purity (220 nm) = 96%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.38 (s, 1H), 8.79 (d, J = 8.4 Hz, 1H), 8.33 (s, 1H), 7.69 
– 7.61 (m, 1H), 7.51 (d, J = 7.3 Hz, 1H), 4.90 (dd, J = 12.4, 5.3 Hz, 1H), 4.14 (s, 2H), 3.80 – 
3.70 (m, 4H), 3.68 – 3.62 (m, 2H), 3.32 (t, J = 5.1 Hz, 2H), 2.86 – 2.63 (m, 3H), 2.12 – 2.05 
(m, 1H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.05, 169.42, 168.58, 168.06, 166.89, 136.90, 136.45, 
131.49, 125.44, 118.95, 116.31, 71.75, 71.24, 70.71, 70.30, 50.80, 49.40, 31.50, 22.77. 
 
MS (ESI+): m/z: found 445.04[M+H]+, calculated 445.15 [M+H]+ 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)acetamide (44c) 
 
44c was synthesized from 17c (95 mg, 0.407 mmol) according to the General Method F. 
Purification by flash column chromatography (0% to 80% EtOAc in cyclohexane) gave a light 
yellow solid (56 mg, 0.056 mmol, 35%). 
 
TLC [CH:EA 2:8]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.5 min, purity (220 nm) = 97%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.43 (s, 1H), 8.83 (d, J = 8.4 Hz, 1H), 8.70 (s, 1H), 7.75 
– 7.64 (m, 1H), 7.55 (d, J = 7.3 Hz, 1H), 4.94 (dd, J = 12.3, 5.4 Hz, 1H), 4.19 (s, 2H), 3.84 – 
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3.76 (m, J = 2.5 Hz, 4H), 3.72 – 3.60 (m, 6H), 3.37 – 3.31 (m, 2H), 2.91 – 2.69 (m, 3H), 2.13 
(ddd, J = 9.4, 5.0, 2.2 Hz, 1H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.24, 169.56, 168.49, 168.18, 166.87, 136.83, 136.36, 
131.45, 125.32, 118.84, 116.24, 71.64, 71.11, 70.84, 70.75, 70.72, 70.08, 50.75, 49.34, 31.44, 
22.71. 
 
MS (ESI+): m/z: found 489.13[M+H]+, calculated 489.17 [M+H]+ 
 
14-Azido-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-
tetraoxatetradecan-1-amide (44d) 
 
44d was synthesized from 17d (105 mg, 0.379 mmol) according to the General Method F. 
Purification by flash column chromatography (0% to 80% EtOAc in cyclohexane) gave a light 
yellow solid (66 mg, 0.123 mmol, 99%). 
 
TLC [CH:EA 2:8]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.6 min, purity (220 nm) = 91%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.45 (s, 1H), 8.85 – 8.75 (m, 2H), 7.73 – 7.64 (m, 1H), 
7.54 (d, J = 7.2 Hz, 1H), 4.94 (dd, J = 12.2, 5.4 Hz, 1H), 4.18 (d, J = 1.5 Hz, 2H), 3.79 (th, 
J = 5.2, 2.8 Hz, 4H), 3.67 – 3.61 (m, 10H), 3.36 (t, J = 5.1 Hz, 2H), 2.91 – 2.68 (m, 3H), 2.17 
– 2.10 (m, 1H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.25, 169.52, 168.48, 168.17, 166.85, 136.82, 136.34, 
131.46, 125.27, 118.82, 116.24, 71.63, 71.06, 70.74, 70.64, 70.61, 70.58, 69.99, 50.72, 49.34, 
31.43, 22.74. 
 
MS (ESI+): m/z: found 533.17[M+H]+, calculated 533.20 [M+H]+ 
  
 105 
 
17-Azido-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-
pentaoxaheptadecan-1-amide (44e) 
  
44e was synthesized from 17e (105 mg, 0.425 mmol) according to the General Method F. 
Purification by flash column chromatography (0% to 80% EtOAc in cyclohexane) gave a light 
yellow solid (34 mg, 0.059 mmol, 55%). 
 
TLC [EA]: Rf = 0.37. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.6 min, purity (220 nm) = 97%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.47 (s, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.78 (s, 1H), 7.71 
(t, J = 7.9 Hz, 1H), 7.56 (d, J = 7.3 Hz, 1H), 4.94 (dd, J = 12.3, 5.4 Hz, 1H), 4.18 (d, J = 2.5 
Hz, 2H), 3.80 (s, 4H), 3.70 – 3.62 (m, 14H), 3.36 (t, J = 5.1 Hz, 2H), 2.94 – 2.67 (m, 3H), 
2.17 – 2.11 (m, 1H). 
 
13C NMR (126 MHz, Chloroform-d) δ 171.03, 169.38, 168.41, 168.00, 166.78, 136.76, 136.25, 
131.40, 125.21, 118.74, 116.17, 71.61, 70.98, 70.67, 70.62, 70.53, 70.47, 69.93, 50.69, 49.29, 
31.39, 22.69. 
 
MS (ESI+): m/z: found 576.22 [M+H]+, calculated 577.23 [M+H]+ 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-
methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)amino)-2-oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ199) 
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MTQ199 was synthesized from 43a (7 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid (13 
mg, 0.010 mmol, 74%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.25. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.4 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.69 (s, 1H), 7.79 (s, 0.75H), 7.74 
(s, 0.25H), 7.42 – 7.26 (m, 5H), 7.20 – 7.04 (m, 2H), 7.02 – 6.73 (m, 4H), 6.69 – 6.58 (m, 2H), 
6.50 – 6.46 (m, 2H), 5.58 (dd, J = 7.8, 5.7 Hz, 1H), 5.44 (d, J = 3.5 Hz, 1H), 5.17 (s, 0.5H), 
5.14 (s, 1.5H), 4.79 – 4.20 (m, 8H), 4.06 – 3.86 (m, 6H), 3.85 – 3.80 (m, 8H), 3.77 (s, 2H), 
3.71 (s, 4H), 3.64 – 3.57 (m, 1H), 3.38 (d, J = 9.9 Hz, 0.75H), 2.97 (d, J = 9.6 Hz, 0.25H), 
2.90 – 2.70 (m, 1H), 2.64 – 2.53 (m, 1H), 2.51 (s, 3H), 2.49 – 2.22 (m, 4H), 2.13 – 1.95 (m, 
4H), 1.88 – 1.79 (m, 4H), 1.74 – 1.68 (m, 2H), 1.62 – 1.50 (m, 3H), 1.37 – 1.28 (m, 2H), 1.22 
– 1.06 (m, 3H), 0.93 (s, 9H). 
 
HRMS: m/z: found 1285.62133 [M+H]+, calculated 1285.62135 [M+H]+ 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-
methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propyl 1-
((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ200) 
 
MTQ200 was synthesized from 43b (8 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid (13 
mg, 0.010 mmol, 74%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.6 min, purity (220 nm) = 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.66 (s, 1H), 7.97 (s, 0.75H), 7.85 
(s, 0.25H), 7.36 – 7.31 (m, 3H), 7.30 – 7.26 (m, 2H), 7.25 – 7.08 (m, 2H), 6.99 – 6.96 (m, 
0.5H), 6.86 – 6.73 (m, 2.75H), 6.69 – 6.59 (m, 2H), 6.49 (s, 1.5H), 6.46 – 6.41 (m, 1.25H), 
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5.54 (dd, J = 8.0, 5.7 Hz, 1H), 5.45 (d, J = 5.0 Hz, 1H), 5.17 (s, 0.5H), 5.14 (s, 1.5H), 4.70 – 
4.40 (m, 7H), 4.34 – 4.24 (m, 1H), 4.05 – 3.92 (m, 3H), 3.91 – 3.86 (m, 2H), 3.85 – 3.81 (m, 
9H), 3.77 (s, 2H), 3.71 (s, 4H), 3.67 – 3.56 (m, 5H), 3.38 (d, J = 9.8 Hz, 0.75H), 2.99 (d, J = 
9.6 Hz, 0.25H), 2.78 (td, J = 13.4, 2.7 Hz, 1H), 2.64 – 2.52 (m, 1H), 2.50 (s, 3H), 2.49 – 2.23 
(m, 4H), 2.06 – 1.92 (m, 2H), 1.90 – 1.80 (m, 2H), 1.66 – 1.51 (m, 5H), 1.48 – 1.37 (m, 1H), 
1.34 – 1.28 (m, 2H), 1.21 – 1.09 (m, 3H), 0.96 (s, 9H), 0.91 – 0.52 (m, 3H). 
 
HRMS: m/z: found 1329.64806 [M+H]+, calculated 1329.64756 [M+H]+ 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-((S)-13-((2S,4R)-4-hydroxy-2-((4-(4-
methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-
3,6,9-trioxa-12-azapentadecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propyl 1-((S)-2-
cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ201) 
 
MTQ201 was synthesized from 43c (9 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid (15 
mg, 0.011 mmol, 81%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.24. 
 
HPLC [30-100% Solvent B, 20 min]: Rt = 17.4 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.66 (s, 1H), 7.81 (s, 0.75H), 7.79 
(s, 0.25H), 7.37 – 7.30 (m, 5H), 7.24 – 6.98 (m, 2H), 6.96 – 6.82 (m, 1H), 6.81 – 6.71 (m, 2H), 
6.69 – 6.57 (m, 2H), 6.53 – 6.38 (m, 3H), 5.57 (dd, J = 7.6, 5.8 Hz, 1H), 5.46 (d, J = 4.3 Hz, 
1H), 5.16 (s, 0.5H), 5.13 (s, 1.5H), 4.76 – 4.46 (m, 7H), 4.38 – 4.27 (m, 1H), 4.05 (d, J = 11.3 
Hz, 1H), 3.98 (d, J = 2.7 Hz, 2H), 3.86 – 3.81 (m, 10H), 3.76 (s, 2H), 3.70 (s, 4H), 3.67 – 3.57 
(m, 10H), 3.38 (d, J = 9.7 Hz, 0.75H), 3.00 (d, J = 9.8 Hz, 0.25H), 2.87 – 2.70 (m, 1H), 2.63 
– 2.52 (m, 1H), 2.51 (s, 3H), 2.50 – 2.22 (m, 4H), 2.14 – 2.05 (m, 2H), 1.95 – 1.82 (m, 2H), 
1.63 – 1.50 (m, 4H), 1.43 – 1.31 (m, 2H), 1.21 – 1.06 (m, 4H), 0.95 (s, 9H), 0.88 – 0.52 (m, 
4H). 
 
HRMS: m/z: found 1373.67337 [M+H]+, calculated 1373.67378 [M+H]+ 
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(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-((S)-16-((2S,4R)-4-hydroxy-2-((4-(4-
methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-14-oxo-
3,6,9,12-tetraoxa-15-azaoctadecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propyl 1-((S)-
2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ202) 
 
MTQ202 was synthesized from 43d (10 mg, 0. 0137 mmol) according to the General Method 
G. Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid 
(17 mg, 0.012 mmol, 89%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.6 min, purity (220 nm) = 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.66 (s, 1H), 7.81 (s, 1H), 7.39 – 
7.28 (m, 5.5H), 7.23 (d, J = 8.7 Hz, 1H), 7.13 – 6.95 (m, 1.5H), 6.87 – 6.78 (m, 1H), 6.77 – 
6.74 (m, 1.5H), 6.70 – 6.59 (m, 2H), 6.49 (s, 1.5H), 6.46 – 6.41 (m, 1H), 5.58 (dd, J = 7.9, 
5.7 Hz, 1H), 5.46 (d, J = 4.7 Hz, 1H), 5.17 (s, 0.5H), 5.13 (s, 1.5H), 4.73 – 4.69 (m, 1H), 4.57 
– 4.48 (m, 5H), 4.37 – 4.30 (m, 1H), 4.07 (d, J = 11.4 Hz, 1H), 4.03 – 3.90 (m, 3H), 3.87 – 
3.81 (m, 10H), 3.76 (s, 2H), 3.70 (s, 4H), 3.66 – 3.55 (m, 14H), 3.38 (d, J = 9.8 Hz, 1H), 2.78 
(td, J = 13.4, 2.7 Hz, 1H), 2.64 – 2.51 (m, 2H), 2.50 (s, 3H), 2.49 – 2.33 (m, 2H), 2.31 – 2.23 
(m, 1H), 2.14 – 2.06 (m, 2H), 1.99 – 1.81 (m, 3H), 1.66 – 1.54 (m, 5H), 1.48 – 1.28 (m, 3H), 
1.22 – 1.05 (m, 3H), 0.95 (s, 9H), 0.88 – 0.53 (m, 2H). 
 
HRMS: m/z: found 1417.69922 [M+H]+, calculated 1417.69999 [M+H]+ 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-((S)-19-((2S,4R)-4-hydroxy-2-((4-(4-
methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-20,20-dimethyl-17-oxo-
3,6,9,12,15-pentaoxa-18-azahenicosyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propyl 1-
((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ203) 
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MTQ203 was synthesized from 43e (10 mg, 0. 0137 mmol) according to the General Method 
G. Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid 
(16 mg, 0.011 mmol, 81%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.23. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.5 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.66 (s, 1H), 7.80 (s, 1H), 7.35 (d, 
J = 1.9 Hz, 5H), 7.16 – 6.95 (m, 2H), 6.85 (dd, J = 8.0, 2.2 Hz, 1H), 6.79 – 6.73 (m, 2H), 6.71 
– 6.59 (m, 2H), 6.52 – 6.40 (m, 3H), 5.58 (dd, J = 7.8, 6.0 Hz, 1H), 5.46 (d, J = 4.0 Hz, 1H), 
5.18 (s, 0.5H), 5.14 (s, 1.5H), 4.72 (t, J = 7.9 Hz, 1H), 4.62 – 4.43 (m, 6H), 4.34 (dd, J = 14.9, 
5.3 Hz, 1H), 4.12 – 4.05 (m, 1H), 3.99 (d, J = 6.3 Hz, 2H), 3.89 – 3.80 (m, 11H), 3.76 (s, 2H), 
3.70 (s, 4H), 3.66 – 3.63 (m, 4H), 3.62 – 3.56 (m, 13H), 3.38 (d, J = 9.9 Hz, 1H), 2.86 – 2.69 
(m, 1H), 2.56 (dd, J = 8.0, 5.0 Hz, 2H), 2.51 (s, 3H), 2.49 – 2.23 (m, 3H), 2.14 – 1.83 (m, 5H), 
1.68 – 1.56 (m, 5H), 1.37 – 1.30 (m, 2H), 1.21 – 1.02 (m, 4H), 0.95 (s, 9H), 0.88 (s, 2H). 
 
HRMS: m/z: found 1461.72591 [M+H]+, calculated 1461.72621 [M+H]+ 
 
(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ204) 
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MTQ204 was synthesized from 44a (5 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 4% EtOH in DCM) gave a light yellow 
solid (10 mg, 0.0096 mmol, 70%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.57. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.5 min, purity (220 nm) = 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.40 – 10.28 (m, 1H), 8.82 – 8.71 
(m, 1H), 8.64 – 8.37 (m, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.73 – 7.63 (m, 1H), 7.57 – 7.47 (m, 
1H), 7.07 – 6.86 (m, 1.5H), 6.83 – 6.74 (m, 1.5H), 6.73 – 6.66 (m, 1H), 6.63 – 6.52 (m, 2H), 
6.47 – 6.34 (m, 3H), 5.74 (t, J = 7.2 Hz, 0.25H), 5.53 – 5.45 (m, 0.75H), 5.42 – 5.33 (m, 
0.75H), 5.22 – 5.03 (m, 2H), 4.93 – 4.84 (m, 1H), 4.75 – 4.63 (m, 2H), 4.53 – 4.46 (m, 0.25H), 
4.06 (d, J = 4.2 Hz, 2H), 3.99 – 3.94 (m, 2H), 3.90 – 3.84 (m, 1H), 3.81 – 3.71 (m, 9H), 3.69 
(s, 2H), 3.62 (s, 2H), 3.61 (s, 2H), 3.30 (d, J = 9.8 Hz, 0.75H), 2.99 (dd, J = 9.7, 3.3 Hz, 
0.25H), 2.81 – 2.56 (m, 4H), 2.46 – 2.36 (m, 1H), 2.33 – 2.15 (m, 2H), 2.07 – 1.98 (m, 2H), 
1.93 – 1.72 (m, 3H), 1.68 – 1.56 (m, 4H), 1.48 – 1.44 (m, 1H), 1.38 – 1.30 (m, 1H), 1.25 – 
1.20 (m, 2H), 1.14 – 1.00 (m, 3H), 0.92 – 0.75 (m, 2H), 0.73 – 0.62 (m, 1H). 
 
 
HRMS: m/z: found 1128.49272 [M+H]+, calculated 1128.49244 [M+H]+ 
 
(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ205) 
 
MTQ205 was synthesized from 44b (6 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 4% EtOH in DCM) gave a light yellow 
solid (11 mg, 0.0093 mmol, 68%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.52. 
 
HPLC [30-100% Solvent B, 20 min]: Rt = 15.8 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.42 (s, 1H), 8.84 (d, J = 8.4 Hz, 
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1H), 8.56 – 8.29 (m, 1H), 7.80 – 7.75 (m, 1H), 7.69 (t, J = 7.9 Hz, 1H), 7.55 (d, J = 7.1 Hz, 
1H), 7.09 (t, J = 7.8 Hz, 0.75H), 7.00 – 6.89 (m, 0.75H), 6.85 – 6.58 (m, 4.75H), 6.50 (s, 
1.5H), 6.47 – 6.39 (m, 1.25H), 5.80 (t, J = 6.5 Hz, 0.25H), 5.56 (t, J = 7.0 Hz, 0.75H), 5.48 
(d, J = 5.0 Hz, 0.75H), 5.12 (s, 0.5H), 5.08 (s, 1.5H), 5.01 – 4.93 (m, 1H), 4.74 (d, J = 5.1 
Hz, 0.25H), 4.63 – 4.50 (m, 2H), 4.15 (s, 2H), 4.02 – 3.92 (m, 3H), 3.89 – 3.79 (m, 9H), 3.77 
(s, 6H), 3.70 (s, 4H), 3.38 (d, J = 9.9 Hz, 0.75H), 3.00 (d, J = 9.7 Hz, 0.25H), 2.93 – 2.69 (m, 
4H), 2.57 – 2.33 (m, 2H), 2.32 – 2.25 (m, 1H), 2.19 – 2.04 (m, 2H), 1.99 – 1.76 (m, 3H), 1.75 
– 1.61 (m, 5H), 1.45 – 1.28 (m, 3H), 1.20 – 1.08 (m, 3H), 0.97 – 0.68 (m, 3H). 
 
 
HRMS: m/z: found 1172.51994 [M+H]+, calculated 1172.51866 [M+H]+ 
 
(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-
1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ206) 
 
MTQ206 was synthesized from 44c (7 mg, 0. 0137 mmol) according to the General Method G. 
Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid (13 
mg, 0.011 mmol, 78%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.50. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.6 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.43 (s, 1H), 8.84 (d, J = 8.4 Hz, 
1H), 8.39 (d, J = 4.6 Hz, 1H), 7.78 (s, 1H), 7.70 (t, J = 7.9 Hz, 1H), 7.56 (d, J = 7.3 Hz, 1H), 
7.10 (t, J = 7.9 Hz, 0.75H), 7.04 – 6.93 (m, 0.75H), 6.88 – 6.71 (m, 2.5H), 6.71 – 6.59 (m, 
2H), 6.46 (d, J = 20.6 Hz, 3H), 5.80 (t, J = 6.9 Hz, 0.25H), 5.63 – 5.51 (m, 0.75H), 5.47 (d, J 
= 3.7 Hz, 0.75H), 5.18 (s, 0.5H), 5.14 (s, 1.5H), 5.00 – 4.89 (m, 1H), 4.76 – 4.71 (m, 0.25H), 
4.52 (t, J = 5.1 Hz, 2H), 4.18 (s, 2H), 3.88 (d, J = 5.2 Hz, 2H), 3.84 (dt, J = 5.8, 2.9 Hz, 9H), 
3.80 – 3.71 (m, 7H), 3.70 (s, 4H), 3.64 – 3.57 (m, 4H), 3.38 (d, J = 9.9 Hz, 0.75H), 3.00 (d, J 
= 9.8 Hz, 0.25H), 2.93 – 2.66 (m, 4H), 2.59 – 2.24 (m, 3H), 2.17 – 1.81 (m, 5H), 1.73 – 1.65 
(m, 2H), 1.56 – 1.51 (m, 1H), 1.46 – 1.02 (m, 8H), 0.98 – 0.50 (m, 3H). 
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HRMS: m/z: found 1216.54470 [M+H]+, calculated 1216.54487 [M+H]+ 
 
(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(14-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)-14-oxo-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ207) 
 
MTQ207 was synthesized from 44d (10 mg, 0. 0137 mmol) according to the General Method 
G. Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid 
(12 mg, 0.0097 mmol, 71%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.50. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.5 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.41 (s, 1H), 8.77 (d, J = 8.4 Hz, 
1H), 8.51 (s, 1H), 7.73 (s, 1H), 7.68 – 7.58 (m, 1H), 7.50 (d, J = 7.3 Hz, 1H), 7.04 (t, J = 7.9 
Hz, 0.75H), 6.97 – 6.85 (m, 1H), 6.79 (dd, J = 8.1, 2.0 Hz, 0.75H), 6.74 – 6.66 (m, 1.75H), 
6.64 – 6.51 (m, 2H), 6.43 (s, 1.5H), 6.36 (t, J = 3.8 Hz, 1.25H), 5.80 – 5.68 (m, 0.25H), 5.51 
(dd, J = 7.6, 5.8 Hz, 0.75H), 5.40 (d, J = 4.3 Hz, 0.75H), 5.12 (s, 0.5H), 5.08 (s, 1.5H), 4.92 
– 4.83 (m, 1H), 4.70 – 4.63 (m, 0.25H), 4.47 (t, J = 5.1 Hz, 2H), 4.10 (d, J = 1.4 Hz, 2H), 
3.94 – 3.85 (m, 1H), 3.82 (t, J = 5.2 Hz, 2H), 3.79 – 3.74 (m, 8H), 3.74 – 3.67 (m, 7H), 3.64 
(s, 4H), 3.62 – 3.57 (m, 2H), 3.52 (s, 6H), 3.31 (d, J = 9.9 Hz, 0.75H), 2.94 (d, J = 9.8 Hz, 
0.25H), 2.86 – 2.55 (m, 4H), 2.53 – 2.18 (m, 3H), 2.12 – 1.71 (m, 5H), 1.68 – 1.55 (m, 4H), 
1.48 – 1.21 (m, 4H), 1.16 – 0.99 (m, 3H), 0.93 – 0.40 (m, 3H). 
 
HRMS: m/z: found 1260.57118 [M+H]+, calculated 1260.57109 [M+H]+ 
 
(2S)-(1R)-3-(3,4-Dimethoxyphenyl)-1-(3-((1-(17-((2-(2,6-dioxopiperidin-3-yl)-1,3-
dioxoisoindolin-4-yl)amino)-17-oxo-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ208) 
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MTQ208 was synthesized from 44e (10 mg, 0. 0137 mmol) according to the General Method 
G. Purification by flash column chromatography (0% to 5% MeOH in DCM) gave a white solid 
(13 mg, 0.0097 mmol, 72%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.5 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.48 (s, 1H), 8.85 (d, J = 8.4 Hz, 
1H), 8.70 (s, 1H), 7.80 (s, 1H), 7.76 – 7.67 (m, 1H), 7.56 (dd, J = 7.3, 0.7 Hz, 1H), 7.11 (t, J 
= 7.9 Hz, 0.75H), 7.04 – 6.93 (m, 0.75H), 6.86 (dd, J = 7.9, 2.2 Hz, 0.75H), 6.83 – 6.70 (m, 
2H), 6.70 – 6.60 (m, 2H), 6.50 (s, 1.5H), 6.43 (t, J = 3.8 Hz, 1.25H), 5.86 – 5.76 (m, 0.25H), 
5.58 (dd, J = 7.7, 5.9 Hz, 0.75H), 5.47 (d, J = 4.1 Hz, 0.75H), 5.19 (s, 0.5H), 5.15 (s, 1.5H), 
5.01 – 4.90 (m, 1H), 4.76 – 4.70 (m, 0.25H), 4.53 (t, J = 5.1 Hz, 2H), 4.18 (d, J = 1.4 Hz, 2H), 
4.02 – 3.91 (m, 1H), 3.89 – 3.81 (m, 10H), 3.81 – 3.75 (m, 7H), 3.71 (s, 4H), 3.69 – 3.66 (m, 
2H), 3.66 – 3.58 (m, 10H), 3.38 (d, J = 9.8 Hz, 0.75H), 3.00 (d, J = 9.8 Hz, 0.25H), 2.91 – 
2.61 (m, 4H), 2.60 – 2.23 (m, 3H), 2.18 – 1.80 (m, 5H), 1.77 – 1.62 (m, 4H), 1.54 – 1.28 (m, 
4H), 1.24 – 1.08 (m, 3H), 1.05 – 0.48 (m, 3H). 
 
HRMS: m/z: found 1304.59712 [M+H]+, calculated 1304.59730 [M+H]+ 
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(S)-(R)-3-(4-((1-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-
oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ328) 
 
MTQ328 was synthesized from 31a (10 mg, 0.0137 mmol) and 43a (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (16 mg, 91%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.49. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.73 min, purity (220 nm) = 97%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.65 (s, 1H), 7.79 (s, 1H), 7.41 – 
7.27 (m, 5.5H), 7.13 – 6.86 (m, 3.5H), 6.76 – 6.49 (m, 5H), 6.43 – 6.38 (m, 1H), 5.51 (dd, J 
= 8.1, 5.7 Hz, 1H), 5.48 (d, J = 5.0 Hz, 1H), 5.20 (d, J = 3.8 Hz, 2H), 4.75 – 4.68 (m, 1H), 
4.63 – 4.44 (m, 6H), 4.33 (dd, J = 15.0, 5.6 Hz, 1H), 4.00 – 3.90 (m, 4H), 3.88 – 3.85 (m, 2H), 
3.83 (d, J = 1.7 Hz, 2H), 3.80 (d, J = 6.9 Hz, 2H), 3.78 (s, 2H), 3.75 (d, J = 2.8 Hz, 4H), 3.71 
(s, 4H), 3.64 (dd, J = 11.3, 3.6 Hz, 1H), 3.37 (s, 1H), 2.77 (td, J = 13.5, 2.7 Hz, 1H), 2.62 – 
2.51 (m, 1H), 2.49 (s, 3H), 2.48 – 2.31 (m, 2H), 2.30 – 2.24 (m, 1H), 2.13 – 2.06 (m, 2H), 
1.94 – 1.76 (m, 3H), 1.71 – 1.63 (m, 3H), 1.62 – 1.51 (m, 3H), 1.45 – 1.36 (m, 1H), 1.35 – 
1.27 (m, 2H), 1.22 – 1.09 (m, 3H), 0.93 (s, 9H), 0.87 – 0.50 (m, 2H). 
 
HRMS: m/z: found 1285.6204 [M+H]+, calculated 1285.62135 [M+H]+ 
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(S)-(R)-3-(4-((1-(2-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-
oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ329) 
 
MTQ329 was synthesized from 31a (10 mg, 0.0137 mmol) and 43b (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (10 mg, 55%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.57. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.85 min, purity (220 nm) = 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.66 (s, 1H), 8.03 (s, 1H), 7.38 – 
7.27 (m, 5H), 7.25 (d, J = 6.0 Hz, 1H), 7.00 – 6.85 (m, 2H), 6.78 – 6.55 (m, 4H), 6.51 (s, 2H), 
6.43 – 6.36 (m, 1H), 5.51 (dd, J = 8.0, 5.7 Hz, 1H), 5.47 (d, J = 4.8 Hz, 1H), 5.24 – 5.16 (m, 
2H), 4.66 – 4.40 (m, 7H), 4.26 (dt, J = 14.8, 5.2 Hz, 1H), 4.04 – 3.98 (m, 2H), 3.91 – 3.86 (m, 
2H), 3.85 – 3.82 (m, 3H), 3.81 – 3.79 (m, 2H), 3.76 (s, 4H), 3.75 (s, 2H), 3.72 (s, 4H), 3.68 – 
3.52 (m, 6H), 3.39 (d, J = 10.0 Hz, 1H), 2.78 (td, J = 13.5, 2.6 Hz, 1H), 2.64 – 2.52 (m, 1H), 
2.50 (s, 3H), 2.48 – 2.32 (m, 3H), 2.30 – 2.22 (m, 1H), 2.13 – 1.86 (m, 4H), 1.83 – 1.70 (m, 
2H), 1.62 – 1.53 (m, 3H), 1.47 – 1.37 (m, 1H), 1.36 – 1.28 (m, 2H), 1.23 – 1.11 (m, 3H), 0.97 
(s, 9H), 0.95 – 0.71 (m, 3H). 
 
HRMS: m/z: found 1329.64624 [M+H]+, calculated 1329.64756 [M+H]+ 
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(S)-(R)-3-(4-((1-((S)-13-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-
azapentadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ330)
 
MTQ330 was synthesized from 31a (10 mg, 0.0137 mmol) and 43c (9 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (17 mg, 90%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.57. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.91 min, purity (220 nm) = 96%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.84 (s, 1H), 7.86 (s, 1H), 7.41 – 
7.27 (m, 6H), 7.10 (t, J = 7.9 Hz, 1H), 7.00 – 6.82 (m, 2H), 6.74 (dd, J = 7.8, 2.0 Hz, 1H), 
6.69 – 6.57 (m, 3H), 6.50 (s, 1H), 6.44 – 6.38 (m, 1H), 5.59 – 5.51 (m, 1H), 5.47 (d, J = 5.0 
Hz, 1H), 5.19 (s, 2H), 4.74 – 4.44 (m, 7H), 4.34 (dd, J = 15.1, 5.4 Hz, 1H), 4.07 – 3.93 (m, 
4H), 3.90 – 3.82 (m, 5H), 3.81 – 3.78 (m, 4H), 3.75 (d, J = 3.0 Hz, 4H), 3.71 (s, 4H), 3.64 (d, 
J = 3.8 Hz, 2H), 3.62 – 3.57 (m, 6H), 3.38 (d, J = 9.8 Hz, 1H), 2.82 – 2.73 (m, 1H), 2.62 – 
2.57 (m, 1H), 2.55 (s, 3H), 2.54 – 2.49 (m, 1H), 2.48 – 2.32 (m, 4H), 2.31 – 2.24 (m, 1H), 
2.14 – 2.06 (m, 2H), 1.94 – 1.71 (m, 3H), 1.62 – 1.53 (m, 3H), 1.47 – 1.29 (m, 3H), 1.22 – 
1.08 (m, 3H), 0.96 (s, 9H), 0.92 – 0.69 (m, 2H). 
 
 
HRMS: m/z: found 1373.67136 [M+H]+, calculated 1373.67378 [M+H]+ 
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(S)-(R)-3-(4-((1-((S)-16-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-14-oxo-3,6,9,12-tetraoxa-
15-azaoctadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ331) 
 
MTQ331 was synthesized from 31a (10 mg, 0.0137 mmol) and 43d (9 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (12 mg, 62%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.61. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.84 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 8.90 (s, 1H), 7.84 (s, 1H), 7.43 – 
7.27 (m, 6H), 7.25 – 7.22 (m, 1H), 6.99 – 6.83 (m, 2H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 6.69 – 
6.58 (m, 3H), 6.50 (s, 1H), 6.43 – 6.40 (m, 1H), 5.56 (dd, J = 7.7, 5.8 Hz, 1H), 5.47 (d, J = 
5.3 Hz, 1H), 5.21 (s, 2H), 4.74 – 4.66 (m, 1H), 4.62 – 4.41 (m, 6H), 4.36 (dd, J = 15.1, 5.2 
Hz, 1H), 4.09 (d, J = 11.2 Hz, 1H), 3.99 (d, J = 5.5 Hz, 2H), 3.86 (t, J = 5.1 Hz, 2H), 3.84 – 
3.80 (m, 6H), 3.76 (d, J = 2.8 Hz, 4H), 3.71 (s, 4H), 3.66 – 3.55 (m, 14H), 3.38 (d, J = 9.8 
Hz, 1H), 2.78 (td, J = 13.4, 2.5 Hz, 1H), 2.57 (s, 3H), 2.55 – 2.41 (m, 4H), 2.39 – 2.34 (m, 
1H), 2.29 – 2.26 (m, 1H), 2.14 – 2.06 (m, 2H), 1.98 – 1.77 (m, 3H), 1.72 – 1.63 (m, 3H), 1.60 
– 1.52 (m, 2H), 1.46 – 1.37 (m, 1H), 1.36 – 1.27 (m, 2H), 1.18 – 1.11 (m, 2H), 0.96 (s, 9H), 
0.90 – 0.54 (m, 2H). 
 
HRMS: m/z: found 1417.70127 [M+H]+, calculated 1417.69999 [M+H]+ 
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(S)-(R)-3-(4-((1-((S)-19-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-20,20-dimethyl-17-oxo-3,6,9,12,15-
pentaoxa-18-azahenicosyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ332) 
 
MTQ332 was synthesized from 31a (10 mg, 0.0137 mmol) and 43e (10 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (13 mg, 65%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.58. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.82 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.89 (s, 1H), 7.82 (s, 1H), 7.36 (s, 
6H), 7.24 – 7.04 (m, 1H), 7.00 – 6.80 (m, 2H), 6.79 – 6.59 (m, 3H), 6.59 – 6.37 (m, 3H), 5.56 
(t, J = 6.1 Hz, 1H), 5.50 – 5.42 (m, 1H), 5.21 (s, 2H), 4.72 (t, J = 7.7 Hz, 1H), 4.60 – 4.46 (m, 
5H), 4.41 – 4.28 (m, 1H), 4.13 – 3.91 (m, 4H), 3.90 – 3.78 (m, 9H), 3.75 (s, 4H), 3.71 (s, 4H), 
3.67 – 3.55 (m, 17H), 3.37 (d, J = 9.4 Hz, 1H), 2.86 – 2.60 (m, 4H), 2.56 (s, 4H), 2.50 – 2.21 
(m, 4H), 2.17 – 2.05 (m, 2H), 1.95 – 1.78 (m, 2H), 1.73 – 1.60 (m, 4H), 1.49 – 1.27 (m, 3H), 
1.20 – 1.04 (m, 3H), 0.95 (s, 9H), 0.89 – 0.50 (m, 2H). 
 
HRMS: m/z: found 1461.72733 [M+H]+, calculated 1461.72621 [M+H]+ 
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(2S)-(1R)-3-(4-((1-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-
oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ333) 
 
MTQ333 was synthesized from 31a (10 mg, 0.0137 mmol) and 44a (5 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (12 mg, 78%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.42. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.36 min, purity (220 nm) = 97%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.51 – 10.33 (m, 1H), 8.83 (dd, J 
= 8.5, 2.0 Hz, 1H), 8.75 – 8.53 (m, 1H), 8.15 (d, J = 7.0 Hz, 1H), 7.77 – 7.68 (m, 1H), 7.68 – 
7.53 (m, 1H), 7.31 – 7.28 (m, 0.25H), 7.18 – 7.08 (m, 0.75H), 7.07 – 6.96 (m, 1H), 6.95 – 6.83 
(m, 1H), 6.75 (dd, J = 8.2, 2.5 Hz, 0.75H), 6.66 – 6.56 (m, 2.75H), 6.52 – 6.40 (m, 2.5H), 
5.81 – 5.75 (m, 0.25H), 5.56 – 5.49 (m, 0.75H), 5.47 (t, J = 4.4 Hz, 0.75H), 5.34 – 5.14 (m, 
2H), 5.01 – 4.89 (m, 1H), 4.80 – 4.69 (m, 2H), 4.59 – 4.52 (m, 0.25H), 4.07 – 3.92 (m, 3H), 
3.90 – 3.80 (m, 4H), 3.80 – 3.74 (m, 8H), 3.71 (d, J = 3.8 Hz, 5H), 3.38 (d, J = 9.7 Hz, 0.75H), 
2.97 (d, J = 9.7 Hz, 0.25H), 2.88 – 2.60 (m, 4H), 2.58 – 2.33 (m, 2H), 2.31 – 2.22 (m, 1H), 
2.16 – 2.06 (m, 2H), 1.96 – 1.84 (m, 2H), 1.67 – 1.55 (m, 5H), 1.47 – 1.37 (m, 1H), 1.34 – 
1.10 (m, 6H), 1.01 – 0.53 (m, 3H). 
 
HRMS: m/z: found 1128.49125 [M+H]+, calculated 1128.49244 [M+H]+ 
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(2S)-(1R)-3-(4-((1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-
1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ334) 
 
MTQ334 was synthesized from 31a (10 mg, 0.0137 mmol) and 44b (6 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (10 mg, 63%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.48 min, purity (220 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.41 (s, 1H), 8.83 (d, J = 8.4 Hz, 
1H), 8.46 – 8.36 (m, 1H), 7.83 (s, 1H), 7.74 – 7.65 (m, 1H), 7.54 (d, J = 7.3 Hz, 1H), 7.30 (t, 
J = 7.9 Hz, 0.25H), 7.11 (t, J = 7.9 Hz, 0.75H), 6.96 – 6.83 (m, 2H), 6.75 (dd, J = 8.0, 2.2 
Hz, 0.75H), 6.68 – 6.54 (m, 3H), 6.50 (s, 1.25H), 6.45 – 6.40 (m, 1H), 5.80 (t, J = 7.0 Hz, 
0.25H), 5.55 (dd, J = 8.0, 5.7 Hz, 0.75H), 5.48 (d, J = 4.8 Hz, 0.75H), 5.17 (s, 2H), 4.95 (dd, 
J = 12.4, 5.4 Hz, 1H), 4.72 (d, J = 4.9 Hz, 0.25H), 4.56 (q, J = 4.7 Hz, 2H), 4.14 (s, 2H), 4.01 
– 3.92 (m, 3H), 3.85 – 3.79 (m, 7H), 3.77 – 3.75 (m, 8H), 3.71 (s, 4H), 3.38 (d, J = 9.8 Hz, 
0.75H), 2.97 (d, J = 9.8 Hz, 0.25H), 2.92 – 2.86 (m, 1H), 2.85 – 2.69 (m, 3H), 2.61 – 2.18 (m, 
4H), 2.10 – 2.06 (m, 1H), 1.93 – 1.82 (m, 2H), 1.66 – 1.54 (m, 5H), 1.47 – 1.36 (m, 1H), 1.34 
– 1.09 (m, 6H), 1.03 – 0.52 (m, 3H). 
 
HRMS: m/z: found 1172.51505 [M+H]+, calculated 1128.49244 [M+H]+ 
  
 121 
 
(2S)-(1R)-3-(4-((1-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-
methoxyphenyl)-1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ335) 
 
MTQ335 was synthesized from 31a (10 mg, 0.0137 mmol) and 44c (7 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (12 mg, 72%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.36. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.44 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.42 (s, 1H), 8.83 (d, J = 8.4 Hz, 
1H), 8.51 – 8.33 (m, 1H), 7.83 (s, 1H), 7.76 – 7.65 (m, 1H), 7.56 (d, J = 7.3 Hz, 1H), 7.33 – 
7.27 (m, 0.25H), 7.10 (t, J = 7.9 Hz, 0.75H), 6.99 – 6.81 (m, 2H), 6.74 (dd, J = 8.1, 2.5 Hz, 
0.75H), 6.67 – 6.47 (m, 4.25H), 6.43 – 6.38 (m, 1H), 5.85 – 5.74 (m, 0.25H), 5.55 (dd, J = 
7.7, 6.0 Hz, 0.75H), 5.48 (d, J = 4.0 Hz, 0.75H), 5.23 (s, 2H), 5.00 – 4.90 (m, 1H), 4.74 – 4.69 
(m, 0.25H), 4.52 (t, J = 4.9 Hz, 2H), 4.18 (s, 2H), 4.00 – 3.85 (m, 3H), 3.84 – 3.76 (m, 9H), 
3.75 (s, 6H), 3.71 (s, 4H), 3.64 – 3.57 (m, 4H), 3.37 (d, J = 9.9 Hz, 0.75H), 2.96 (d, J = 9.6 
Hz, 0.25H), 2.92 – 2.67 (m, 4H), 2.45 – 2.05 (m, 5H), 1.94 – 1.84 (m, 2H), 1.69 – 1.52 (m, 
6H), 1.45 – 1.27 (m, 3H), 1.22 – 1.07 (m, 3H), 1.04 – 0.49 (m, 3H). 
 
HRMS: m/z: found 1216.54480 [M+H]+, calculated 1216.54487 [M+H]+ 
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(2S)-(1R)-3-(4-((1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-14-
oxo-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ336) 
 
MTQ336 was synthesized from 31a (10 mg, 0.0137 mmol) and 44d (7 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (13 mg, 76%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.35. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.39 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.48 (s, 1H), 8.84 (d, J = 8.5 Hz, 
1H), 8.69 – 8.47 (m, 1H), 7.83 (s, 1H), 7.71 (t, J = 7.8 Hz, 1H), 7.56 (d, J = 7.3 Hz, 1H), 7.34 
– 7.28 (m, 0.25H), 7.11 (t, J = 7.7 Hz, 0.75H), 7.00 – 6.83 (m, 2H), 6.75 (d, J = 7.4 Hz, 
0.75H), 6.69 – 6.52 (m, 3H), 6.50 (s, 1.25H), 6.44 – 6.40 (m, 1H), 5.80 (t, J = 6.5 Hz, 0.25H), 
5.56 (t, J = 6.5 Hz, 0.75H), 5.51 – 5.40 (m, 0.75H), 5.23 (s, 2H), 5.00 – 4.89 (m, 1H), 4.75 – 
4.68 (m, 0.25H), 4.53 (s, 2H), 4.18 (s, 2H), 3.99 – 3.85 (m, 3H), 3.83 (d, J = 5.5 Hz, 7H), 3.77 
(d, J = 7.5 Hz, 8H), 3.71 (s, 4H), 3.68 – 3.63 (m, 2H), 3.58 (s, 6H), 3.37 (d, J = 9.4 Hz, 0.75H), 
3.00 – 2.93 (m, 0.25H), 2.90 – 2.60 (m, 4H), 2.58 – 2.22 (m, 3H), 2.20 – 1.83 (m, 5H), 1.65 
(d, J = 9.8 Hz, 3H), 1.56 (d, J = 10.4 Hz, 2H), 1.38 – 1.10 (m, 6H), 1.05 – 0.49 (m, 3H). 
 
HRMS: m/z: found 1260.57131 [M+H]+, calculated 1260.57109 [M+H]+ 
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(2S)-(1R)-3-(4-((1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-17-
oxo-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-3-methoxyphenyl)-
1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ337) 
 
MTQ337 was synthesized from 31a (10 mg, 0.0137 mmol) and 44e (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (16 mg, 90%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.41 min, purity (220 nm) = 97%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.48 (s, 1H), 8.84 (d, J = 8.4 Hz, 
1H), 8.76 (s, 1H), 7.84 (s, 1H), 7.75 – 7.66 (m, 1H), 7.57 (dd, J = 7.3, 0.7 Hz, 1H), 7.31 (d, J 
= 7.8 Hz, 0.25H), 7.10 (t, J = 7.9 Hz, 0.75H), 7.00 – 6.81 (m, 2H), 6.77 – 6.72 (m, 0.75H), 
6.69 – 6.54 (m, 3H), 6.49 (s, 1.25H), 6.43 – 6.39 (m, 1H), 5.80 (t, J = 7.1 Hz, 0.25H), 5.56 
(dd, J = 7.8, 5.7 Hz, 0.75H), 5.48 (d, J = 4.8 Hz, 0.75H), 5.24 (s, 2H), 5.04 – 4.89 (m, 1H), 
4.75 – 4.69 (m, 0.25H), 4.52 (t, J = 5.1 Hz, 2H), 4.18 (d, J = 1.4 Hz, 2H), 4.00 – 3.89 (m, 1H), 
3.90 – 3.85 (m, 2H), 3.85 – 3.80 (m, 7H), 3.80 – 3.73 (m, 9H), 3.71 (s, 4H), 3.69 – 3.62 (m, 
4H), 3.60 (s, 4H), 3.59 (s, 3H), 3.37 (d, J = 9.8 Hz, 0.75H), 2.96 (d, J = 9.6 Hz, 0.25H), 2.91 
– 2.69 (m, 4H), 2.60 – 2.24 (m, 3H), 2.19 – 1.99 (m, 3H), 1.88 – 1.73 (m, 2H), 1.70 – 1.61 (m, 
3H), 1.59 – 1.51 (m, 2H), 1.48 – 1.27 (m, 3H), 1.22 – 1.06 (m, 3H), 1.02 – 0.50 (m, 3H). 
 
HRMS: m/z: found 1304.5975 [M+H]+, calculated 1304.5973 [M+H]+ 
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 (S)-(R)-3-(3-((1-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-
oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ338) 
 
MTQ338 was synthesized from 31b (12 mg, 0.0165 mmol) and 43a (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (16 mg, 91%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.38. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.73 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.84 (s, 1H), 7.83 (s, 1H), 7.33 (s, 
5H), 7.14 – 7.00 (m, 2H), 6.95 – 6.78 (m, 2H), 6.78 – 6.70 (m, 2H), 6.68 – 6.47 (m, 3H), 6.45 
– 6.36 (m, 1H), 5.51 (t, J = 6.7 Hz, 1H), 5.45 (s, 1H), 5.20 (s, 2H), 4.78 – 4.43 (m, 7H), 4.31 
(dd, J = 15.4, 3.9 Hz, 1H), 4.05 – 3.89 (m, 4H), 3.88 (d, J = 5.6 Hz, 1H), 3.83 (s, 2H), 3.79 
(d, J = 7.7 Hz, 2H), 3.75 (s, 7H), 3.71 (s, 4H), 3.68 – 3.60 (m, 1H), 3.38 (d, J = 9.7 Hz, 1H), 
3.00 – 2.64 (m, 4H), 2.54 (s, 3H), 2.49 – 2.33 (m, 3H), 2.30 – 2.23 (m, 1H), 2.17 – 1.66 (m, 
7H), 1.59 – 1.49 (m, 2H), 1.42 – 1.28 (m, 2H), 1.21 – 1.06 (m, 3H), 0.94 (s, 9H), 0.88 – 0.52 
(m, 2H). 
 
HRMS: m/z: found 1285.62041 [M+H]+, calculated 1285.62135 [M+H]+ 
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(S)-(R)-3-(3-((1-(2-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-
oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ339) 
 
MTQ339 was synthesized from 31b (12 mg, 0.0165 mmol) and 43b (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (13 mg, 71%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.91 min, purity (220 nm) = 97%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.89 (d, J = 7.6 Hz, 1H), 8.11 (s, 
1H), 7.42 – 7.27 (m, 6H), 7.09 (t, J = 7.9 Hz, 1H), 6.96 – 6.64 (m, 5H), 6.61 – 6.49 (m, 2H), 
6.45 – 6.30 (m, 1H), 5.58 – 5.50 (m, 1H), 5.48 – 5.40 (m, 1H), 5.19 (s, 2H), 4.78 – 4.35 (m, 
7H), 4.33 – 4.17 (m, 1H), 4.08 – 3.92 (m, 3H), 3.91 – 3.86 (m, 2H), 3.84 – 3.82 (m, 2H), 3.81 
– 3.79 (m, 2H), 3.78 – 3.74 (m, 7H), 3.71 (s, 4H), 3.69 – 3.56 (m, 5H), 3.38 (d, J = 10.0 Hz, 
1H), 2.81 – 2.59 (m, 3H), 2.57 (s, 3H), 2.47 – 2.33 (m, 3H), 2.32 – 2.22 (m, 2H), 2.14 – 1.94 
(m, 3H), 1.93 – 1.67 (m, 4H), 1.59 – 1.51 (m, 2H), 1.43 – 1.29 (m, 2H), 1.20 – 1.07 (m, 3H), 
0.98 (s, 9H), 0.93 – 0.52 (m, 3H). 
 
HRMS: m/z: found 1329.64738 [M+H]+, calculated 1329.64756 [M+H]+ 
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(S)-(R)-3-(3-((1-((S)-13-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-
azapentadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ340) 
 
MTQ340 was synthesized from 31b (12 mg, 0.0165 mmol) and 43c (9 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (15 mg, 80%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.96 min, purity (220 nm) = 97%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.85 (d, J = 4.3 Hz, 1H), 7.85 (d, 
J = 2.8 Hz, 1H), 7.44 – 7.32 (m, 6H), 7.30 – 7.27 (m, 1H), 6.96 – 6.77 (m, 3H), 6.76 – 6.60 
(m, 3H), 6.50 (s, 1H), 6.44 – 6.39 (m, 1H), 5.54 (dd, J = 7.8, 6.0 Hz, 1H), 5.47 (d, J = 4.1 Hz, 
1H), 5.19 (s, 2H), 4.70 – 4.45 (m, 7H), 4.33 (dd, J = 15.1, 5.4 Hz, 1H), 4.08 – 4.03 (m, 1H), 
3.97 (d, J = 3.2 Hz, 2H), 3.87 – 3.82 (m, 5H), 3.81 (d, J = 1.9 Hz, 2H), 3.79 (s, 2H), 3.76 (s, 
4H), 3.71 (s, 4H), 3.66 – 3.60 (m, 5H), 3.59 (s, 4H), 3.38 (d, J = 9.8 Hz, 1H), 2.84 – 2.72 (m, 
1H), 2.64 – 2.58 (m, 1H), 2.56 (s, 3H), 2.51 – 2.35 (m, 5H), 2.31 – 2.24 (m, 1H), 2.18 – 2.03 
(m, 3H), 1.94 – 1.70 (m, 3H), 1.60 – 1.51 (m, 2H), 1.45 – 1.27 (m, 3H), 1.21 – 1.08 (m, 3H), 
0.96 (s, 9H), 0.92 – 0.53 (m, 3H). 
 
HRMS: m/z: found 1373.67431 [M+H]+, calculated 1373.67378 [M+H]+ 
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(S)-(R)-3-(3-((1-((S)-16-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-14-oxo-3,6,9,12-tetraoxa-
15-azaoctadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ341) 
 
MTQ341 was synthesized from 31b (12 mg, 0.0165 mmol) and 43d (9 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (13 mg, 67%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.28. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.89 min, purity (220 nm) = 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.89 (s, 1H), 7.83 (s, 1H), 7.45 – 
7.28 (m, 6H), 7.11 (t, J = 7.9 Hz, 1H), 6.96 – 6.71 (m, 4H), 6.70 – 6.47 (m, 3H), 6.45 – 6.39 
(m, 1H), 5.55 (t, J = 6.5 Hz, 1H), 5.50 – 5.42 (m, 1H), 5.21 (s, 2H), 4.76 – 4.56 (m, 2H), 4.55 
– 4.45 (m, 5H), 4.35 (dd, J = 14.4, 5.1 Hz, 1H), 4.14 – 4.03 (m, 1H), 3.99 (s, 2H), 3.90 – 3.78 
(m, 9H), 3.76 (s, 4H), 3.71 (s, 4H), 3.65 – 3.55 (m, 13H), 3.37 (d, J = 9.7 Hz, 1H), 2.84 – 2.73 
(m, 1H), 2.69 – 2.61 (m, 1H), 2.57 (s, 3H), 2.50 – 2.35 (m, 3H), 2.32 – 2.25 (m, 1H), 2.18 – 
2.01 (m, 3H), 1.95 – 1.81 (m, 2H), 1.75 – 1.60 (m, 4H), 1.54 (s, 1H), 1.47 – 1.27 (m, 3H), 
1.20 – 1.02 (m, 3H), 0.96 (s, 9H), 0.89 – 0.63 (m, 2H). 
 
HRMS: m/z: found 1417.69865 [M+H]+, calculated 1417.69999 [M+H]+ 
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(S)-(R)-3-(3-((1-((S)-19-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-20,20-dimethyl-17-oxo-3,6,9,12,15-
pentaoxa-18-azahenicosyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ342) 
 
MTQ342 was synthesized from 31b (12 mg, 0.0165 mmol) and 43e (10 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (0% to 6% 
MeOH in DCM) gave a white solid (15 mg, 75%). 
 
TLC [DCM:MeOH 90:10]: Rf = 0.56. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.88 min, purity (220 nm) = 95%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 8.87 (s, 1H), 7.82 (s, 1H), 7.36 (s, 
5H), 7.30 – 7.27 (m, 1H), 7.11 (t, J = 7.9 Hz, 1H), 6.96 – 6.86 (m, 1H), 6.86 – 6.60 (m, 5H), 
6.49 (s, 1H), 6.44 – 6.40 (m, 1H), 5.54 (dd, J = 7.9, 5.7 Hz, 1H), 5.47 (d, J = 3.5 Hz, 1H), 
5.21 (s, 2H), 4.76 – 4.56 (m, 2H), 4.55 – 4.46 (m, 5H), 4.35 (dd, J = 15.1, 5.4 Hz, 1H), 4.13 
– 4.04 (m, 1H), 3.99 (d, J = 6.3 Hz, 2H), 3.88 – 3.79 (m, 9H), 3.76 (d, J = 0.7 Hz, 4H), 3.71 
(s, 4H), 3.65 (s, 4H), 3.62 – 3.55 (m, 13H), 3.37 (d, J = 9.9 Hz, 1H), 2.84 – 2.69 (m, 2H), 2.56 
(s, 3H), 2.52 – 2.24 (m, 5H), 2.18 – 2.01 (m, 3H), 1.94 – 1.79 (m, 2H), 1.75 – 1.60 (m, 4H), 
1.55 – 1.27 (m, 4H), 1.20 – 1.05 (m, 3H), 0.95 (s, 9H), 0.88 – 0.49 (m, 3H). 
 
HRMS: m/z: found 1461.72644 [M+H]+, calculated 1461.72621 [M+H]+ 
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(2S)-(1R)-3-(3-((1-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-
oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ343) 
 
MTQ343 was synthesized from 31b (12 mg, 0.0165 mmol) and 44a (5 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (6 mg, 40%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.40. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.42 min, purity (220 nm) = 95%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.44 (s, 1H), 8.85 (d, J = 8.4 Hz, 
1H), 8.80 – 8.69 (m, 1H), 8.23 – 8.08 (m, 1H), 7.82 – 7.69 (m, 1H), 7.60 (dd, J = 7.2, 2.6 Hz, 
1H), 7.34 – 7.29 (m, 0.25H), 7.12 (t, J = 7.9 Hz, 0.75H), 7.00 – 6.60 (m, 6H), 6.53 – 6.43 (m, 
2H), 5.82 – 5.75 (m, 0.25H), 5.55 (dd, J = 7.9, 5.7 Hz, 0.75H), 5.49 (d, J = 3.9 Hz, 0.75H), 
5.34 – 5.20 (m, 2H), 5.03 – 4.94 (m, 1H), 4.80 – 4.69 (m, 2H), 4.62 – 4.53 (m, 0.25H), 4.14 
(d, J = 2.7 Hz, 2H), 4.10 – 3.90 (m, 4H), 3.87 – 3.80 (m, 5H), 3.80 – 3.76 (m, 6H), 3.74 (d, J 
= 1.8 Hz, 3H), 3.39 (d, J = 9.9 Hz, 0.75H), 3.07 – 2.99 (m, 0.25H), 2.90 – 2.67 (m, 4H), 2.58 
– 2.25 (m, 3H), 2.20 – 1.73 (m, 6H), 1.62 – 1.50 (m, 3H), 1.48 – 1.30 (m, 3H), 1.26 – 1.05 (m, 
4H), 1.01 – 0.50 (m, 3H). 
 
HRMS: m/z: found 1128.49199 [M+H]+, calculated 1128.49244 [M+H]+ 
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(2S)-(1R)-3-(3-((1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-
1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ344) 
 
MTQ344 was synthesized from 31b (12 mg, 0.0165 mmol) and 44b (6 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (10 mg, 63%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.42. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.55 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.42 (s, 1H), 8.82 (d, J = 8.5 Hz, 
1H), 8.61 – 8.43 (m, 1H), 7.84 (s, 1H), 7.68 (t, J = 7.9 Hz, 1H), 7.53 (d, J = 7.4 Hz, 1H), 7.33 
– 7.28 (m, 0.25H), 7.11 (t, J = 7.9 Hz, 0.75H), 6.98 – 6.70 (m, 4H), 6.70 – 6.58 (m, 1.75H), 
6.50 (s, 1.25H), 6.45 – 6.40 (m, 1H), 5.81 – 5.73 (m, 0.25H), 5.54 (dd, J = 7.9, 5.8 Hz, 0.75H), 
5.48 (d, J = 5.0 Hz, 0.75H), 5.17 (s, 2H), 4.95 (dd, J = 11.9, 5.3 Hz, 1H), 4.78 – 4.71 (m, 
0.25H), 4.55 (s, 2H), 4.14 (s, 2H), 3.99 – 3.87 (m, 3H), 3.85 – 3.78 (m, 7H), 3.75 (d, J = 1.9 
Hz, 8H), 3.72 (s, 4H), 3.38 (d, J = 9.8 Hz, 0.75H), 3.05 – 2.94 (m, 0.25H), 2.93 – 2.60 (m, 
4H), 2.59 – 2.03 (m, 6H), 1.94 – 1.83 (m, 2H), 1.71 – 1.62 (m, 3H), 1.60 – 1.51 (m, 2H), 1.35 
– 1.22 (m, 3H), 1.20 – 1.03 (m, 3H), 1.02 – 0.48 (m, 3H). 
 
HRMS: m/z: found 1172.51801 [M+H]+, calculated 1172.51866 [M+H]+ 
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(2S)-(1R)-3-(3-((1-(2-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)amino)-2-oxoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-
methoxyphenyl)-1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ345) 
 
MTQ345 was synthesized from 31b (12 mg, 0.0165 mmol) and 44c (7 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (13 mg, 78%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.49 min, purity (220 nm) = 98%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.42 (s, 1H), 8.83 (d, J = 8.5 Hz, 
1H), 8.52 – 8.34 (m, 1H), 7.88 – 7.81 (m, 1H), 7.70 (t, J = 7.9 Hz, 1H), 7.56 (d, J = 8.1 Hz, 
1H), 7.30 (d, J = 7.9 Hz, 0.25H), 7.11 (t, J = 7.9 Hz, 0.75H), 6.95 – 6.73 (m, 4H), 6.70 – 6.62 
(m, 1.75H), 6.49 (s, 1.25H), 6.45 – 6.41 (m, 1H), 5.80 – 5.73 (m, 0.25H), 5.54 (dd, J = 8.0, 
5.7 Hz, 0.75H), 5.48 (d, J = 4.9 Hz, 0.75H), 5.24 (s, 0.5H), 5.23 (s, 1.5H), 4.99 – 4.90 (m, 
1H), 4.75 (d, J = 5.4 Hz, 0.25H), 4.51 (q, J = 5.2 Hz, 2H), 4.18 (s, 2H), 3.95 (d, J = 13.8 Hz, 
1H), 3.85 (dt, J = 12.9, 3.5 Hz, 5H), 3.82 – 3.80 (m, 4H), 3.79 – 3.77 (m, 2H), 3.76 (d, J = 
1.7 Hz, 4H), 3.74 (dd, J = 6.1, 3.1 Hz, 2H), 3.71 (s, 4H), 3.63 – 3.57 (m, 4H), 3.37 (d, J = 9.8 
Hz, 0.75H), 2.99 (d, J = 9.7 Hz, 0.25H), 2.91 – 2.73 (m, 4H), 2.58 – 2.25 (m, 3H), 2.18 – 2.02 
(m, 3H), 1.93 (dd, J = 14.0, 5.4 Hz, 1H), 1.73 – 1.63 (m, 3H), 1.59 – 1.52 (m, 2H), 1.46 – 
1.39 (m, 1H), 1.34 – 1.24 (m, 3H), 1.19 – 1.06 (m, 3H), 1.02 – 0.52 (m, 3H). 
 
HRMS: m/z: found 1216.54526 [M+H]+, calculated 1216.54487 [M+H]+ 
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(2S)-(1R)-3-(3-((1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-14-
oxo-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-1-(3-
methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-
2-carboxylate (MTQ346) 
 
MTQ346 was synthesized from 31b (12 mg, 0.0165 mmol) and 44d (7 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (13 mg, 76%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.27. 
 
HPLC [30-100% Solvent B, 20 min]: Rt = 15.86 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) (mixture of rotamers) δ 10.48 (s, 1H), 8.84 (d, J = 8.4 Hz, 
1H), 8.71 – 8.53 (m, 1H), 7.84 (s, 1H), 7.77 – 7.66 (m, 1H), 7.56 (d, J = 7.3 Hz, 1H), 7.34 – 
7.28 (m, 0.25H), 7.11 (t, J = 7.9 Hz, 0.75H), 6.95 – 6.59 (m, 6H), 6.49 (s, 1H), 6.45 – 6.41 
(m, 1H), 5.82 – 5.74 (m, 0.25H), 5.54 (dd, J = 7.9, 5.8 Hz, 0.75H), 5.47 (d, J = 4.3 Hz, 0.75H), 
5.25 (s, 0.5H), 5.23 (s, 1.5H), 5.00 – 4.89 (m, 1H), 4.77 – 4.71 (m, 0.25H), 4.57 – 4.47 (m, 
2H), 4.17 (d, J = 1.4 Hz, 2H), 3.96 – 3.85 (m, 3H), 3.84 – 3.79 (m, 7H), 3.78 (s, 3H), 3.76 (s, 
4H), 3.73 – 3.62 (m, 7H), 3.61 – 3.55 (m, 6H), 3.37 (d, J = 9.7 Hz, 0.75H), 2.99 (d, J = 9.5 
Hz, 0.25H), 2.90 – 2.66 (m, 4H), 2.62 – 2.26 (m, 3H), 2.18 – 1.92 (m, 4H), 1.71 – 1.51 (m, 
6H), 1.46 – 1.26 (m, 3H), 1.22 – 1.07 (m, 3H), 1.03 – 0.50 (m, 3H). 
 
HRMS: m/z: found 1260.57145 [M+H]+, calculated 1260.57109 [M+H]+ 
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(2S)-(1R)-3-(3-((1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-17-
oxo-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazol-4-yl)methoxy)-4-methoxyphenyl)-
1-(3-methoxyphenyl)propyl 1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (MTQ347) 
 
MTQ347 was synthesized from 31b (12 mg, 0.0165 mmol) and 44e (8 mg, 0. 0137 mmol) 
according to the General Method G. Purification by flash column chromatography (CH  
EA:MeCN = 90:10) gave a white solid (11 mg, 62%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.41. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.47 min, purity (220 nm) = 98%. 
 
1H NMR (500 MHz, Chloroform-d) (mixture of rotamers) δ 10.49 (s, 1H), 8.85 (d, J = 8.5 Hz, 
1H), 8.73 (s, 1H), 7.85 (d, J = 5.0 Hz, 1H), 7.71 (t, J = 7.9 Hz, 1H), 7.64 – 7.52 (m, 1H), 7.31 
– 7.29 (m, 0.25H), 7.11 (t, J = 7.9 Hz, 0.75H), 6.95 – 6.62 (m, 5.75H), 6.49 (s, 1.25H), 6.46 
– 6.42 (m, 1H), 5.80 – 5.74 (m, 0.25H) 5.54 (dd, J = 8.0, 5.7 Hz, 0.75H), 5.47 (d, J = 5.2 Hz, 
0.75H), 5.26 (s, 0.5H), 5.24 (s, 1.5H), 4.97 (dd, J = 11.6, 4.8 Hz, 1H), 4.75 (d, J = 5.0 Hz, 
0.25H), 4.55 – 4.49 (m, 2H), 4.18 (d, J = 4.1 Hz, 2H), 3.97 – 3.86 (m, 3H), 3.85 – 3.82 (m, 
4H), 3.81 (s, 3H), 3.79 (s, 4H), 3.76 (d, J = 1.4 Hz, 4H), 3.71 (s, 4H), 3.70 – 3.66 (m, 2H), 
3.64 – 3.60 (m, 6H), 3.59 (s, 4H), 3.37 (d, J = 9.8 Hz, 0.75H), 2.99 (d, J = 9.8 Hz, 0.25H), 
2.90 – 2.71 (m, 4H), 2.60 – 2.34 (m, 2H), 2.31 – 2.24 (m, 1H), 2.19 – 1.99 (m, 3H), 1.97 – 
1.90 (m, 1H), 1.67 – 1.54 (m, 5H), 1.47 – 1.35 (m, 1H), 1.35 – 1.22 (m, 3H), 1.21 – 1.06 (m, 
3H), 1.03 – 0.51 (m, 3H). 
 
HRMS: m/z: found 1304.59619 [M+H]+, calculated 1304.59730 [M+H]+ 
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2-Allylisoindoline-1,3-dione (55) 
 
K2CO3 (85.0 g, 611.7 mmol) and allylbromide (74.0 g, 53.0 mL, 611.7 mmol) were added to a 
solution of phtalimide (90.0 g, 611.7 mmol) in DMF (250 mL). After stirring at room 
temperature for 3h, EtO2 (900 mL) was added and the mixture was washed with sat. aq. NaCl 
solution (3 × 200 mL). The solvent was removed under reduced pressure to give a white solid 
which was used for the next step without further purification. 
 
2-(4-(Trimethylsilyl)but-2-en-1-yl)isoindoline-1,3-dione (56) 
 
 
 
Grubbs I generation catalyst (9% loading, 5.1g) and allyltrimethylsilane (79.3 g, 110 mL, 694 
mmol) were added to a solution of 55 (13.0 g, 69.4 mmol) in CH2Cl2 (500 mL). After 
refluxing at 60°C for 4h, tris(hydrodxymethyl)phosphine (1 M solution in i-PrOH, 58 mL) was 
added and the mixture was stirred under reflux for 12 h. Then sat. aq. NaCl solution (100 
mL) was added and the aqueous phase was extracted with CH2Cl2 (3 × 200 mL). The 
combined organic phase was dried over MgSO4 and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash column chromatography (CH  
CH:EA=85:15) gave a light yellow solid (12.5 g, 45.8 mmol, 66%). 
 
TLC [CH:EA 8:2]: Rf = 0.46. 
 
1H NMR: (300 MHz, Chloroform-d) δ 7.84 (dd, J = 5.4, 3.1 Hz, 2H), 7.70 (dd, J = 5.5, 3.1 Hz, 
2H), 5.87 (ddt, J = 17.1, 10.1, 5.7 Hz, 1H), 5.30 – 5.12 (m, 2H), 4.28 (dt, J = 5.7, 1.5 Hz, 2H). 
 
13C NMR: (75 MHz, Chloroform-d) δ 167.98, 134.06, 132.23, 131.65, 123.39, 117.84, 40.15. 
 
 
4-(Trimethylsilyl)but-2-en-1-aminen (57) 
 
 
Hydrazine hydrate (50-60%, 1.14 mL, 18.29 mmol) was added to a solution of 56 (2.5 g, 9.14 
mmol) in MeOH (90 mL). After stirring at 75°C for 24h, DCM (200 mL) was added and the 
mixture was washed with NaOH (1 M solution, 3 x 10 mL). The organic phase was dried over 
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MgSO4 and the solvent was removed under reduced pressure. The given yellow residue was 
used in the next step without further purification. 
 
 
 
4-(Trimethylsilyl)-N-(3-(trimethylsilyl)prop-2-yn-1-yl)but-2-en-1-amine (59a) 
 
 
57 (5.27 mmol) in 20 ml EtOH was added into a solution of 3-(trimethylsilyl)propiolaldehyde 
(1.00 g, 7.91 mmol) and Ti(OiPr)4 (2.34 mL, 7.91 mmol) in 32 ml EtOH and stirred at -78°C. 
After 4h stirring at -78°C, sodium borohydride (590 mg, 15.81 mmol) was added to the solution 
at that temperature, which was stirred until no gas evolution was observed. H2O was added to 
the reaction mixture, which was extracted with CH2Cl2 (200 mL). The organic layer was dried 
over MgSO4 and the solvent was removed under reduced pressure. Purification by flash column 
chromatography (DCM + 0.4% DIPEA  [(DCM:Et2O)=95:5] + 0.4% DIPEA) gave 59a as a 
light yellow oil (903 mg, 3.57 mmol, 68%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.5. 
 
MS (ESI+): m/z: found 254.07 [M+H]+, calculated 254.18 [M+H]+ 
 
1H NMR: (300 MHz, Chloroform-d) (mixture of cis/trans isomers) δ 5.66 – 5.49 (m, 1H), 5.40 
– 5.29 (m, 1H), 3.43 – 3.38 (m, 2H), 3.33 – 3.22 (m, 2H), 1.57 – 1.42 (m, 2H), 1.31 (s, 1H), 
0.16 (s, 9H), 0.03 – -0.03 (m, 9H). 
 
13C NMR: (75 MHz, Chloroform-d) (major) δ 130.22, 126.03, 104.68, 87.95, 50.66, 38.21, 
22.91, 0.16, -1.82. 
 
 
4-(Trimethylsilyl)-N-(4-(trimethylsilyl)but-3-yn-2-yl)but-2-en-1-amine (59b) 
 
 
57 (16.56 mmol) in 20 ml EtOH was added into a solution of 4-(trimethylsilyl)-3-butyn-2-one 
(4.1 mL, 24.85 mmol) and Ti(OiPr)4 (7.3 mL, 24.85 mmol) in 146 ml EtOH and stirred at -
78°C. After 3h stirring at -78°C, sodium borohydride (1.88 g, 49.7 mmol) was added to the 
solution at that temperature, which was stirred until no gas evolution was observed. H2O was 
added to the reaction mixture, which was extracted with CH2Cl2 (300 mL). The organic layer 
was dried over MgSO4 and the solvent was removed under reduced pressure. Purification by 
flash column chromatography (DCM + 0.4% DIPEA  [(DCM:Et2O)=95:5] + 0.4% DIPEA) 
gave 59b as a light yellow oil (2.83 g, 10.6 mmol, 64%). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.32. 
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MS (ESI+): m/z: found 268.00 [M+H]+, calculated 268.19 [M+H]+ 
 
1H NMR: (500 MHz, Chloroform-d) (mixture of cis/trans isomers) δ 5.49 – 5.35 (m, 1H), 5.26 
– 5.15 (m, 1H), 3.36 – 3.17 (m, 2H), 3.11 – 3.00 (m, 1H), 1.31 – 1.14 (m, 5H), 0.99 (s, 1H), 
0.00 (s, 9H), -0.14 – -0.18 (m, 9H). 
 
13C NMR: (126 MHz, Chloroform-d) (major) δ 129.77, 126.42, 108.91, 86.85, 49.70, 44.86, 
22.86, 22.36, 0.26, -1.84. 
 
 
(S)-6-Oxo-N-(4-(trimethylsilyl)but-2-en-1-yl)-N-(3-(trimethylsilyl)prop-2-yn-1-
yl)piperidine-2-carboxamide (60a) 
 
To a solution of (S)-6-oxo-2-piperidinecarboxylic acid (0.91 g, 6.39 mmol) in DMF (53 mL) 
were added 59a (1.35 g, 15.33 mmol), DIPEA (2.2 mL, 12.79 mmol) and HATU (2.43 g, 6.39 
mmol). After 2h stirring at room temperature Et2O (200 mL) was added to the reaction and 
washed with sat. aq. NaCl solution (3 × 30 mL). The organic layer was dried over MgSO4, the 
solvent was removed under reduced pressure and the crude title compound was used for the 
next step without further purification.    
 
 
 (2S)-6-Oxo-N-(4-(trimethylsilyl)but-2-en-1-yl)-N-(4-(trimethylsilyl)but-3-yn-2-
yl)piperidine-2-carboxamide (60b) 
 
To a solution of (S)-6-oxo-2-piperidinecarboxylic acid (1.79 g, 12.56 mmol) in DMF (104 mL) 
were added HATU (4.77 g, 12.56 mmol), DIPEA (4.38 mL, 25.12 mmol) and 59b (2.8 g, 
10.47 mmol), DIPEA. After 2h stirring at room temperature Et2O (500 mL) was added to the 
reaction and washed with sat. aq. NaCl solution (3 × 70 mL). The organic layer was dried 
over MgSO4, the solvent was removed under reduced pressure and the crude title compound 
was used for the next step without further purification.    
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(S)-tert-Butyl 2-oxo-6-((4-(trimethylsilyl)but-2-en-1-yl)(3-(trimethylsilyl)prop-2-yn-1-
yl)carbamoyl)piperidine-1-carboxylate (61a) 
 
DIPEA (1.84 mL, 10.66 mmol), Boc2O (4.64 g, 21.32 mmol) and DMAP (0.65 g, 5.33 mmol) 
were added into a solution of 60a in DCM (53 mL). After 16 h stirring at room temperature 
sat. aq. NaCl solution (25 mL) was added to the reaction and the organic phase was 
separated. The aqueous phase was extracted with CH2Cl2 (3 × 50 mL), the combined organic 
layers were dried over MgSO4 and the solvent was removed under reduced pressure. 
Purification by flash column chromatography (CH  CH:EA=7:3]) gave a yellow oil (1.55 g, 
3.24 mmol, 61% for 2 steps).  
 
TLC [CH:EA 6:4]: Rf = 0.47. 
 
MS (ESI+): m/z: found 501.45 [M+Na]+, calculated 501.26 [M+Na]+ 
 
1H NMR: (500 MHz, Chloroform-d) (mixture of cis/trans isomers) δ 5.76 – 5.60 (m, 1H), 5.40 
– 5.14 (m, 1H), 5.03 – 4.91 (m, 1H), 4.35 – 3.88 (m, 4H), 2.64 – 2.55 (m, 1H), 2.49 – 2.39 (m, 
1H), 2.02 – 1.66 (m, 4H), 1.51 – 1.43 (m, 11H), 0.15 (d, J = 9.4 Hz, 9H), 0.05 – -0.01 (m, 9H). 
 
13C NMR: (major) (126 MHz, Chloroform-d) δ 171.35, 171.29, 152.83, 132.90, 121.88, 100.68, 
88.95, 83.21, 55.95, 48.62, 36.98, 34.54, 28.15, 25.88, 23.11, 18.23, 0.00, -1.78. 
 
 
(S)-tert-Butyl 2-oxo-6-((4-(trimethylsilyl)but-2-en-1-yl)((S)-4-(trimethylsilyl)but-3-yn-2-
yl)carbamoyl)piperidine-1-carboxylate (61b) and (S)-tert-butyl 2-oxo-6-((4-
(trimethylsilyl)but-2-en-1-yl)((R)-4-(trimethylsilyl)but-3-yn-2-yl)carbamoyl)piperidine-1-
carboxylate (61c) 
 
  
DIPEA (3.65 mL, 20.94 mmol), Boc2O (9.13 g, 41.88 mmol) and DMAP (1.28 g, 10.47 mmol) 
were added into a solution of 60b in DCM (104 mL). After 16 h stirring at room temperature 
sat. aq. NaCl solution (150 mL) was added to the reaction and the organic phase was 
separated. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL), the combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced pressure. 
Purification by flash column chromatography (CH  CH:EA = 8:2]) gave 61b and 61c as 
yellow oil (61b: 1.50 g, 3.1 mmol; 61c:1.59 g, 3.2 mmol. Yield in total: 61% for 2 steps).  
 
61b: 
TLC [CH:EA 6:4]: Rf= 0.43. 
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MS (ESI+): m/z: found 515.24 [M+Na]+, calculated 515.27 [M+Na]+ 
 
1H NMR: (500 MHz, Chloroform-d) (mixture of cis/trans isomers) δ 5.71 – 5.28 (m, 3H), 4.83 
– 4.61 (m, 1H), 4.44 – 3.80 (m, 2H), 2.56 (dt, J = 17.3, 5.0 Hz, 1H), 2.46 – 2.33 (m, 1H), 1.97 
– 1.86 (m, 3H), 1.69 – 1.59 (m, 1H), 1.49 – 1.44 (m, 11H), 1.32 – 1.26 (m, 3H), 0.16 – 0.13 
(m, 9H), 0.06 – -0.03 (m, 9H). 
 
13C NMR: (major) (126 MHz, Chloroform-d) (major) δ 171.50, 171.21, 153.90, 130.32, 125.81, 
105.25, 89.13, 83.11, 56.25, 46.80, 43.82, 41.52, 34.69, 28.12, 26.17, 22.95, 20.30, 18.41, -
0.01, -1.72. 
 
61c: 
TLC [CH:EA 6:4]: Rf = 0.57. 
 
MS (ESI+): m/z: found 515.28 [M+Na]+, calculated 515.27 [M+Na]+ 
 
1H NMR: (500 MHz, Chloroform-d) (mixture of cis/trans isomers) δ 5.83 – 5.13 (m, 3H), 4.96 
– 4.63 (m, 1H), 4.23 – 3.83 (m, 2H), 2.65 – 2.50 (m, 1H), 2.49 – 2.35 (m, 1H), 1.99 – 1.62 (m, 
4H), 1.51 – 1.43 (m, 11H), 1.41 – 1.27 (m, 3H), 0.20 – 0.08 (m, 9H), 0.04 – -0.07 (m, 9H). 
 
13C NMR: (major) (126 MHz, Chloroform-d) (major) δ 171.41, 170.75, 152.65, 130.96, 125.25, 
104.59, 89.22, 83.17, 56.10, 47.02, 43.50, 34.55, 28.14, 26.15, 23.01, 21.27, 18.19, -0.01, -
1.72. 
 
 
(6S)-tert-Butyl 2-hydroxy-6-((4-(trimethylsilyl)but-2-en-1-yl)(3-(trimethylsilyl)prop-2-
yn-1-yl)carbamoyl)piperidine-1-carboxylate (62a) 
 
DIBAL-H (4.8 ml, 4.8 mmol) (1 M in DCM) was added into a solution of 61a (1.55 g, 3.24 
mmol) in THF (extra dry, 32 mL) dropwise at -78°C under Ar for 10 min. Then 2 spoons of 
Na2SO4-10H2O were added into the solution and stirred at -78°C. After raising to RT, another 
1 spoon of Na2SO4 were added and stirred for 15 min. Then the mixture was filtered through 
celite and the solvent was removed under reduced pressure. The resulting residue was used in 
the next step without purification. 
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(6S)-tert-Butyl 2-hydroxy-6-((4-(trimethylsilyl)but-2-en-1-yl)((S)-4-(trimethylsilyl)but-3-
yn-2-yl)carbamoyl)piperidine-1-carboxylate (62b) 
 
DIBAL-H (4.05 ml, 4.05 mmol) (1 M in DCM) was added into a solution of 61b (1.33 g, 2.70 
mmol) in THF (extra dry, 27 mL) dropwise at -78°C under Ar for 10 min. Then 2 spoons of 
Na2SO4.10H2O were added into the solution and stirred at -78°C. After raising to RT, another 
1 spoon of Na2SO4 were added and stirred for 15 min. Then the mixture was filtered through 
celite and the solvent was removed under reduced pressure. The resulting residue was used in 
the next step without purification. 
 
 
(6S)-tert-Butyl 2-hydroxy-6-((4-(trimethylsilyl)but-2-en-1-yl)((R)-4-(trimethylsilyl)but-3-
yn-2-yl)carbamoyl)piperidine-1-carboxylate (62c) 
 
DIBAL-H (4.50 ml, 4.50 mmol) (1 M in DCM) was added into a solution of 61c (1.48 g, 3.00 
mmol) in THF (extra dry, 30 mL) dropwise at -78°C under Ar for 10 min. Then 2 spoons of 
Na2SO4.10H2O were added into the solution and stirred at -78°C. After raising to RT, another 
1 spoon of Na2SO4 were added and stirred for 15 min. Then the mixture was filtered through 
celite and the solvent was removed under reduced pressure. The resulting residue was used in 
the next step without purification. 
 
 
(1S,5R,6R)-3-(3-(Trimethylsilyl)prop-2-yn-1-yl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-2-
one (63a) 
 
62a (1.62 mmol) was dissolved in DCM (84 mL) and cooled down to -78°C. Then a solution 
of HF in pyridine (70% in pyridine) (5% of DCM, 6.4 mL) was added into the solution at  
-78°C and warmed to 0°C. The reaction mixture was stirred for 1h at 0°C and then sat. CaCO3 
(30 mL) and NaOH (10 M, 30 ml) were added. The product was extracted with DCM. 
Purification by flash column chromatography (EA + 2% TEA  EA + 2% TEA + 2% MeOH) 
gave yellow solid (303 mg, 1.0 mmol, 64% for 2 steps).  
 
TLC [DCM:MeOH 95:5]: Rf = 0.39. 
 
MS (ESI+): m/z: found 291.17 [M+H]+, calculated 291.19 [M+H]+ 
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1H NMR (500 MHz, Chloroform-d) δ 5.68 (ddd, J = 17.2, 10.2, 8.4 Hz, 1H), 5.08 – 4.97 (m, 
2H), 4.55 (d, J = 17.4 Hz, 1H), 4.04 (d, J = 17.4 Hz, 1H), 3.96 (dd, J = 13.8, 10.7 Hz, 1H), 
3.75 (d, J = 3.4 Hz, 1H), 3.23 (dd, J = 13.8, 1.8 Hz, 1H), 2.86 – 2.80 (m, 1H), 2.69 (q, J = 
8.5 Hz, 1H), 2.28 – 2.20 (m, 1H), 2.04 (s, 1H), 1.70 – 1.49 (m, 5H), 0.14 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 174.44, 139.17, 115.24, 101.22, 88.29, 57.83, 52.78, 
49.98, 49.72, 39.73, 29.57, 28.19, 16.85, 0.00. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 10.86 min, purity (220 nm) ≥ 99%. 
 
 
(1S,5R,6R)-3-((S)-4-(Trimethylsilyl)but-3-yn-2-yl)-5-vinyl-3,10-diazabicyclo[4.3.1]decan-
2-one (63b) 
 
62b (2.70 mmol) was dissolved in DCM (140 mL) and cooled down to -78°C. Then a solution 
of HF in pyridine (70% in pyridine) (5% of DCM, 10.7 mL) was added into the solution at  
-78°C and warmed to 0°C. The reaction mixture was stirred for 1h at 0°C and then sat. CaCO3 
(82 mL) and NaOH (10 M, 82 ml) were added. The product was extracted with DCM. 
Purification by flash column chromatography (EA + 2% TEA  EA + 2% TEA + 2% MeOH) 
gave yellow solid (481 mg, 1.58 mmol, 50% for 2 steps). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.53. 
 
MS (ESI+): m/z: found 305.26 [M+H]+, calculated 305.20 [M+H]+ 
 
1H NMR (500 MHz, Chloroform-d) δ 5.76 – 5.67 (m, 1H), 5.61 (q, J = 6.9 Hz, 1H), 5.11 – 4.98 
(m, 2H), 3.88 – 3.71 (m, 2H), 3.27 (dd, J = 14.5, 1.7 Hz, 1H), 2.88 – 2.77 (m, 1H), 2.48 (q, J 
= 8.5 Hz, 1H), 2.23 (d, J = 12.0 Hz, 1H), 2.17 (s, 1H), 1.72 – 1.47 (m, 5H), 1.31 (d, J = 6.9 
Hz, 3H), 0.14 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 173.78, 139.16, 115.14, 105.10, 88.22, 57.90, 52.97, 
50.47, 45.83, 44.30, 29.49, 27.97, 19.82, 16.94, 0.04. 
 
 
 
(1S,5R,6R)-3-((R)-4-(Trimethylsilyl)but-3-yn-2-yl)-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-2-one (63c) 
 
62c (3.00 mmol) was dissolved in DCM (155 mL) and cooled down to -78°C. Then a solution 
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of HF in pyridine (70% in pyridine) (5% of DCM, 11.9 mL) was added into the solution at  
-78°C and warmed to 0°C. The reaction mixture was stirred for 1h at 0°C and then sat. CaCO3 
(91 mL) and NaOH (10 M, 91 ml) were added. The product was extracted with DCM. 
Purification by flash column chromatography (EA + 2% TEA  EA + 2% TEA + 2% MeOH) 
gave yellow solid (303 mg, 1.0 mmol, 53% for 2 steps). 
 
TLC [DCM:MeOH 95:5]: Rf = 0.42. 
 
MS (ESI+): m/z: found 305.29 [M+H]+, calculated 305.20 [M+H]+ 
 
1H NMR (500 MHz, Chloroform-d) δ 5.79 – 5.62 (m, 2H), 5.08 – 4.96 (m, 2H), 3.81 – 3.66 (m, 
2H), 3.41 (dd, J = 13.5, 1.8 Hz, 1H), 2.83 (dd, J = 6.7, 4.2 Hz, 1H), 2.61 (q, J = 8.5 Hz, 1H), 
2.35 (s, 1H), 2.26 – 2.19 (m, 1H), 1.69 – 1.49 (m, 5H), 1.28 (d, J = 7.0 Hz, 3H), 0.12 (s, 9H). 
 
13C NMR (126 MHz, Chloroform-d) δ 173.47, 139.22, 115.04, 105.30, 87.81, 58.00, 52.82, 
50.10, 45.15, 43.95, 29.80, 28.28, 20.14, 16.83, 0.06. 
 
(1S,5R,6R)-10-((3,5-Dichlorophenyl)sulfonyl)-3-(prop-2-yn-1-yl)-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-2-one (45a) 
 
3,5-Dichlorobenzenesulfonyl chloride (108 mg, 0.44 mmol) and DIPEA (67 mg, 0.52 mmol) 
were added into a solution of 63a (77 mg, 0.26 mmol) in MeCN (3 mL) and stirred at RT for 
16h. After removing solvent under reduced pressure, the residue was dissolved in MeOH (1 
mL) and stirred at RT for 1.5 h. Purification by flash column chromatography (CH  CH:EA 
= 8:2) gave light yellow solid (65 mg, 0.15 mmol, 58% for 2 steps). 
 
TLC [CH:EA 8:2]: Rf = 0.27. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.74 – 7.65 (m, 2H), 7.61 – 7.52 (m, 1H), 5.81 (ddd, J 
= 17.0, 10.0, 8.9 Hz, 1H), 5.21 – 5.11 (m, 2H), 4.70 (d, J = 6.0 Hz, 1H), 4.64 (dd, J = 17.2, 
2.5 Hz, 1H), 4.04 – 3.94 (m, 2H), 3.91 (dd, J = 17.2, 2.5 Hz, 1H), 3.20 (dd, J = 14.2, 1.9 Hz, 
1H), 2.76 – 2.66 (m, 1H), 2.28 (d, J = 13.2 Hz, 1H), 2.21 (t, J = 2.4 Hz, 1H), 1.62 – 1.47 
(m, 3H), 1.36 – 1.16 (m, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ 170.07, 144.14, 137.19, 136.51, 132.87, 125.04, 
117.27, 78.68, 71.85, 57.01, 55.08, 51.00, 49.44, 39.45, 27.68, 26.38, 15.56. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.90 min, purity (220 nm) ≥ 99%. 
 
HRMS: m/z: found 427.06484 [M+H]+, calculated 427.06445 [M+H]+ 
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(1S,5R,6R)-3-((S)-but-3-yn-2-yl)-10-((3,5-dichlorophenyl)sulfonyl)-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-2-one (45b) 
 
3,5-Dichlorobenzenesulfonyl chloride (452 mg, 1.84 mmol) and DIPEA (170 mg, 1.31 mmol) 
were added into a solution of 63b (200 mg, 0.66 mmol) in MeCN (6 mL) and stirred at RT for 
16h. After removing solvent under reduced pressure, the residue was dissolved in MeOH (2 
mL) and stirred at RT for 1.5 h. Purification by flash column chromatography (CH  CH:EA 
= 8:2) gave light yellow solid (150 mg, 0.34 mmol, 52% for 2 steps).  
 
TLC [CH:EA 8:2]: Rf = 0.33. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.70 (d, J = 1.8 Hz, 2H), 7.56 (t, J = 1.8 Hz, 1H), 5.83 
(ddd, J = 16.8, 10.2, 9.0 Hz, 1H), 5.61 (qd, J = 6.8, 2.3 Hz, 1H), 5.19 – 5.10 (m, 2H), 4.74 
(d, J = 5.9 Hz, 1H), 3.98 (t, J = 5.8 Hz, 1H), 3.80 (dd, J = 14.9, 10.8 Hz, 1H), 3.32 – 3.24 
(m, 1H), 2.45 (q, J = 9.1 Hz, 1H), 2.32 – 2.23 (m, 2H), 1.56 – 1.45 (m, 3H), 1.34 (d, J = 6.9 
Hz, 3H), 1.32 – 1.19 (m, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ 169.28, 144.18, 137.31, 136.54, 132.87, 125.09, 
117.09, 82.20, 72.55, 57.05, 55.12, 50.31, 46.59, 44.10, 27.78, 26.26, 19.79, 15.67. 
 
HRMS: m/z: found 441.08061 [M+H]+, calculated 441.08010 [M+H]+ 
 
(1S,5R,6R)-3-((R)-But-3-yn-2-yl)-10-((3,5-dichlorophenyl)sulfonyl)-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-2-one (45c) 
 
 
3,5-Dichlorobenzenesulfonyl chloride (452 mg, 1.84 mmol) and DIPEA (170 mg, 1.31 mmol) 
were added into a solution of 63c (200 mg, 0.66 mmol) in MeCN (6 mL) and stirred at RT for 
16h. After removing solvent under reduced pressure, the residue was dissolved in MeOH (2 
mL) and stirred at RT for 1.5 h. Purification by flash column chromatography (CH  CH:EA 
= 8:2) gave light yellow solid (147 mg, 0.33 mmol, 50% for 2 steps).  
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TLC [CH:EA 8:2]: Rf = 0.41. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.69 (d, J = 1.8 Hz, 2H), 7.56 (t, J = 1.8 Hz, 1H), 5.88 
– 5.78 (m, 1H), 5.69 (qd, J = 7.0, 2.2 Hz, 1H), 5.20 – 5.09 (m, 2H), 4.69 (d, J = 6.0 Hz, 1H), 
4.02 (t, J = 5.7 Hz, 1H), 3.70 (dd, J = 14.1, 10.6 Hz, 1H), 3.38 (dd, J = 14.1, 1.5 Hz, 1H), 
2.63 (q, J = 8.7 Hz, 1H), 2.30 – 2.23 (m, 2H), 1.60 – 1.49 (m, 3H), 1.33 (d, J = 7.0 Hz, 3H), 
1.32 – 1.17 (m, 2H). 
 
13C NMR (126 MHz, Chloroform-d) δ 169.26, 144.20, 137.39, 136.51, 132.84, 125.04, 
117.11, 82.83, 71.87, 57.21, 55.22, 49.77, 46.03, 43.68, 27.96, 26.59, 19.98, 15.59. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.81 min, purity (220 nm) ≥ 99%. 
 
HRMS: m/z: found 441.08022 [M+H]+, calculated 441.08010 [M+H]+ 
 
(2S,4R)-1-((S)-2-(2-(2-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-
3,10-diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)acetamido)-3,3-
dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-
carboxamide (MTQ498) 
 
MTQ498 was synthesized from 45a (4 mg, 0.01 mmol) and 43a (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (6 mg, 61%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.74 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.60 (s, 1H), 7.67 (s, 1H), 7.63 – 7.59 (m, 3H), 7.49 (t, J 
= 1.8 Hz, 1H), 7.33 – 7.28 (m, 4H), 7.02 (d, J = 9.2 Hz, 1H), 5.66 (ddd, J = 16.8, 10.3, 8.7 
Hz, 1H), 5.04 – 4.96 (m, 2H), 4.81 (d, J = 14.9 Hz, 1H), 4.73 (t, J = 8.0 Hz, 1H), 4.60 – 4.53 
(m, 3H), 4.51 – 4.45 (m, 3H), 4.26 (dd, J = 15.0, 5.2 Hz, 1H), 4.21 (d, J = 14.8 Hz, 1H), 3.97 
(d, J = 14.7 Hz, 1H), 3.91 – 3.84 (m, 4H), 3.76 – 3.69 (m, 2H), 3.61 (dd, J = 11.2, 3.6 Hz, 
1H), 3.28 – 3.23 (m, 1H), 2.90 (d, J = 4.6 Hz, 1H), 2.55 (q, J = 9.7, 8.6 Hz, 1H), 2.47 – 2.41 
(m, 4H), 2.13 – 2.05 (m, 2H), 1.42 – 1.32 (m, 3H), 1.16 – 1.06 (m, 2H), 0.89 (s, 9H). 
 
HRMS: m/z: found 984.3058 [M+H]+, calculated 984.3058 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-(2-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-
vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ499) 
 
MTQ499 was synthesized from 45a (4 mg, 0.01 mmol) and 43b (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (6 mg, 56%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.81 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 8.05 (s, 1H), 7.70 (t, J = 5.5 Hz, 1H), 7.66 
– 7.64 (m, 2H), 7.57 – 7.53 (m, 1H), 7.42 (d, J = 9.4 Hz, 1H), 7.30 (s, 4H), 5.68 (ddd, J = 
17.2, 10.0, 8.8 Hz, 1H), 5.07 – 4.92 (m, 2H), 4.75 – 4.70 (m, 2H), 4.67 – 4.56 (m, 4H), 4.49 – 
4.42 (m, 3H), 4.35 (dd, J = 15.0, 5.6 Hz, 1H), 4.05 – 3.96 (m, 3H), 3.90 (ddd, J = 13.1, 7.3, 
3.2 Hz, 3H), 3.83 (d, J = 16.0 Hz, 1H), 3.71 (dd, J = 11.3, 3.6 Hz, 1H), 3.68 – 3.63 (m, 1H), 
3.61 – 3.57 (m, 1H), 3.51 (ddt, J = 15.0, 8.8, 2.9 Hz, 2H), 3.28 – 3.21 (m, 1H), 2.50 (s, 3H), 
2.42 (ddd, J = 13.1, 8.8, 4.4 Hz, 2H), 2.23 (dd, J = 13.2, 7.7 Hz, 2H), 1.40 (t, J = 12.4 Hz, 
3H), 1.24 – 1.12 (m, 2H), 1.01 (s, 9H). 
 
HRMS: m/z: found 1028.3323 [M+H]+, calculated 1028.3327 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-
oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide  (MTQ500) 
 
MTQ500 was synthesized from 45a (4 mg, 0.01 mmol) and 43c (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (8 mg, 75%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.79 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.75 (s, 1H), 7.67 (d, J = 1.8 Hz, 2H), 7.55 
(t, J = 1.8 Hz, 1H), 7.43 (t, J = 5.9 Hz, 1H), 7.37 – 7.32 (m, 4H), 7.27 – 7.26 (m, 1H), 5.73 
(ddd, J = 17.0, 10.1, 8.8 Hz, 1H), 5.11 – 5.03 (m, 2H), 4.73 – 4.64 (m, 4H), 4.52 (ddd, J = 
18.3, 8.1, 5.2 Hz, 5H), 4.35 (dd, J = 15.0, 5.4 Hz, 1H), 4.02 – 3.99 (m, 2H), 3.99 – 3.94 (m, 
2H), 3.85 (t, J = 5.3 Hz, 2H), 3.71 – 3.56 (m, 10H), 3.32 – 3.25 (m, 1H), 3.20 (d, J = 4.0 Hz, 
1H), 2.63 – 2.57 (m, 1H), 2.54 – 2.48 (m, 4H), 2.24 – 2.12 (m, 2H), 1.51 – 1.44 (m, 3H), 1.26 
– 1.16 (m, 2H), 0.96 (s, 9H). 
 
HRMS: m/z: found 1072.3588 [M+H]+, calculated 1072.3589 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-17-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-
oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15-tetraoxa-3-azaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ501) 
 
MTQ501 was synthesized from 45a (4 mg, 0.01 mmol) and 43d (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (8 mg, 72%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.79 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.75 (s, 1H), 7.68 (d, J = 1.7 Hz, 2H), 7.55 
(t, J = 1.7 Hz, 1H), 7.44 (t, J = 6.1 Hz, 1H), 7.36 (d, J = 3.2 Hz, 4H), 7.24 (d, J = 8.6 Hz, 
1H), 5.73 (ddd, J = 17.0, 10.1, 8.8 Hz, 1H), 5.11 – 5.01 (m, 2H), 4.81 – 4.72 (m, 2H), 4.68 (d, 
J = 5.9 Hz, 1H), 4.61 (d, J = 14.8 Hz, 1H), 4.58 – 4.47 (m, 5H), 4.37 (dd, J = 15.0, 5.4 Hz, 
1H), 4.03 – 3.93 (m, 4H), 3.89 – 3.81 (m, 2H), 3.72 – 3.52 (m, 14H), 3.36 (d, J = 4.1 Hz, 1H), 
3.27 (dd, J = 14.2, 1.7 Hz, 1H), 2.62 – 2.49 (m, 5H), 2.23 (d, J = 13.3 Hz, 1H), 2.18 – 2.11 
(m, 1H), 1.47 (td, J = 6.6, 6.0, 2.3 Hz, 3H), 1.27 – 1.18 (m, 2H), 0.95 (s, 9H). 
 
HRMS: m/z: found 1116.3859 [M+H]+, calculated 1116.3851 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-20-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-
oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15,18-pentaoxa-3-azaicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ502) 
 
MTQ502 was synthesized from 45a (4 mg, 0.01 mmol) and 43e (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (7 mg, 64%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.21. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.78 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.72 (s, 1H), 7.70 – 7.66 (m, 2H), 7.57 – 
7.53 (m, 1H), 7.41 (t, J = 5.9 Hz, 1H), 7.38 – 7.32 (m, 4H), 7.24 (s, 1H), 5.74 (ddd, J = 17.1, 
10.1, 8.8 Hz, 1H), 5.12 – 5.03 (m, 2H), 4.82 – 4.71 (m, 2H), 4.68 (d, J = 5.9 Hz, 1H), 4.63 (d, 
J = 14.9 Hz, 1H), 4.58 – 4.48 (m, 5H), 4.36 (dd, J = 14.9, 5.3 Hz, 1H), 4.05 – 3.94 (m, 4H), 
3.88 – 3.82 (m, 2H), 3.69 – 3.56 (m, 18H), 3.28 (dd, J = 14.1, 1.5 Hz, 1H), 3.19 (d, J = 4.0 
Hz, 1H), 2.64 – 2.52 (m, 2H), 2.51 (s, 3H), 2.23 (d, J = 13.5 Hz, 1H), 2.17 – 2.09 (m, 1H), 
1.52 – 1.43 (m, 3H), 1.26 – 1.17 (m, 2H), 0.95 (s, 9H). 
 
HRMS: m/z: found 1160.4113 [M+H]+, calculated 1160.4113 [M+H]+ 
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2-(2-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ503) 
 
MTQ503 was synthesized from 45a (4 mg, 0.01 mmol) and 44a (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (5 mg, 60%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.36. 
 
HPLC [50-100% Solvent B, 20 min]: Rt = 6.49 min, purity (254 nm) = 96%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.51 (d, J = 28.2 Hz, 1H), 8.83 (dd, J = 11.6, 8.4 Hz, 
1H), 7.97 (d, J = 4.6 Hz, 1H), 7.86 – 7.63 (m, 4H), 7.59 (dd, J = 7.3, 3.4 Hz, 1H), 7.53 (dt, J 
= 4.5, 1.8 Hz, 1H), 5.89 – 5.71 (m, 1H), 5.19 – 5.07 (m, 3H), 4.82 – 4.69 (m, 3H), 4.34 – 4.24 
(m, 1H), 4.16 – 4.08 (m, 3H), 4.07 – 3.90 (m, 4H), 3.65 – 3.42 (m, 1H), 2.94 – 2.66 (m, 4H), 
2.29 – 2.13 (m, 2H), 1.52 – 1.37 (m, 3H), 1.31 – 1.18 (m, 2H). 
 
HRMS: m/z: found 827.17767 [M+H]+, calculated 827.17758 [M+H]+ 
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2-(2-(2-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ504) 
 
MTQ504 was synthesized from 45a (4 mg, 0.01 mmol) and 44b (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (7 mg, 77%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.32. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.67 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.45 (s, 1H), 9.01 – 8.76 (m, 2H), 7.76 – 7.69 (m, 2H), 
7.67 (dd, J = 5.3, 1.9 Hz, 2H), 7.58 (dd, J = 7.3, 0.7 Hz, 1H), 7.54 (dt, J = 3.8, 1.9 Hz, 1H), 
5.74 (dddd, J = 17.3, 10.1, 8.7, 1.7 Hz, 1H), 5.15 – 5.04 (m, 2H), 5.04 – 4.94 (m, 1H), 4.78 
(dd, J = 14.9, 7.7 Hz, 1H), 4.69 (dt, J = 4.1, 1.7 Hz, 1H), 4.64 – 4.49 (m, 3H), 4.23 – 4.10 (m, 
2H), 4.04 – 3.90 (m, 4H), 3.82 – 3.70 (m, 4H), 3.28 (dt, J = 14.3, 2.2 Hz, 1H), 2.97 – 2.72 (m, 
3H), 2.71 – 2.57 (m, 1H), 2.28 – 2.10 (m, 2H), 1.52 – 1.42 (m, 3H), 1.31 – 1.15 (m, 2H). 
 
HRMS: m/z: found 871.2043 [M+H]+, calculated 871.2038 [M+H]+ 
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2-(2-(2-(2-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)-N-(2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ505) 
 
MTQ505 was synthesized from 45a (4 mg, 0.01 mmol) and 44c (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (7 mg, 80%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.57 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.46 (s, 1H), 8.92 – 8.67 (m, 2H), 7.76 – 7.66 (m, 4H), 
7.58 (dd, J = 7.3, 0.7 Hz, 1H), 7.54 (dt, J = 3.2, 1.9 Hz, 1H), 5.84 – 5.64 (m, 1H), 5.10 (s, 
1H), 5.06 (d, J = 5.9 Hz, 1H), 5.02 – 4.93 (m, 1H), 4.79 – 4.63 (m, 3H), 4.55 – 4.46 (m, 2H), 
4.20 (d, J = 1.7 Hz, 2H), 4.03 – 3.92 (m, 2H), 3.85 (t, J = 5.2 Hz, 2H), 3.83 – 3.75 (m, 4H), 
3.67 – 3.62 (m, 2H), 3.60 – 3.55 (m, 2H), 3.30 (dd, J = 14.2, 1.6 Hz, 1H), 2.96 – 2.74 (m, 3H), 
2.67 – 2.55 (m, 1H), 2.29 – 2.11 (m, 2H), 1.53 – 1.42 (m, 3H), 1.31 – 1.17 (m, 2H). 
 
HRMS: m/z: found 915.22996 [M+H]+, calculated 915.23001 [M+H]+ 
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14-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (MTQ506) 
 
MTQ506 was synthesized from 45a (4 mg, 0.01 mmol) and 44d (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (7 mg, 76%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.61 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.50 (s, 1H), 8.98 – 8.78 (m, 2H), 7.76 – 7.68 (m, 4H), 
7.58 (dd, J = 7.3, 0.7 Hz, 1H), 7.54 (t, J = 1.8 Hz, 1H), 5.82 – 5.67 (m, 1H), 5.12 – 5.08 (m, 
1H), 5.07 – 5.03 (m, 1H), 5.02 – 4.94 (m, 1H), 4.79 – 4.62 (m, 3H), 4.57 – 4.47 (m, 2H), 4.19 
(d, J = 1.4 Hz, 2H), 4.03 – 3.92 (m, 2H), 3.90 – 3.84 (m, 2H), 3.80 (s, 4H), 3.72 – 3.66 (m, 
2H), 3.64 – 3.55 (m, 6H), 3.30 (d, J = 14.2 Hz, 1H), 2.94 – 2.73 (m, 3H), 2.61 (q, J = 8.9 Hz, 
1H), 2.29 – 2.11 (m, 2H), 1.52 – 1.41 (m, 3H), 1.31 – 1.16 (m, 2H). 
 
HRMS: m/z: found 959.25696 [M+H]+, calculated 959.25622 [M+H]+ 
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17-(4-(((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaheptadecan-1-amide (MTQ507) 
 
MTQ507 was synthesized from 45a (4 mg, 0.01 mmol) and 44e (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (8 mg, 82%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.51 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.49 (s, 1H), 9.00 – 8.75 (m, 2H), 7.70 (dd, J = 10.0, 
1.6 Hz, 4H), 7.61 – 7.52 (m, 2H), 5.74 (ddd, J = 17.4, 10.6, 8.9 Hz, 1H), 5.15 – 4.92 (m, 3H), 
4.78 (dd, J = 14.8, 4.0 Hz, 1H), 4.73 – 4.59 (m, 2H), 4.56 – 4.46 (m, 2H), 4.19 (d, J = 1.2 Hz, 
2H), 4.03 – 3.91 (m, 2H), 3.86 (t, J = 5.2 Hz, 2H), 3.80 (s, 4H), 3.73 – 3.68 (m, 2H), 3.67 – 
3.57 (m, 10H), 3.30 (d, J = 14.0 Hz, 1H), 2.94 – 2.75 (m, 3H), 2.61 (q, J = 8.6 Hz, 1H), 2.30 
– 2.07 (m, 2H), 1.52 – 1.42 (m, 3H), 1.34 – 1.17 (m, 2H). 
 
HRMS: m/z: found 1003.28266 [M+H]+, calculated 1003.28244 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-
vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)acetamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-
carboxamide (MTQ508) 
 
MTQ508 was synthesized from 45b (4 mg, 0.01 mmol) and 43a (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (7 mg, 67%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.94 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.66 (s, 1H), 7.90 (t, J = 5.9 Hz, 1H), 7.68 (s, 1H), 7.59 
(d, J = 1.8 Hz, 2H), 7.54 – 7.52 (m, 1H), 7.37 (s, 4H), 7.19 (d, J = 8.8 Hz, 1H), 6.13 (q, J = 
7.0 Hz, 1H), 5.72 (dt, J = 17.1, 9.5 Hz, 1H), 5.15 – 5.08 (m, 2H), 4.84 (t, J = 7.9 Hz, 1H), 
4.70 (dt, J = 14.4, 3.7 Hz, 1H), 4.58 (s, 1H), 4.55 – 4.48 (m, 5H), 4.06 (d, J = 14.6 Hz, 1H), 
3.99 – 3.92 (m, 2H), 3.91 – 3.86 (m, 1H), 3.85 – 3.80 (m, 1H), 3.74 – 3.67 (m, 2H), 3.36 (dd, 
J = 14.9, 10.5 Hz, 1H), 3.30 – 3.23 (m, 1H), 2.77 (s, 1H), 2.54 – 2.46 (m, 5H), 2.24 – 2.18 (m, 
1H), 2.11 (d, J = 13.1 Hz, 1H), 1.61 (d, J = 7.0 Hz, 3H), 1.54 – 1.48 (m, 3H), 1.17 – 1.04 (m, 
2H), 0.98 (s, 9H). 
 
HRMS: m/z: found 998.3224 [M+H]+, calculated 998.3221 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-(2-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-
5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ509) 
 
MTQ509 was synthesized from 45b (4 mg, 0.01 mmol) and 43b (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (7 mg, 73%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.05 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.72 (s, 1H), 7.65 (dd, J = 1.8, 0.6 Hz, 2H), 
7.58 – 7.53 (m, 1H), 7.39 (t, J = 5.9 Hz, 1H), 7.34 (s, 4H), 7.31 (d, J = 9.0 Hz, 1H), 6.10 (q, 
J = 7.0 Hz, 1H), 5.72 (dt, J = 17.1, 9.4 Hz, 1H), 5.16 – 5.06 (m, 2H), 4.72 – 4.64 (m, 2H), 
4.62 – 4.53 (m, 4H), 4.47 (ddd, J = 14.3, 5.5, 3.8 Hz, 1H), 4.36 (dd, J = 15.0, 5.4 Hz, 1H), 
4.08 (d, J = 11.3 Hz, 1H), 3.98 (d, J = 15.7 Hz, 1H), 3.96 – 3.84 (m, 4H), 3.68 – 3.56 (m, 4H), 
3.55 – 3.50 (m, 1H), 3.45 (dd, J = 14.8, 10.8 Hz, 1H), 3.31 (s, 1H), 3.14 (d, J = 14.1 Hz, 1H), 
2.57 – 2.47 (m, 5H), 2.26 (d, J = 12.9 Hz, 1H), 2.17 (dd, J = 13.5, 7.9 Hz, 1H), 1.60 (d, J = 
7.0 Hz, 3H), 1.57 – 1.51 (m, 3H), 1.31 – 1.21 (m, 2H), 0.97 (s, 9H). 
 
HRMS: m/z: found 1042.3485 [M+H]+, calculated 1042.3483 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-14-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ510) 
 
MTQ510 was synthesized from 45b (4 mg, 0.01 mmol) and 43c (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (10 mg, 88%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.23. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.12min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.72 – 7.63 (m, 3H), 7.59 – 7.53 (m, 1H), 
7.43 (t, J = 5.9 Hz, 1H), 7.39 – 7.32 (m, 4H), 7.28 (s, 1H), 6.10 (q, J = 6.9 Hz, 1H), 5.73 (dt, 
J = 17.0, 9.5 Hz, 1H), 5.16 – 5.05 (m, 2H), 4.74 – 4.65 (m, 2H), 4.60 – 4.47 (m, 5H), 4.35 (dd, 
J = 15.0, 5.3 Hz, 1H), 4.09 (d, J = 11.4 Hz, 1H), 4.01 (d, J = 4.1 Hz, 2H), 3.97 – 3.93 (m, 
1H), 3.84 (t, J = 5.3 Hz, 2H), 3.63 (tdd, J = 14.0, 10.4, 6.2 Hz, 9H), 3.46 (dd, J = 14.8, 10.8 
Hz, 1H), 3.23 (d, J = 4.3 Hz, 1H), 3.11 – 3.05 (m, 1H), 2.56 – 2.47 (m, 5H), 2.28 (d, J = 13.4 
Hz, 1H), 2.18 – 2.10 (m, 1H), 1.61 (d, J = 7.0 Hz, 3H), 1.54 (d, J = 11.1 Hz, 3H), 1.32 – 1.20 
(m, 2H), 0.96 (s, 9H). 
 
HRMS: m/z: found 1086.3753 [M+H]+, calculated 1086.3746 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-17-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15-tetraoxa-3-azaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ511) 
 
MTQ511 was synthesized from 45b (4 mg, 0.01 mmol) and 43d (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (10 mg, 86%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.17. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.07 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.70 – 7.65 (m, 2H), 7.63 (s, 1H), 7.57 – 
7.54 (m, 1H), 7.41 (t, J = 5.8 Hz, 1H), 7.38 – 7.32 (m, 4H), 7.26 – 7.22 (m, 1H), 6.12 (q, J = 
6.9 Hz, 1H), 5.73 (dt, J = 17.1, 9.5 Hz, 1H), 5.18 – 5.03 (m, 2H), 4.73 (t, J = 7.9 Hz, 1H), 
4.68 (d, J = 5.9 Hz, 1H), 4.59 – 4.47 (m, 5H), 4.35 (dd, J = 14.9, 5.3 Hz, 1H), 4.10 (d, J = 
11.3 Hz, 1H), 4.07 – 3.98 (m, 2H), 3.97 – 3.94 (m, 1H), 3.86 (t, J = 5.2 Hz, 2H), 3.68 – 3.58 
(m, 13H), 3.46 (dd, J = 14.8, 10.7 Hz, 1H), 3.30 – 3.25 (m, 1H), 3.07 (d, J = 13.8 Hz, 1H), 
2.58 – 2.48 (m, 5H), 2.29 (d, J = 13.5 Hz, 1H), 2.19 – 2.09 (m, 1H), 1.62 (d, J = 7.0 Hz, 3H), 
1.58 – 1.51 (m, 3H), 1.34 – 1.22 (m, 2H), 0.95 (s, 9H). 
 
HRMS: m/z: found 1130.4008 [M+H]+, calculated 1130.4008 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-20-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15,18-pentaoxa-3-azaicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ512) 
 
MTQ512 was synthesized from 45b (4 mg, 0.01 mmol) and 43e (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (10 mg, 73%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.21. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.08 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.71 – 7.65 (m, 2H), 7.62 (s, 1H), 7.58 – 
7.53 (m, 1H), 7.43 – 7.32 (m, 5H), 7.29 – 7.27 (m, 1H), 6.12 (q, J = 6.9 Hz, 1H), 5.73 (dt, J 
= 17.1, 9.5 Hz, 1H), 5.17 – 5.06 (m, 2H), 4.74 (t, J = 7.9 Hz, 1H), 4.68 (d, J = 5.9 Hz, 1H), 
4.60 – 4.47 (m, 5H), 4.35 (dd, J = 14.9, 5.3 Hz, 1H), 4.10 (d, J = 11.5 Hz, 1H), 4.04 – 3.93 
(m, 3H), 3.87 (t, J = 5.2 Hz, 2H), 3.70 – 3.59 (m, 17H), 3.46 (dd, J = 14.8, 10.7 Hz, 1H), 3.19 
(s, 1H), 3.08 (d, J = 14.5 Hz, 1H), 2.60 – 2.49 (m, 5H), 2.30 (d, J = 13.2 Hz, 1H), 2.17 – 2.08 
(m, 1H), 1.62 (d, J = 7.0 Hz, 3H), 1.59 – 1.51 (m, 3H), 1.36 – 1.28 (m, 1H), 1.25 – 1.16 (m, 
1H), 0.95 (s, 9H). 
 
HRMS: m/z: found 1174.4276 [M+H]+, calculated 1174.4270 [M+H]+ 
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2-(2-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ513) 
 
MTQ513 was synthesized from 45b (4 mg, 0.01 mmol) and 44a (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (6 mg, 74%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.36. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.56 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) diastereomers mixture δ 10.44 (d, J = 7.9 Hz, 1H), 8.81 
(dd, J = 21.3, 8.4 Hz, 1H), 8.68 (s, 1H), 7.99 (s, 0.5H), 7.79 (s, 0.5H), 7.73 – 7.63 (m, 2H), 
7.60 – 7.53 (m, 2H), 7.52 – 7.48 (m, 1H), 6.23 (q, J = 6.9 Hz, 0.5H), 6.10 (q, J = 7.0 Hz, 
0.5H), 5.74 (ddt, J = 23.3, 17.3, 9.5 Hz, 1H). 
 
HRMS: m/z: found 841.19396 [M+H]+, calculated 841.19323 [M+H]+ 
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2-(2-(2-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ514) 
 
MTQ514 was synthesized from 45b (4 mg, 0.01 mmol) and 44b (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (8 mg, 84%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.26. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.83 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.45 (d, J = 4.2 Hz, 1H), 8.85 (dd, J = 8.5, 3.9 Hz, 1H), 
8.67 (d, J = 42.6 Hz, 1H), 7.73 – 7.69 (m, 1H), 7.68 – 7.61 (m, 3H), 7.59 – 7.50 (m, 2H), 6.11 
(q, J = 7.0 Hz, 1H), 5.71 (dtd, J = 16.6, 9.5, 6.4 Hz, 1H), 5.15 – 5.04 (m, 2H), 5.00 (dd, J = 
12.2, 5.4 Hz, 1H), 4.73 – 4.66 (m, 1H), 4.61 – 4.49 (m, 2H), 4.22 – 4.12 (m, 2H), 3.99 – 3.91 
(m, 3H), 3.83 – 3.73 (m, 4H), 3.46 (ddd, J = 14.5, 10.7, 3.5 Hz, 1H), 3.05 (d, J = 14.7 Hz, 
1H), 2.94 – 2.73 (m, 3H), 2.56 – 2.47 (m, 1H), 2.28 (d, J = 13.1 Hz, 1H), 2.20 – 2.13 (m, 1H), 
1.63 – 1.60 (m, 3H), 1.56 – 1.50 (m, 3H), 1.33 – 1.18 (m, 2H). 
 
HRMS: m/z: found 885.21874 [M+H]+, calculated 885.21944 [M+H]+ 
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2-(2-(2-(2-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)-N-(2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ515) 
 
MTQ515 was synthesized from 45b (4 mg, 0.01 mmol) and 44c (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (9 mg, 97%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.30. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.81 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.46 (d, J = 2.7 Hz, 1H), 8.92 – 8.79 (m, 1H), 8.70 (d, 
J = 36.0 Hz, 1H), 7.75 – 7.69 (m, 1H), 7.68 (ddd, J = 7.9, 1.8, 0.7 Hz, 2H), 7.64 (d, J = 6.2 
Hz, 1H), 7.62 – 7.49 (m, 2H), 6.12 (p, J = 7.0 Hz, 1H), 5.80 – 5.65 (m, 1H), 5.15 – 5.05 (m, 
2H), 5.01 – 4.94 (m, 1H), 4.77 – 4.69 (m, 1H), 4.57 – 4.46 (m, 2H), 4.25 – 4.14 (m, 2H), 3.95 
(t, J = 5.3 Hz, 1H), 3.88 – 3.84 (m, 2H), 3.83 – 3.76 (m, 4H), 3.68 – 3.56 (m, 4H), 3.46 (dd, 
J = 14.8, 10.8 Hz, 1H), 3.08 (d, J = 14.6 Hz, 1H), 2.93 – 2.74 (m, 3H), 2.52 (q, J = 9.2 Hz, 
1H), 2.29 (d, J = 12.8 Hz, 1H), 2.20 – 2.12 (m, 1H), 1.62 (dd, J = 7.0, 1.9 Hz, 3H), 1.54 (d, J 
= 10.5 Hz, 3H), 1.32 – 1.18 (m, 2H). 
 
HRMS: m/z: found 929.24548 [M+H]+, calculated 929.24566 [M+H]+ 
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14-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (MTQ516) 
 
MTQ516 was synthesized from 45b (4 mg, 0.01 mmol) and 44d (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (9 mg, 88%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.82 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.51 (s, 1H), 8.94 – 8.70 (m, 2H), 7.74 – 7.70 (m, 1H), 
7.69 – 7.67 (m, 2H), 7.64 (d, J = 6.5 Hz, 1H), 7.59 – 7.56 (m, 1H), 7.55 – 7.52 (m, 1H), 6.12 
(p, J = 7.1 Hz, 1H), 5.73 (dtd, J = 17.1, 9.4, 4.2 Hz, 1H), 5.16 – 5.03 (m, 2H), 5.02 – 4.95 (m, 
1H), 4.71 (t, J = 5.2 Hz, 1H), 4.60 – 4.47 (m, 2H), 4.24 – 4.14 (m, 2H), 3.96 (t, J = 5.4 Hz, 
1H), 3.88 (t, J = 4.9 Hz, 2H), 3.80 (s, 4H), 3.71 – 3.67 (m, 2H), 3.65 – 3.57 (m, 6H), 3.45 
(ddd, J = 15.1, 10.7, 4.6 Hz, 1H), 3.08 (t, J = 13.4 Hz, 1H), 2.93 – 2.76 (m, 3H), 2.53 (q, J = 
8.9 Hz, 1H), 2.30 (d, J = 13.4 Hz, 1H), 2.21 – 2.11 (m, 1H), 1.63 (d, J = 7.0 Hz, 3H), 1.57 – 
1.51 (m, 3H), 1.35 – 1.28 (m, 1H), 1.25 – 1.18 (m, 1H). 
 
HRMS: m/z: found 973.27224 [M+H]+, calculated 973.27187 [M+H]+ 
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17-(4-((S)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaheptadecan-1-amide (MTQ517) 
 
MTQ517 was synthesized from 45b (4 mg, 0.01 mmol) and 44e (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (9 mg, 86%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.87 min, purity (254 nm) ≥ 99%. 
 
1H NMR (500 MHz, Chloroform-d) δ 10.50 (s, 1H), 8.85 (d, J = 8.5 Hz, 2H), 7.74 – 7.70 (m, 
1H), 7.68 (d, J = 1.8 Hz, 2H), 7.64 (s, 1H), 7.59 – 7.55 (m, 1H), 7.54 (q, J = 1.8 Hz, 1H), 6.12 
(q, J = 7.0 Hz, 1H), 5.80 – 5.66 (m, 1H), 5.16 – 5.05 (m, 2H), 5.03 – 4.94 (m, 1H), 4.75 – 4.67 
(m, 1H), 4.59 – 4.46 (m, 2H), 4.19 (d, J = 3.7 Hz, 2H), 3.96 (t, J = 5.3 Hz, 1H), 3.87 (t, J = 
5.2 Hz, 2H), 3.80 (s, 4H), 3.71 – 3.58 (m, 12H), 3.49 – 3.40 (m, 1H), 3.11 – 3.05 (m, 1H), 2.93 
– 2.74 (m, 3H), 2.53 (q, J = 9.5 Hz, 1H), 2.31 (d, J = 13.4 Hz, 1H), 2.20 – 2.11 (m, 1H), 1.64 
– 1.62 (m, 3H), 1.57 – 1.51 (m, 3H), 1.35 – 1.29 (m, 1H), 1.25 – 1.19 (m, 1H). 
 
HRMS: m/z: found 1017.29857 [M+H]+, calculated 1017.29809 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-
vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)acetamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-
carboxamide (MTQ518) 
 
MTQ518 was synthesized from 45c (4 mg, 0.01 mmol) and 43a (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (6 mg, 64%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.04 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.76 (t, J = 6.1 Hz, 1H), 7.68 (d, J = 1.8 Hz, 
2H), 7.63 (s, 1H), 7.56 (t, J = 1.8 Hz, 1H), 7.38 (s, 4H), 6.96 (d, J = 9.2 Hz, 1H), 6.23 (q, J 
= 7.0 Hz, 1H), 5.66 (ddd, J = 17.0, 10.1, 8.6 Hz, 1H), 4.98 (dd, J = 10.1, 1.1 Hz, 1H), 4.89 
(d, J = 17.0 Hz, 1H), 4.77 (t, J = 7.9 Hz, 1H), 4.72 (d, J = 6.0 Hz, 1H), 4.68 – 4.48 (m, 5H), 
4.46 – 4.37 (m, 1H), 4.06 (d, J = 14.7 Hz, 1H), 3.98 – 3.77 (m, 5H), 3.75 – 3.65 (m, 2H), 3.13 
(dd, J = 14.1, 1.5 Hz, 1H), 2.84 (s, 1H), 2.57 – 2.39 (m, 5H), 2.32 – 2.12 (m, 2H), 1.54 – 1.43 
(m, 3H), 1.41 (d, J = 7.1 Hz, 3H), 1.34 – 1.26 (m, 2H), 0.97 (s, 9H). 
 
HRMS: m/z: found 998.32293 [M+H]+, calculated 998.32213 [M+H]+ 
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(2S,4R)-1-((S)-2-(2-(2-(2-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-
5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ519) 
 
MTQ519 was synthesized from 45c (4 mg, 0.01 mmol) and 43b (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (5 mg, 47%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.11 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.66 (s, 1H), 8.16 (s, 1H), 7.92 (t, J = 5.9 Hz, 1H), 7.66 
(d, J = 1.9 Hz, 2H), 7.55 (t, J = 1.8 Hz, 1H), 7.45 – 7.35 (m, 1H), 7.27 (d, J = 1.2 Hz, 4H), 
5.85 (q, J = 7.0 Hz, 1H), 5.57 (ddd, J = 17.8, 10.2, 8.4 Hz, 1H), 4.92 (d, J = 10.3 Hz, 1H), 
4.77 – 4.61 (m, 4H), 4.60 – 4.42 (m, 4H), 4.34 (dd, J = 15.0, 5.6 Hz, 1H), 4.04 – 3.83 (m, 5H), 
3.80 – 3.47 (m, 7H), 3.03 (d, J = 14.4 Hz, 1H), 2.49 (s, 3H), 2.42 – 2.23 (m, 3H), 2.15 – 2.04 
(m, 1H), 1.46 (d, J = 7.1 Hz, 3H), 1.40 – 1.25 (m, 5H), 1.05 (s, 9H). 
 
HRMS: m/z: found 1042.34904 [M+H]+, calculated 1042.34835 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-14-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12-trioxa-3-azatetradecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ520) 
 
MTQ520 was synthesized from 45c (4 mg, 0.01 mmol) and 43c (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (7 mg, 63%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.12 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.71 (s, 1H), 7.68 (d, J = 1.8 Hz, 2H), 7.56 
(t, J = 1.8 Hz, 1H), 7.47 (t, J = 5.7 Hz, 1H), 7.39 – 7.29 (m, 4H), 7.20 (d, J = 9.0 Hz, 1H), 
6.10 (q, J = 7.2 Hz, 1H), 5.62 (ddd, J = 17.1, 10.2, 8.9 Hz, 1H), 4.98 – 4.90 (m, 1H), 4.80 (d, 
J = 16.9 Hz, 1H), 4.76 – 4.67 (m, 2H), 4.60 – 4.45 (m, 5H), 4.43 – 4.33 (m, 1H), 4.10 – 3.99 
(m, 3H), 3.96 – 3.78 (m, 3H), 3.71 – 3.58 (m, 10H), 3.14 (s, 1H), 2.98 (dd, J = 14.3, 1.4 Hz, 
1H), 2.56 – 2.43 (m, 4H), 2.40 – 2.25 (m, 2H), 2.21 – 2.09 (m, 1H), 1.55 – 1.38 (m, 6H), 1.30 
– 1.23 (m, 2H), 0.96 (s, 9H). 
 
HRMS: m/z: found 1086.37535 [M+H]+, calculated 1086.37456 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-17-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15-tetraoxa-3-azaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ521) 
 
MTQ521 was synthesized from 45c (4 mg, 0.01 mmol) and 43d (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (8 mg, 68%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.21. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.12 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.67 (s, 1H), 7.75 (s, 1H), 7.69 (d, J = 1.8 Hz, 2H), 7.60 
(t, J = 5.9 Hz, 1H), 7.55 (t, J = 1.8 Hz, 1H), 7.37 (s, 4H), 7.17 (d, J = 8.8 Hz, 1H), 6.19 (q, J 
= 7.0 Hz, 1H), 5.67 – 5.53 (m, 1H), 4.92 (dd, J = 10.0, 1.1 Hz, 1H), 4.84 – 4.69 (m, 3H), 4.60 
– 4.36 (m, 6H), 4.07 – 3.81 (m, 5H), 3.80 – 3.70 (m, 2H), 3.69 – 3.56 (m, 13H), 2.90 (dd, J = 
14.3, 1.5 Hz, 1H), 2.58 – 2.40 (m, 4H), 2.39 – 2.22 (m, 2H), 2.20 – 2.06 (m, 1H), 1.57 – 1.33 
(m, 6H), 1.32 – 1.24 (m, 2H), 0.95 (s, 9H). 
 
HRMS: m/z: found 1130.39944 [M+H]+, calculated 1130.40078 [M+H]+ 
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(2S,4R)-1-((S)-2-(tert-butyl)-20-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-
2-oxo-5-vinyl-3,10-diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-4-oxo-
6,9,12,15,18-pentaoxa-3-azaicosan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (MTQ522) 
 
MTQ522 was synthesized from 45c (4 mg, 0.01 mmol) and 43e (7 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (0% to 7% MeOH in 
DCM) gave a white solid (7 mg, 62%). 
 
TLC [DCM:MeOH 93:7]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.10 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 8.70 (s, 1H), 7.72 (d, J = 1.8 Hz, 2H), 7.69 (s, 1H), 7.58 
(t, J = 1.8 Hz, 1H), 7.50 – 7.33 (m, 5H), 7.24 (d, J = 8.3 Hz, 1H), 6.18 (q, J = 7.0 Hz, 1H), 
5.64 (ddd, J = 16.9, 10.0, 8.7 Hz, 1H), 4.96 (dd, J = 10.2, 1.1 Hz, 1H), 4.90 – 4.71 (m, 3H), 
4.63 – 4.46 (m, 5H), 4.46 – 4.34 (m, 1H), 4.13 – 4.06 (m, 1H), 4.05 – 3.92 (m, 3H), 3.90 – 
3.78 (m, 2H), 3.73 – 3.56 (m, 18H), 3.27 (d, J = 4.3 Hz, 1H), 3.06 – 2.90 (m, 1H), 2.67 – 2.48 
(m, 4H), 2.47 – 2.29 (m, 2H), 2.20 – 2.09 (m, 1H), 1.62 – 1.42 (m, 6H), 1.37 – 1.28 (m, 2H), 
0.98 (s, 9H). 
 
HRMS: m/z: found 1174.42451 [M+H]+, calculated 1174.42699 [M+H]+ 
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2-(2-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ523) 
 
MTQ523 was synthesized from 45c (4 mg, 0.01 mmol) and 44a (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (7 mg, 80%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.39. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.71 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) (diastereomers mixture) δ 10.49 (s, 0.5H), 10.35 (s, 0.5H), 
8.83 (dd, J = 8.4, 2.3 Hz, 1H), 8.41 (s, 1H, br), 8.01 (s, 0.5H), 7.82 (s, 0.5H), 7.77 – 7.68 (m, 
3H), 7.61 (d, J = 7.3 Hz, 1H), 7.59 – 7.51 (m, 1H), 6.12 (q, J = 7.2 Hz, 0.5H), 5.99 (q, J = 
7.4 Hz, 0.5H), 5.83 – 5.59 (m, 1H), 5.22 – 4.82 (m, 3H), 4.77 – 4.63 (m, 3H), 4.14 – 3.90 (m, 
5H), 3.79 – 3.62 (m, 1.5H), 3.28 (dd, J = 14.6, 1.2 Hz, 0.5H), 2.97 – 2.66 (m, 3H), 2.42 – 2.15 
(m, 3H), 1.54 – 1.48 (m, 3H), 1.47 – 1.34 (m, 3H), 1.29 – 1.19 (m, 2H). 
 
HRMS: m/z: found 841.19364 [M+H]+, calculated 841.19323 [M+H]+ 
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2-(2-(2-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-N-(2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ524) 
 
MTQ524 was synthesized from 45c (4 mg, 0.01 mmol) and 44b (4 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (4 mg, 50%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.32. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.93 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.43 (s, 1H), 8.87 (d, J = 8.3 Hz, 1H), 8.62 (s, 1H), 7.77 
– 7.71 (m, 1H), 7.70 (t, J = 1.9 Hz, 2H), 7.63 – 7.57 (m, 2H), 7.56 (t, J = 1.8 Hz, 1H), 6.15 – 
6.00 (m, 1H), 5.72 – 5.55 (m, 1H), 5.03 – 4.91 (m, 2H), 4.84 (d, J = 17.0 Hz, 1H), 4.74 (d, J 
= 5.4 Hz, 1H), 4.60 – 4.48 (m, 2H), 4.20 – 4.12 (m, 2H), 3.98 – 3.89 (m, 3H), 3.81 – 3.73 (m, 
4H), 3.66 (dd, J = 14.2, 10.6 Hz, 1H), 3.03 (d, J = 14.0 Hz, 1H), 2.93 – 2.73 (m, 3H), 2.47 – 
2.27 (m, 2H), 2.22 – 2.12 (m, 1H), 1.53 – 1.40 (m, 6H), 1.29 – 1.19 (m, 2H). 
 
HRMS: m/z: found 885.21980 [M+H]+, calculated 885.21944 [M+H]+ 
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2-(2-(2-(2-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)-N-(2-
(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (MTQ525) 
 
MTQ525 was synthesized from 45c (4 mg, 0.01 mmol) and 44c (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (7 mg, 72%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.90 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.44 (s, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.51 (d, J = 10.7 
Hz, 1H), 7.77 – 7.68 (m, 3H), 7.65 (d, J = 1.6 Hz, 1H), 7.61 – 7.52 (m, 2H), 6.17 – 6.06 (m, 
1H), 5.71 – 5.55 (m, 1H), 5.01 – 4.91 (m, 2H), 4.83 (d, J = 17.2 Hz, 1H), 4.78 – 4.72 (m, 1H), 
4.55 – 4.43 (m, 2H), 4.21 (s, 2H), 3.97 – 3.90 (m, 1H), 3.87 – 3.80 (m, 4H), 3.78 – 3.73 (m, 
2H), 3.68 – 3.55 (m, 5H), 3.03 (d, J = 14.1 Hz, 1H), 2.95 – 2.75 (m, 3H), 2.45 – 2.27 (m, 2H), 
2.21 – 2.12 (m, 1H), 1.55 – 1.39 (m, 6H), 1.31 – 1.21 (m, 2H). 
 
HRMS: m/z: found 929.24586 [M+H]+, calculated 929.24566 [M+H]+ 
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14-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxatetradecan-1-amide (MTQ526) 
 
MTQ526 was synthesized from 45c (4 mg, 0.01 mmol) and 44d (5 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (6 mg, 61%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.92 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.48 (s, 1H), 8.85 (d, J = 7.9 Hz, 1H), 8.65 (d, J = 9.1 
Hz, 1H), 7.76 – 7.72 (m, 1H), 7.70 (d, J = 1.8 Hz, 2H), 7.66 (s, 1H), 7.58 (dd, J = 7.3, 0.8 Hz, 
1H), 7.55 (td, J = 1.8, 1.2 Hz, 1H), 6.13 (q, J = 7.1 Hz, 1H), 5.71 – 5.55 (m, 1H), 5.00 – 4.91 
(m, 2H), 4.87 – 4.74 (m, 2H), 4.51 (t, J = 5.0 Hz, 2H), 4.20 (d, J = 1.0 Hz, 2H), 3.97 – 3.90 
(m, 1H), 3.88 – 3.77 (m, 6H), 3.71 – 3.65 (m, 3H), 3.64 – 3.57 (m, 6H), 3.07 – 2.97 (m, 1H), 
2.94 – 2.73 (m, 3H), 2.44 – 2.28 (m, 2H), 2.22 – 2.13 (m, 1H), 1.55 – 1.39 (m, 6H), 1.29 – 
1.20 (m, 2H). 
 
HRMS: m/z: found 973.27295 [M+H]+, calculated 973.27187 [M+H]+ 
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17-(4-((R)-1-((1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-2-oxo-5-vinyl-3,10-
diazabicyclo[4.3.1]decan-3-yl)ethyl)-1H-1,2,3-triazol-1-yl)-N-(2-(2,6-dioxopiperidin-3-
yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaheptadecan-1-amide (MTQ527) 
 
MTQ527 was synthesized from 45c (4 mg, 0.01 mmol) and 44e (6 mg, 0. 010 mmol) according 
to the General Method G. Purification by flash column chromatography (CH  EA:MeCN = 
90:10) gave a white solid (6 mg, 58%). 
 
TLC [DCM:MeOH 97:3]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.88 min, purity (254 nm) ≥ 99%. 
 
1H NMR (300 MHz, Chloroform-d) δ 10.49 (s, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.73 (d, J = 9.9 
Hz, 1H), 7.76 – 7.68 (m, 3H), 7.65 (s, 1H), 7.60 – 7.53 (m, 2H), 6.14 (q, J = 6.9 Hz, 1H), 5.71 
– 5.54 (m, 1H), 5.00 – 4.89 (m, 2H), 4.86 – 4.74 (m, 2H), 4.54 – 4.46 (m, 2H), 4.19 (d, J = 
1.0 Hz, 2H), 3.97 – 3.90 (m, 1H), 3.86 – 3.77 (m, 6H), 3.70 – 3.56 (m, 13H), 3.04 – 2.71 (m, 
4H), 2.42 – 2.27 (m, 2H), 2.20 – 2.11 (m, 1H), 1.54 – 1.41 (m, 6H), 1.30 – 1.21 (m, 2H). 
 
HRMS: m/z: found 1017.29876 [M+H]+, calculated 1017.29809 [M+H]+ 
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(S)-2-((4-methoxybenzyl)oxy)propan-1-ol (98) 
 
The preparation of 98 followed a procedure described in literatures109, 110.  
 
(S)-1-(((1-iodopropan-2-yl)oxy)methyl)-4-methoxybenzene(99) 
 
To a stirred solution of 98 (0.50 g, 2.55 mmol) in DCM (25 mL) was added imidazole (502 mg, 
7.65 mmol) and Ph3P (802 mg, 3.06 mmol). After cooling to 0°C, iodine (842 mg, 3.32 mmol) 
was added and the mixture was allowed to warm to room temperature. The mixture was stirred 
at rt in the dark for 24h. Then 20 ml 1.75M Na2SO3 aqueous solution was added and the mixture 
was stirred for 30 min at RT. The aqueous phase was extracted with DCM (20 ml x 3) and the 
combined organic phase was dried over MgSO4. After filteration, the filtrate was concentrated 
under reduced pressure and the residue was purified by flash column chromatography (CH  
CH:EA = 90:10) to give 99 (602 mg, 1.9 mmol, 77%) as yellow oil. 
 
1H NMR (300 MHz, Chloroform-d) δ 7.27 – 7.17 (m, 2H), 6.86 – 6.75 (m, 2H), 4.49 – 4.32 (m, 
2H), 3.72 (s, 3H), 3.42 (m, 1H), 3.24 – 3.10 (m, 2H), 1.21 (d, J = 6.1 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 159.40, 130.33, 129.46, 113.96, 73.76, 70.70, 55.41, 20.46, 11.63. 
 
(S)-1-(((1-bromopropan-2-yl)oxy)methyl)-4-methoxybenzene(100) 
 
Carbon tetrabromide (1.0 g, 3.1 mmol) was added to a solution of 98 (0.5 g, 2.55 mmol) in 
DCM (25 mL). The resulting solution was cooled to 0°C and Ph3P (802 mg, 3.1 mmol) was 
added. The reaction mixture was stirred at room temperature for 24h. The solvent was removed 
under reduced pressure and the residue was purified by flash column chromatography (CH  
CH:EA = 90:10) to give 100 (460 mg, 1.8 mmol, 70%) as yellow oil. 
 
1H NMR (300 MHz, Chloroform-d) δ 7.32 (d, J = 7.9 Hz, 2H), 6.91 (d, J = 7.9 Hz, 2H), 3.83 
(s, 3H), 3.75 (q, J = 5.6 Hz, 1H), 3.53 – 3.33 (m, 2H), 1.33 (d, J = 6.0 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 159.38, 130.33, 129.40, 113.94, 73.96, 70.87, 55.37, 36.61, 19.02. 
 
 
(S)-1-(((1-bromopropan-2-yl)oxy)methyl)-4-methoxybenzene (101) 
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To a solution of 98 (161 mg, 0.82 mmol), Et3N (342 µL, 2.46 mmol), and DMAP (20 mg, 0.16 
mmol) in DCM (4 mL) was added p-toluenesulfonyl chloride (234 mg, 1.23 mmol) at 0°C and 
the reaction mixture was stirred at RT for 24h. Then 5 ml water was added and the mixture 
was extracted with DCM (15 ml x 3) and the combined organic phase was dried over MgSO4. 
After filteration, the filtrate was concentrated under reduced pressure and the residue was 
purified by flash column chromatography (CH  CH:EA = 90:10) to give 101 (205 mg, 0.59 
mmol, 71%) as yellow oil. 
 
 
1H NMR (300 MHz, Chloroform-d) δ 7.78 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 7.19 
(d, J = 8.5 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.51 – 4.29 (m, 2H), 4.05 – 3.92 (m, 2H), 3.79 
(s, 3H), 3.74 (td, J = 6.2, 4.7 Hz, 1H), 2.43 (s, 3H), 1.14 (d, J = 6.4 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 159.28, 144.82, 133.03, 130.21, 129.86, 129.26, 127.96, 113.82, 
72.77, 72.03, 71.00, 55.31, 21.66, 16.82. 
 
 
(S)-ethyl 2-(bis(4-methoxyphenyl)(phenyl)methoxy)propanoate (DMT-1) 
 
20 mL Pyridine was added to a mixture of 4,4′-dimethoxytrityl chloride (3.3 g, 1 mmol) and 
(−)-ethyl L-lactate (11.8 g, 10 mmol) at RT. The mixture was stirred at RT for 16h. Then 20 ml 
sat. NaHCO3 and 300 ml EA were added and the mixture was washed with brine (30 ml x 3). 
The organic phase was dried over MgSO4 and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (CH  CH:EA = 90:10) to give 
DMT-1 (3.96 g,  95%) as yellow oil. 
 
 
1H NMR (300 MHz, Chloroform-d) δ 7.40 (d, J = 7.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 4H), 7.22 
– 7.11 (m, 3H), 6.73 (dd, J = 8.7, 2.6 Hz, 4H), 4.12 – 4.05 (m, 1H), 3.70 (s, 6H), 3.62 (q, J 
= 7.1 Hz, 2H), 1.27 (d, J = 6.7 Hz, 3H), 0.98 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.69, 158.59, 145.02, 136.25, 136.07, 130.52, 130.46, 
128.47, 127.72, 126.86, 113.01, 112.97, 69.47, 60.21, 55.20, 26.92, 20.07, 13.90. 
MS (ESI+):  m/z: found 442.97 [M+Na]+, calculated 443.18 [M+Na]+ 
(S)-2-(bis(4-methoxyphenyl)(phenyl)methoxy)propan-1-ol (DMT-2) 
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LiAlH4 solution (1M in THF, 11.1 ml, 11.1 mmol) was added slowly to a stirred solution of 
DMT-1 (3.9 g, 9.28 mmol) in 50 mL of THF at 0°C under argon. After 30min, the reaction 
mixture was allowed to warm to room temperature and the mixture was stirred at rt for 1h. 
After it was cooled back to 0°C, the reaction was quenched by the sequential addition of water 
(0.46 mL), 15% NaOH aqueous solution (0.46 mL) and water (1.4 mL). After allowing the 
mixture to warm to room temperature, the white solid was removed by filtration while washing 
with Et2O. The filtrate was washed with saturated aqueous NaCl, dried, and concentrated. The 
crude product was purified by flash chromatography on silica gel with EtOAc/CH (4/1) as 
eluents to give DMT-2 as a yellow oil (3.42 g, 98%). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.38 – 7.34 (m, 2H), 7.24 – 7.10 (m, 7H), 6.75 (d, J = 
8.9 Hz, 4H), 3.92 – 3.84 (m, 1H), 3.71 (s, 6H), 3.70 – 3.67 (m, 1H), 3.05 (dd, J = 9.3, 3.4 
Hz, 1H), 2.92 (dd, J = 9.2, 7.8 Hz, 1H), 1.02 (d, J = 6.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 158.66, 145.02, 136.25, 130.19, 128.30, 127.96, 126.94, 
113.28, 69.00, 67.25, 55.34, 27.07, 19.15. 
 
(S)-2-(bis(4-methoxyphenyl)(phenyl)methoxy)propyl 4-methylbenzenesulfonate (103) 
 
To a solution of DMT-2 (2.18 g, 5.8 mmol), Et3N (2.4 mL, 17.3 mmol), and DMAP (0.14 g, 1.2 
mmol) in DCM (50 mL) was added p-toluenesulfonyl chloride (1.7 g, 8.7 mmol) at 0°C and the 
reaction mixture was stirred at rt overnight. Then 10 ml water was added and the mixture was 
extracted with DCM (15 ml x 3) and the combined organic phase was dried over MgSO4. After 
filteration, the filtrate was concentrated under reduced pressure and the residue was purified 
by flash column chromatography (CH  CH:EA = 85:15) to give 103 (2.1 g, 67%) as yellow 
oil. 
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1H NMR (300 MHz, Chloroform-d) δ 7.83 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.42 
– 7.19 (m, 11H), 6.87 – 6.77 (m, 4H), 4.07 – 3.99 (m, 1H), 3.81 (m, 7H), 3.46 (d, J = 5.1 
Hz, 1H), 2.47 (d, J = 3.4 Hz, 3H), 1.23 – 0.96 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ 158.58, 147.36, 145.53, 139.49, 136.56, 130.20, 129.68, 
129.13, 127.91, 127.77, 127.71, 113.17, 86.57, 74.79, 67.08, 55.25, 21.64, 18.75. 
 
1,3,6,9,12-Pentaoxa-2-thiacyclotetradecane 2,2-dioxide (87) 
 
Under the atmosphere of Ar, SOCl2 (2.3 mL, 31.20 mmol, in 50 mL DCM) was added over 1 h 
to a stirring solution of tetraethylene glycol (3.03 g, 15.60 mmol), DIPEA (13.0 mL, 74.88 mmol) 
and DMAP (0.10 g, 0.78 mmol) in DCM (300 mL) at 0°C. After the addition, the mixture was 
stirred at 0°C for 1 h and quenched with cold brine (100 mL). The organic layer was collected 
and the aqueous layer was extracted with DCM (50 mL, twice). The combined organic layer 
was dried over anhydrous Na2SO4, concentrated, purified by flash chromatography on silica gel 
with EtOAc/CH (1/1) as eluents to give macrocyclic sulfite 1,3,6,9,12-pentaoxa-2-
thiacyclotetradecane 2-oxide (2.15 g, 9.2 mmol, 59%) as brown oil.  
1,3,6,9,12-pentaoxa-2-thiacyclotetradecane 2-oxide (2.10 g, 8.74 mmol) was dissolved in a 
mixture of CH3CN (80 mL), DCM (80 mL) and water (120 mL) at 0°C. NaIO4 (2.29 g, 10.76 
mmol) and RuCl3‧3H2O (0.01 g, 0.04 mmol) were sequentially added to the reaction mixture 
and the resulting mixture was stirred at 0°C for 1 h. The organic layer was collected and the 
aqueous layer was extracted with DCM (100 mL, twice). The combined organic layer was dried 
over anhydrous Na2SO4, filtrated through a pad of celite, concentrated, purified by flash 
chromatography on silica gel with EtOAc/CH (1/1) as eluents to give 87 as a white solid (1.78 
g, 7.1 mmol, 81%). 
 
TLC [CH/EtOAc=4:6]: Rf= 0.39. 
 
1H NMR (500 MHz, Chloroform-d) δ 4.47 – 4.41 (m, 4H), 3.84 – 3.79 (m, 4H), 3.69 – 3.60 (m, 
8H). 
 
13C NMR (126 MHz, CDCl3) δ 72.28, 70.82, 70.78, 68.53. 
 
General Method I for Solid Phase Synthesis of PEG linkers 
Wang resin (1 eq.) was swelled with THF, then tBuOK (1.5 eq.) was added. After stirring for 
30 min, a cyclic sulfite (2 eq.) was added and stirred overnight, after which the resin was 
washed with water and THF. A solution of TsOH/dioxane/H2O (1 mmol/19 ml/ 1 ml) was 
added to the resin and the mixture was stirred at 60°C for 4h followed by washing with THF, 
DCM and dioxane. The resin was reacted with tBuOK (2 eq.) in dioxane for 30 min, then 103 
(2.2 eq.) was added and stirred overnight at 60°C. This step was repeated for another 2 times 
before the DMTr protection group was removed by TsOH/DCM/THF solution. The resulting 
alcohol was then coupled with cyclic sulfite (2 eq.) in the presence of tBuOK (1.5 eq.) in DMF 
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and deprotected by TsOH/dioxane/H2O at 60°C. The resin was swelled with DCM and reacted 
with TsCl (1.5 eq.), TEA (3 eq.) and DMAP (0.2 eq.) at RT for 9h. Then the resin was washed 
with THF, DCM, DMF, and reacted with NaN3 (5 eq.) in DMF) in the presence of 18-crown-6 
(cat.) at 60°C. Then the resin was washed with water, DMF, THF and DCM. The azido alcohol 
was cleaved from the resin by treating with 50% TFA in DCM, followed by the oxidation with 
Jones reagent (4 eq.) in aceton at 0°C for 4h. The purification by preparative HPLC gave the 
desired methyl PEG linker.  
 
(S)-14-azido-11-methyl-3,6,9,12-tetraoxatetradecan-1-oic acid (114) 
 
114 (11 mg, 7% for 9 steps) was synthesized from 106, 103 and 85 sequentially according to 
the General Method I.  
TLC [DCM + 5% MeOH + 1% HCOOH]: Rf= 0.36. 
 
1H NMR (500 MHz, Chloroform-d) δ 4.15 (s, 2H), 3.76 (dd, J = 5.7, 2.9 Hz, 2H), 3.73 – 3.64 
(m, 9H), 3.52 – 3.44 (m, 2H), 3.42 – 3.31 (m, 2H), 1.18 (d, J = 6.4 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3) δ 171.68, 75.39, 75.20, 71.49, 70.71, 70.47, 70.10, 69.09, 68.01, 
50.96, 16.74. 
 
(2S,4R)-1-((2S,14S)-17-azido-2-(tert-butyl)-14-methyl-4-oxo-6,9,12,15-tetraoxa-3-
azaheptadecan-1-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-
carboxamide (116) 
 
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (11 mg, 24 µmol) was added to a solution 
of PEG-linker 114 (7mg, 24 µmol) in DCM (4 ml). HATU (14 mg, 36 µmol) was added and 
the pH adjusted to >9 by addition of DIPEA (21 µL, 120 µmol). After stirring overnight at RT 
the reaction mixture was extracted with water. The organic phase was dried over magnesium 
sulfate and evaporated to dryness. The crude product was purified by preparative HPLC (30-
80% MeCN in H2O) to afford 116 as a colorless oil (7 mg, 10 µmol, 41%). 
TLC [DCM + 5% MeOH]: Rf= 0.22. 
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1H NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 7.30 (s, 5H), 7.22 (d, J = 6.4 Hz, 1H), 4.68 
– 4.64 (m, 1H), 4.53 – 4.40 (m, 3H), 4.30 (dd, J = 15.1, 5.2 Hz, 1H), 4.11 – 3.87 (m, 3H), 
3.71 – 3.52 (m, 12H), 3.46 – 3.35 (m, 2H), 3.34 – 3.22 (m, 2H), 2.54 – 2.38 (m, 4H), 2.08 (dd, 
J = 12.6, 7.9 Hz, 1H), 1.09 (d, J = 6.3 Hz, 3H), 0.90 (s, 9H). 
 
13C NMR (126 MHz, CDCl3) δ 171.43, 170.89, 170.82, 151.32, 146.97, 138.77, 129.91, 129.50, 
128.25, 75.27, 75.17, 71.00, 70.62, 70.44, 70.29, 70.20, 70.09, 67.98, 58.53, 57.44, 56.77, 
50.96, 43.22, 35.95, 34.82, 26.38, 16.75, 15.16. 
 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.61 min, purity (220 nm) ≥ 99%. 
 
MS (ESI+):  m/z: found 704.39 [M+H]+, calculated 704.34 [M+H]+ 
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